Antisense modulation of phospholipid scramblase 4 expression

ABSTRACT

Antisense compounds, compositions and methods are provided for modulating the expression of phospholipid scramblase 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phospholipid scramblase 4. Methods of using these compounds for modulation of phospholipid scramblase 4 expression and for treatment of diseases associated with expression of phospholipid scramblase 4 are provided.

FIELD OF THE INVENTION

[0001] The present invention provides compositions and methods for modulating the expression of phospholipid scramblase 4. In particular, this invention relates to compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding phospholipid scramblase 4. Such compounds have been shown to modulate the expression of phospholipid scramblase 4.

BACKGROUND OF THE INVENTION

[0002] The plasma membranes of cellular organisms act as diffusion barriers and conduits of communication between the cell cytoplasm and the extracellular environment. The major functions of plasma membranes are to exchange metabolites, transfer signals and provide a lipid bilayer surface into which specific membrane proteins and multi-protein complexes are embedded. The various classes of phospholipids found in the plasma membrane are distributed over the bilayer leaflets in a non-random fashion. The outer leaflet of the lipid bilayer is rich in choline phospholipids while the inner leaflet is comprised primarily of aminophospholipids. This membrane asymmetry is critical and defective regulation of transbilayer lipid distribution may result in serious clinical manifestations, as illustrated by Scott syndrome, a bleeding disorder caused by impaired function of phospholipid scramblase, an enzyme that mediates redistribution of plasma membrane phospholipids in activated, injured or apoptotic cells (Bevers et al., Biochmicia et Biophysica Acta, 1999, 1439, 317-330).

[0003] Phospholipid asymmetry is maintained by the action of three enzymes. The first is an ATP-dependent aminophospholipid translocase which acts as an inward-directed pump specific for phosphatidylserine and phosphatidylethanolamine. The second is an outward-directed pump, known as floppase, with little selectivity for the polar headgroup of the phospholipid. Finally, the Ca2+-dependent enzyme activity known as phospholipid scramblase facilitates ATP-independent bi-directional migration of all phospholipid classes across the bilayer, resulting in a loss of phospholipid asymmetry in the plasma membrane (Bevers et al., Lupus, 1998, 7, S126-131; Bevers et al., Biochmicia et Biophysica Acta, 1999, 1439, 317-330).

[0004] As was first demonstrated in platelets and later found in other peripheral blood cells, smooth muscle cells and tumorigenic cells, the Ca2+-influx accompanying cellular activation inhibits aminophospholipid translocase activity and activates phospholipid scramblase activity, inducing fast transbilayer movement of all phospholipids and progressive loss of membrane asymmetry. Stimulation with a variety of physiological and non-physiological agonists also results in appreciable randomization of lipids over both membrane leaflets. This process of lipid scrambling is most clearly manifested by surface exposure of phosphatidylserine (PS). Surface exposure of PS has several important physiological and pathological implications. PS exposure is a prerequisite for formation of tenase and prothrombinase complexes of coagulation factors on the surface of platelets; thus the phospholipid scramblase enzyme promotes blood coagulation by enhancing the rate of thrombin formation by activated platelets, leading to activation of the plasma complement system (Solum, Arterioscler. Thromb. Vasc. Biol., 1999, 19, 2841-2846). PS exposure also provides a cell-cell recognition signal which may be an early event in apoptosis to ensure removal of injured and apoptotic cells by macrophages and other reticuloendothelial cells in order to avoid release of their inflammatory contents (Bevers et al., Lupus, 1998, 7, S126-131; Bevers et al., Biol. Chem., 1998, 379, 973-986; Bevers et al., Biochmicia et Biophysica Acta, 1999, 1439, 317-330; Fadok et al., Cell Death and Differentiation, 1998, 5, 551-562; Verhoven et al., Cell Death and Differentiation, 1999, 6, 262-270). Consequently, control mechanisms of transmembrane phospholipid distribution is an area of intense study, and inhibition of the scramblase enzyme that regulates the movement of PS to the cell surface represents a potential therapeutic target for the maintenance of membrane asymmetry (Zhao et al., J. Biol. Chem., 1998, 273, 6603-6606).

[0005] A phospholipid scramblase was identified as a novel interferon stimulated gene (ISG). The expression of phospholipid scramblase 1, as an ISG, was upregulated by interferon-alpha, interferon-beta and interferon-gamma. Interferons are a family of cytokines that mediate a diverse range of functions including antiviral, antiproliferative and antitumor activities in the cell. Given the previously described role of phospholipid scramblase 1 in apoptosis, these data indicate that the pharmacological modulation of phospholipid scramblase activity and/or expression may be an appropriate point of therapeutic intervention in pathological conditions such as cancer, immunomodulation and inflammation. (Der et al., Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 15623-15628).

[0006] Phospholipid scramblase 4 (also known as PLSCR4, HuPLSCR4, MuPLSCR4 and LOC57088) was isolated as one of three new members of the phospholipid scramblase gene family (Wiedmer et al., Biochim. Biophys. Acta, 2000, 1467, 244-253). All three of these novel family members have a conserved motif of amino acid residues shown in phospholipid scramblase 1 to bind Ca2+ and directly participate in the Ca2+-induced active conformation of the polypeptide, and to be required for Ca2+-accelerated transbilayer movement of lipids (Wiedmer et al., Biochim. Biophys. Acta, 2000, 1467, 244-253; Zhou et al., Biochemistry, 1998, 37, 2356-2360). Upon identification of sequences in the EST database potentially encoding these three new phospholipid scramblase family members, a full-length cDNA encoding phospholipid scramblase 4 was obtained by PCR from human multiple tissue cDNA (Wiedmer et al., Biochim. Biophys. Acta, 2000, 1467, 244-253). Like phospholipid scramblase 1, the N-terminus of the phospholipid scramblase 4 protein, bears a number of PXXP and PPXY motifs, which may serve as potential sites for interaction with proteins containing SH3 domains and WW domains, respectively, found in proteins with signaling or regulatory function. Northern analyses demonstrated that the phospholipid scramblase 4 gene is expressed as a 4-kilobase mRNA transcript in all tissues examined, including heart, brain, placenta, lung, liver, kidney, pancreas, spleen, thymus, testis, uterus, and prostate, but phospholipid scramblase 4 mRNA was below the limits of detection in peripheral blood lymphocytes. Importantly, phospholipid scramblase 4 was the only family member found expressed in brain. Phospholipid scramblase 3 is unique among the family members in its location on chromosome 17p13.1, whereas phospholipid scramblases 1, 2, and 4 all reside in a cluster on chromosome 3 at the 3q23 locus. (Wiedmer et al., Biochim. Biophys. Acta, 2000, 1467, 244-253).

[0007] Recently, a phospholipid scramblase activity was demonstrated on lymphocytes activated by artificially elevating cytosolic Ca2+. Prior to this study, neither this scramblase activity in lymphocytes, nor the scramblase in any nucleated cell had been characterized in detail. The Ca2+-activated and apoptosis-activated scramblase activity as well as the impact of the Scott mutation on the behavior of the scramblase activity in apoptotic lymphocytes was studied, and the results suggest that Ca2+ and apoptosis operate through separate pathways to activate the same scramblase. This activity was not attributed to a particular scramblase isoform, however. Nonetheless, the activity of phospholipid scramblases is not limited to platelets or anucleated cells (Williamson et al., Biochemistry, 2001, 40, 8065-8072).

[0008] Currently, there are no known therapeutic agents which effectively inhibit the synthesis of phospholipid scramblase 4 and investigative strategies aimed at modulating phospholipid scramblase 4 function have involved the use of inhibitors such as synthetic organic compounds, antibodies, and peptides or peptidomimetics.

[0009] A synthetic organic compound, R5421, was found to selectively inhibit Ca2+-induced lipid scrambling and mimic the membrane lipid defects observed in platelets, erythrocytes and lymphocytes from patients with Scott syndrome. It should be noted, however, that this observation was made before the isolation of phospholipid scramblase 4 and that the identity of the membrane protein(s) involved in the collapse of membrane asymmetry was still considered to be obscure (Dekkers et al., Blood, 1998, 91, 2133-2138).

[0010] Disclosed in the PCT publications WO 97/37225 and WO 99/19352 are a preparation of a phospholipid scramblase, a recombinant DNA sequence encoding a phospholipid scramblase protein and expression vectors used to express the protein. Also disclosed are inhibitors of phospholipid scramblase including monoclonal antibodies, and generally disclosed are antisense nucleotides derived from a DNA sequence encoding a phospholipid scramblase, as well as peptides and peptidomimetics. Further disclosed are methods to treat various diseases and/or conditions using said inhibitors, methods to quantitate the amount of phospholipid scramblase present, cells genetically engineered not to express phospholipid scramblase and those wherein the phospholipid scramblase promoter is altered to increase or decrease the expression of the gene (Wiedmer and Sims, 1999; Wiedmer and Sims, 1997).

[0011] Disclosed in the PCT publication WO 99/36536 are methods to extend the viability of mammalian cells by inhibiting the expression of a phospholipid scramblase, wherein the inhibition is via a phospholipid scramblase antisense RNA molecule, a mutant or truncated form of a phospholipid scramblase such as an alternatively spliced phospholipid scramblase mRNA, a scramblase containing non-conservative substitutions, and by preventing posttranslational modifications such as fatty acylation. Also disclosed are methods to decrease the viability of metastatic or cancer cells by increasing the expression of phospholipid scramblase. Further disclosed are methods for diagnosing cancers comprising quantitation of the levels of phospholipid scramblase in human patients (Sims et al., 1999).

[0012] It should be noted, however, that the aforementioned PCT Publications refer to the first identified phospholipid scramblase 1, and not to the more recently identified isoform, phospholipid scramblase 4. To date, no antisense nucleotide molecules that specifically target phospholipid scramblase 4 appear in the art.

[0013] Disclosed in the PCT publication WO 00/53734 is a nucleic acid sequence selected from a group of which phospholipid scramblase 4 is a member; an allelic variant of said sequence; a sequence complementary to said sequence; a nucleic acid sequence 90% to 95% homologous to said sequence; the genomic sequence, promoter, enhancer, silencer, exon and intron structure and splice variants of phospholipid scramblase 4; BAC, PAC, cosmid clones, and expression vectors comprising said sequence; the antisense form of said nucleic acid sequence; the phospholipid scramblase 4 polypeptide; and an antibody which binds to said polypeptide (Thierauch et al., 2000).

[0014] Disclosed in the PCT publication WO 01/12662 is an isolated polynucleotide selected from the group of which phospholipid scramblase 4 is a member, an isolated polynucleotide encoding the phospholipid scramblase 4 polypeptide, a naturally occurring polynucleotide sequence having at least 90% sequence identity to phospholipid scramblase 4, a polynucleotide sequence complementary to the phospholipid scramblase 4, a cell transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to said polynucleotide, a transgenic organism comprising said recombinant polynucleotide, a method for screening a compound for effectiveness as an agonist or an antagonist of said polypeptide, and a method for screening a compound for effectiveness in altering expression of said target polynucleotide, wherein said target polynucleotide comprises the phospholipid scramblase 4 nucleotide sequence. Antisense molecules and compositions are generally claimed (Lal et al., 2001).

[0015] Disclosed in the PCT publication WO 01/64894 is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to the phospholipid scramblase 4 sequence, a fragment of at least 20 nucleotides of the phospholipid scramblase 4 sequence, a naturally occurring allelic variant of a biologically active polypeptide comprising the amino acid sequence of phospholipid scramblase 4 protein, and a nucleic acid molecule comprising the complement of said nucleic acid sequences. Also claimed are the isolated phospholipid scramblase 4 polypeptide and naturally occurring variants, as well as vectors, host cells, a method for producing said polypeptide, antibodies which selectively binds to said polypeptide, and a method for detecting the presence of said nucleic acid molecule or said polypeptide (Glucksmann, 2001).

[0016] Consequently, there remains a long felt need for additional agents capable of effectively inhibiting phospholipid scramblase 4 function.

[0017] Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of phospholipid scramblase 4 expression.

[0018] The present invention provides compositions and methods for modulating phospholipid scramblase 4, including the variant PLSCR4B.

SUMMARY OF THE INVENTION

[0019] The present invention is directed to compounds, particularly antisense oligonucleotides, which are targeted to a nucleic acid encoding phospholipid scramblase 4, and which modulate the expression of phospholipid scramblase 4. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further provided are methods of modulating the expression of phospholipid scramblase 4 in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of phospholipid scramblase 4 by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

[0020] The present invention employs oligomeric compounds, particularly antisense oligonucleotides, for use in modulating the function of nucleic acid molecules encoding phospholipid scramblase 4, ultimately modulating the amount of phospholipid scramblase 4 produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding phospholipid scramblase 4. As used herein, the terms “target nucleic acid” and “nucleic acid encoding phospholipid scramblase 4” encompass DNA encoding phospholipid scramblase 4, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as “antisense”. The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of phospholipid scramblase 4. In the context of the present invention, “modulation” means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

[0021] It is preferred to target specific nucleic acids for antisense. “Targeting” an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding phospholipid scramblase 4. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5′-AUG (in transcribed mRNA molecules; 5′-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the “AUG codon,” the “start codon” or the “AUG start codon”. A minority of genes have a translation initiation codon having the RNA sequence 5′-GUG, 5′-UUG or 5′-CUG, and 5′-AUA, 5′-ACG and 5′-CUG have been shown to function in vivo. Thus, the terms “translation initiation codon” and “start codon” can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, “start codon” and “translation initiation codon” refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding phospholipid scramblase 4, regardless of the sequence(s) of such codons.

[0022] It is also known in the art that a translation termination codon (or “stop codon”) of a gene may have one of three sequences, i.e., 5′-UAA, 5′-UAG and 5′-UGA (the corresponding DNA sequences are 5′-TAA, 5′-TAG and 5′-TGA, respectively). The terms “start codon region” and “translation initiation codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation initiation codon. Similarly, the terms “stop codon region” and “translation termination codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation termination codon.

[0023] The open reading frame (ORF) or “coding region,” which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5′ untranslated region (5′UTR), known in the art to refer to the portion of an mRNA in the 5′ direction from the translation initiation codon, and thus including nucleotides between the 5′ cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3′ untranslated region (3′UTR), known in the art to refer to the portion of an mRNA in the 3′ direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3′ end of an mRNA or corresponding nucleotides on the gene. The 5′ cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5′-most residue of the mRNA via a 5′-5′ triphosphate linkage. The 5′ cap region of an mRNA is considered to include the 5′ cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5′ cap region may also be a preferred target region.

[0024] Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as “introns,” which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as “exons” and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

[0025] It is also known in the art that alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as “variants”. More specifically, “pre-mRNA variants” are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and extronic regions.

[0026] Upon excision of one or more exon or intron regions or portions thereof during splicing, pre-mRNA variants produce smaller “mRNA variants”. Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as “alternative splice variants”. If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.

[0027] It is also known in the art that variants can be produced through the use of alternative signals to start or stop transcription and that pre-mRNAs and mRNAs can possess more that one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as “alternative start variants” of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as “alternative stop variants” of that pre-mRNA or mRNA. One specific type of alternative stop variant is the “polyA variant” in which the multiple transcripts produced result from the alternative selection of one of the “polyA stop signals” by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites.

[0028] Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

[0029] In the context of this invention, “hybridization” means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. “Complementary,” as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, “specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

[0030] Antisense and other compounds of the invention which hybridize to the target and inhibit expression of the target are identified through experimentation, and the sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The target sites to which these preferred sequences are complementary are hereinbelow referred to as “active sites” and are therefore preferred sites for targeting. Therefore another embodiment of the invention encompasses compounds which hybridize to these active sites.

[0031] Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

[0032] For use in kits and diagnostics, the antisense compounds of the present invention, either alone or in combination with other antisense compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

[0033] Expression patterns within cells or tissues treated with one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds which affect expression patterns.

[0034] Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, FEBS Lett., 2000, 480, 17-24; Celis, et al., FEBS Lett., 2000, 480, 2-16), SAGE (serial analysis of gene expression)(Madden, et al., Drug Discov. Today, 2000, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, Methods Enzymol., 1999, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 1976-81), protein arrays and proteomics (Celis, et al., FEBS Lett., 2000, 480, 2-16; Jungblut, et al., Electrophoresis, 1999, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., FEBS Lett., 2000, 480, 2-16; Larsson, et al., J. Biotechnol., 2000, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., Anal. Biochem., 2000, 286, 91-98; Larson, et al., Cytometry, 2000, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, Curr. Opin. Microbiol., 2000, 3, 316-21), comparative genomic hybridization (Carulli, et al., J. Cell Biochem. Suppl., 1998, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, Eur. J. Cancer, 1999, 35, 1895-904) and mass spectrometry methods (reviewed in (To, Comb. Chem. High Throughput Screen, 2000, 3, 235-41).

[0035] The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

[0036] In the context of this invention, the term “oligonucleotide” refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

[0037] While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 50 nucleobases (i.e. from about 8 to about 50 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

[0038] As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2′, 3′ or 5′ hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3′ to 5′ phosphodiester linkage.

[0039] Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

[0040] Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates, 5′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and borano-phosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3′ to 3′, 5′ to 5′ or 2′ to 2′ linkage. Preferred oligonucleotides having inverted polarity comprise a single 3′ to 3′ linkage at the 3′-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

[0041] Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

[0042] Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

[0043] Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

[0044] In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991, 254, 1497-1500.

[0045] Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular —CH₂—NH—O—CH₂—, —CH₂—N(CH₃)—O—CH₂— [known as a methylene (methylimino) or MMI backbone], —CH₂—O—N(CH₃) —CH₂—, —CH₂— N(CH₃)—N(CH₃)—CH₂— and —O—N(CH₃)—CH₂—CH₂— [wherein the native phosphodiester backbone is represented as —O—P—O—CH₂—] of the above referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above referenced U.S. Pat. No. 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

[0046] Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2′ position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_(n)O]_(m)CH₃, O(CH₂)_(n)OCH₃, O(CH₂)_(n)NH₂, O(CH₂)_(n)CH₃, O(CH₂)_(n)ONH₂, and O(CH₂)_(n)ON[(CH₂)_(n)CH₃)]₂, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2′ position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, poly-alkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2′-methoxyethoxy (2′—O—CH₂CH₂OCH₃, also known as 2′—O-(2-methoxyethyl) or 2′-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2′-dimethylaminooxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2′-DMAOE, as described in examples hereinbelow, and 2′-dimethylamino-ethoxyethoxy (also known in the art as 2′-O-dimethylamino-ethoxyethyl or 2′-DMAEOE), i.e., 2′—O—CH₂—O—CH₂—N(CH₂)₂, also described in examples hereinbelow.

[0047] A further prefered modification includes Locked Nucleic Acids (LNAs) in which the 2′-hydroxyl group is linked to the 3′ or 4′ carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methelyne (—CH₂—)_(n) group bridging the 2′ oxygen atom and the 4′ carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

[0048] Other preferred modifications include 2′-methoxy (2′—O—CH₃), 2′-aminopropoxy (2′—OCH₂CH₂CH₂NH₂), 2′-allyl (2′—CH₂-CH═CH₂), 2′-O-allyl (2′-O—CH₂—CH═CH₂) and 2′-fluoro (2′-F). The 2′-modification may be in the arabino (up) position or ribo (down) position. A preferred 2′-arabino modification is 2′-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

[0049] Oligonucleotides may also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (—C≡—C—CH₃) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine(1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B. ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications.

[0050] Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and U.S. Pat. No. 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

[0051] Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugates groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent Application PCT/U.S. Pat. No. 92/09196, filed Oct. 23, 1992 the entire disclosure of which is incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937. Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in U.S. patent application Ser. No. 09/334,130 (filed Jun. 15, 1999) which is incorporated herein by reference in its entirety.

[0052] Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

[0053] It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. “Chimeric” antisense compounds or “chimeras,” in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

[0054] Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

[0055] The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

[0056] The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules. The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S. Pat. Nos. 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

[0057] The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

[0058] The term “prodrug” indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published Dec. 9, 1993 or in WO 94/26764 and U.S. Pat. No. 5,770,713 to Imbach et al.

[0059] The term “pharmaceutically acceptable salts” refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

[0060] Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., “Pharmaceutical Salts,” J. of Pharma Sci., 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a “pharmaceutical addition salt” includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

[0061] For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

[0062] The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of phospholipid scramblase 4 is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

[0063] The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding phospholipid scramblase 4, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding phospholipid scramblase 4 can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of phospholipid scramblase 4 in a sample may also be prepared.

[0064] The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2′-O-methoxyethyl modification are believed to be particularly useful for oral administration.

[0065] Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred topical formulations include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearolyphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C₁₋₁₀ alkyl ester (e.g. isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in U.S. patent application Ser. No. 09/315,298 filed on May 20, 1999 which is incorporated herein by reference in its entirety.

[0066] Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Prefered bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucholic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate, sodium glycodihydrofusidate. Prefered fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g. sodium). Also prefered are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly prefered combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Particularly preferred complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylamino-methylethylene P(TDAE), polyaminostyrene (e.g. p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcynaoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for oligonucleotides and their preparation are described in detail in U.S. patent application Ser. Nos. 08/886,829 (filed Jul. 1, 1997), 09/108,673 (filed Jul. 1, 1998), 09/256,515 (filed Feb. 23, 1999), 09/082,624 (filed May 21, 1998) and 09/315,298 (filed May 20, 1999) each of which is incorporated herein by reference in their entirety.

[0067] Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

[0068] Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

[0069] The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[0070] The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

[0071] In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

[0072] Emulsions

[0073] The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

[0074] Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

[0075] Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

[0076] Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

[0077] A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

[0078] Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

[0079] Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

[0080] The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

[0081] In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: Controlled Release of Drugs: Polymers and Aggregate Systems, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 271).

[0082] The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

[0083] Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

[0084] Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385-1390; Ritschel, Meth. Find. Exp. Clin. Pharmacol., 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385; Ho et al., J. Pharm. Sci., 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

[0085] Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories—surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of these classes has been discussed above.

[0086] Liposomes

[0087] There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term “liposome” means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

[0088] Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages in vivo.

[0089] In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

[0090] Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

[0091] Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

[0092] Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

[0093] Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

[0094] Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., Biochem. Biophys. Res. Commun., 1987, 147, 980-985)

[0095] Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., Journal of Controlled Release, 1992, 19, 269-274).

[0096] One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

[0097] Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., Journal of Drug Targeting, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., Antiviral Research, 1992, 18, 259-265).

[0098] Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. S. T. P. Pharma. Sci., 1994, 4, 6, 466).

[0099] Liposomes also include “sterically stabilized” liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_(M1), or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., FEBS Letters, 1987, 223, 42; Wu et al., Cancer Research, 1993, 53, 3765).

[0100] Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (Ann. N.Y. Acad. Sci., 1987, 507, 64) reported the ability of monosialoganglioside G_(M1), galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (Proc. Natl. Acad. Sci. U.S.A., 1988, 85, 6949). U.S. Pat. No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_(M1) or a galactocerebroside sulfate ester. U.S. Pat. No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

[0101] Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (Bull. Chem. Soc. Jpn., 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum et al. (FEBS Lett., 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Pat. Nos. 4,426,330 and 4,534,899). Klibanov et al. (FEBS Lett., 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (Biochimica et Biophysica Acta, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Pat. Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Pat. No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Pat. No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Pat. Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

[0102] A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Pat. No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Pat. No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

[0103] Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

[0104] Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the “head”) provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

[0105] If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

[0106] If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

[0107] If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

[0108] If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

[0109] The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

[0110] Penetration Enhancers

[0111] In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

[0112] Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

[0113] Surfactants: In connection with the present invention, surfactants (or “surface-active agents”) are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., J. Pharm. Pharmacol., 1988, 40, 252).

[0114] Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; El Hariri et al., J. Pharm. Pharmacol., 1992, 44, 651-654).

[0115] Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term “bile salts” includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucholic acid (sodium glucholate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Swinyard, Chapter 39 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Yamamoto et al., J. Pharm. Exp. Ther., 1992, 263, 25; Yamashita et al., J. Pharm. Sci., 1990, 79, 579-583).

[0116] Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, J. Chromatogr., 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines)(Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Buur et al., J. Control Rel., 1990, 14, 43-51).

[0117] Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., J. Pharm. Pharmacol., 1987, 39, 621-626).

[0118] Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

[0119] Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

[0120] Carriers

[0121] Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, “carrier compound” or “carrier” can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4′isothiocyano-stilbene-2,2′-disulfonic acid (Miyao et al., Antisense Res. Dev., 1995, 5, 115-121; Takakura et al., Antisense & Nucl. Acid Drug Dev., 1996, 6, 177-183).

[0122] Excipients

[0123] In contrast to a carrier compound, a “pharmaceutical carrier” or “excipient” is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

[0124] Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

[0125] Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

[0126] Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

[0127] Other Components

[0128] The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

[0129] Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

[0130] Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone; tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, The Merck Manual of Diagnosis and Therapy, 15th Ed. 1987, pp. 1206-1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide)i or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, The Merck Manual of Diagnosis and Therapy, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

[0131] In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

[0132] The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC₅ ₀s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

[0133] While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES Example 1 Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2′-alkoxy amidites

[0134] 2′-Deoxy and 2′-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham Mass. or Glen Research, Inc. Sterling Va.). Other 2′-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Pat. No. 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2′-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

[0135] Oligonucleotides containing 5-methyl-2′-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., Nucleic Acids Research, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling Va. or ChemGenes, Needham Mass.).

[0136] 2′-Fluoro amidites

[0137] 2′-Fluorodeoxyadenosine amidites

[0138] 2′-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., J. Med. Chem., 1993, 36, 831-841] and U.S. Pat. No. 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2′-deoxy-2′-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2′-alpha-fluoro atom is introduced by a S_(N)2-displacement of a 2′-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3′,5′-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5′-dimethoxytrityl-(DMT) and 5′-DMT-3′-phosphoramidite intermediates.

[0139] 2′-Fluorodeoxyguanosine

[0140] The synthesis of 2′-deoxy-2′-fluoroguanosine was accomplished using tetraisopropyldisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5′-DMT- and 5′-DMT-3′-phosphoramidites.

[0141] 2′-Fluorouridine

[0142] Synthesis of 2′-deoxy-2′-fluorouridine was accomplished by the modification of a literature procedure in which 2,2′-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5′-DMT and 5′-DMT-3′phosphoramidites.

[0143] 2′-Fluorodeoxycytidine

[0144] 2′-deoxy-2′-fluorocytidine was synthesized via amination of 2′-deoxy-2′-fluorouridine, followed by selective protection to give N4-benzoyl-2′-deoxy-2′-fluorocytidine. Standard procedures were used to obtain the 5′-DMT and 5′-DMT-3′phosphoramidites.

[0145] 2′-O-(2-Methoxyethyl) modified amidites

[0146] 2′-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., Helvetica Chimica Acta, 1995, 78, 486-504.

[0147] 2,2′-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

[0148] 5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenyl-carbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60° C. at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4° C.).

[0149] 2′-O-Methoxyethyl-5-methyluridine

[0150] 2,2′-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160° C. After heating for 48 hours at 155-160° C., the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

[0151] 2′-O-Methoxyethyl-5′-O-dimethoxytrityl-5-methyluridine

[0152] 2′-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2×500 mL of saturated NaHCO₃ and 2×500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

[0153] 3′-O-Acetyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyluridine

[0154] 2′-O-Methoxyethyl-5′-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35° C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2×200 mL of saturated sodium bicarbonate and 2×200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

[0155] 3′-O-Acetyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyl-4-triazoleuridine

[0156] A first solution was prepared by dissolving 3′-O-acetyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to −5° C. and stirred for 0.5 h using an overhead stirrer. POCl₃ was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10° C., and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1×300 mL of NaHCO₃ and 2×300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

[0157] 2′-O-Methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine

[0158] A solution of 3′-O-acetyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2×200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH₃ gas was added and the vessel heated to 100° C. for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

[0159] N4-Benzoyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine

[0160] 2′-O-Methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl₃ (700 mL) and extracted with saturated NaHCO₃ (2×300 mL) and saturated NaCl (2×300 mL), dried over MgSO₄ and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5% Et₃NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

[0161] N4-Benzoyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine-3′-amidite

[0162] N4-Benzoyl-2′-O-methoxyethyl-5′-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH₂Cl₂ (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO₃ (1×300 mL) and saturated NaCl (3×300 mL). The aqueous washes were back-extracted with CH₂Cl₂ (300 mL), and the extracts were combined, dried over MgSO₄ and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

[0163] 2′-O-(Aminooxyethyl) nucleoside amidites and 2′-O-(dimethylaminooxyethyl) nucleoside amidites

[0164] 2′-(Dimethylaminooxyethoxy) nucleoside amidites

[0165] 2′-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2′-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

[0166] 5′-O-tert-Butyldiphenylsilyl-O²-2′-anhydro-5-methyluridine

[0167] O²-2′-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0 g, 0.416 mmol), dimethylaminopyridine (0.66 g, 0.013 eq, 0.0054 mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8 g, 119.0 mL, 1.1 eq, 0.458 mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2×1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600 mL) and the solution was cooled to −10° C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3×200 mL) and dried (40° C., 1 mm Hg, 24 h) to 149 g (74.8%) of white solid. TLC and NMR were consistent with pure product.

[0168] 5′-O-tert-Butyldiphenylsilyl-2′-O-(2-hydroxyethyl)-5-methyluridine

[0169] In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5′-O-tert-Butyldiphenylsilyl-O²-2′-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160° C. was reached and then maintained for 16 h (pressure <100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1 mm Hg) in a warm water bath (40-100° C.) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2 kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84 g, 50%), contaminated starting material (17.4 g) and pure reusable starting material 20 g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

[0170] 2′-O-([2-phthalimidoxy)ethyl]-5′-t-butyldiphenylsilyl-5-methyluridine

[0171] 5′-O-tert-Butyldiphenylsilyl-2′-O-(2-hydroxyethyl)-5-methyluridine (20 g, 36.98 mmol) was mixed with triphenylphosphine (11.63 g, 44.36 mmol) and N-hydroxyphthalimide (7.24 g, 44.36 mmol). It was then dried over P₂O₅ under high vacuum for two days at 40° C. The reaction mixture was flushed with argon and dry THF (369.8 mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98 mL, 44.36 mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2′-O-([2-phthalimidoxy)ethyl]-5′-t-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

[0172] 5′-O-tert-butyldiphenylsilyl-2′-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

[0173] 2′-O-([2-phthalimidoxy)ethyl]-5′-t-butyldiphenylsilyl-5-methyluridine (3.1 g, 4.5 mmol) was dissolved in dry CH₂Cl₂ (4.5 mL) and methylhydrazine (300 mL, 4.64 mmol) was added dropwise at −10° C. to 0° C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH₂Cl₂ and the combined organic phase was washed with water, brine and dried over anhydrous Na₂SO₄. The solution was concentrated to get 2′-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5 mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was strirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5′-O-tert-butyldiphenylsilyl-2′-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%).

[0174] 5′-O-tert-Butyldiphenylsilyl-2′-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

[0175] 5′-O-tert-butyldiphenylsilyl-2′-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77 g, 3.12 mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6 mL). Sodium cyanoborohydride (0.399, 6.13 mmol) was added to this solution at 10° C. under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10° C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10 mL) was added and extracted with ethyl acetate (2×20 mL). Ethyl acetate phase was dried over anhydrous Na₂SO₄, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6 mL). Formaldehyde (20% w/w, 30 mL, 3.37 mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10° C. in an ice bath, sodium cyanoborohydride (0.39 g, 6.13 mmol) was added and reaction mixture stirred at 10° C. for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO₃ (25 mL) solution was added and extracted with ethyl acetate (2×25 mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH₂Cl₂ to get 5′-O-tert-butyldiphenylsilyl-2′-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6 g, 80%).

[0176] 2′-O-(dimethylaminooxyethyl)-5-methyluridine

[0177] Triethylamine trihydrofluoride (3.91 mL, 24.0 mmol) was dissolved in dry THF and triethylamine (1.67 mL, 12 mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5′-O-tert-butyldiphenylsilyl-2′-O-[N,N-dimethylaminooxyethyl]-5-methyluridine (1.40 g, 2.4 mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH₂Cl₂ to get 2′-O-(dimethylaminooxyethyl)-5-methyluridine (766 mg, 92.5%).

[0178] 5′-O-DMT-2′-O-(dimethylaminooxyethyl)-5-methyluridine

[0179] 2′-O-(dimethylaminooxyethyl)-5-methyluridine (750 mg, 2.17 mmol) was dried over P₂O₅ under high vacuum overnight at 40° C. It was then co-evaporated with anhydrous pyridine (20 mL). The residue obtained was dissolved in pyridine (11 mL) under argon atmosphere. 4-dimethylaminopyridine (26.5 mg, 2.60 mmol), 4,4′-dimethoxytrityl chloride (880 mg, 2.60 mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH₂Cl₂ (containing a few drops of pyridine) to get 5′-O-DMT-2′-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13 g, 80%).

[0180] 5′-O-DMT-2′-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

[0181] 5′-O-DMT-2′-O-(dimethylaminooxyethyl)-5-methyluridine (1.08 g, 1.67 mmol) was co-evaporated with toluene (20 mL). To the residue N,N-diisopropylamine tetrazonide (0.29 g, 1.67 mmol) was added and dried over P₂O₅ under high vacuum overnight at 40° C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4 mL) and 2-cyanoethyl-N,N,N¹, N¹-tetraisopropylphosphoramidite (2.12 mL, 6.08 mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70 mL) and washed with 5% aqueous NaHCO₃ (40 mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5′-O-DMT-2′-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04 g, 74.9%).

[0182] 2′-(Aminooxyethoxy) nucleoside amidites

[0183] 2′-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2′-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

[0184] N2-isobutyryl-6-O-diphenylcarbamoyl-2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

[0185] The 2′-O-aminooxyethyl guanosine analog may be obtained by selective 2′-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2′-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3′-O-isomer. 2′-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2′-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2′-O-(2-hydroxyethyl)-5′-O-(4,4′-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2′-O-([2-phthalmidoxy]ethyl)-5′-O-(4,4′-dimethoxytrityl)guanosine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

[0186] 2′-dimethylaminoethoxyethoxy (2′-DMAEOE) nucleoside amidites

[0187] 2′-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2′-O-dimethylaminoethoxyethyl, i.e., 2′—O—CH₂—O—CH₂—N(CH₂)₂, or 2′-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

[0188] 2′-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

[0189] 2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetra-hydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O-²-,2′-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155° C. for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3×200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

[0190] 5′-O-dimethoxytrityl-2′-O-[2(2-N,N-dimethylaminoethoxy) ethyl)]-5-methyl uridine

[0191] To 0.5 g (1.3 mmol) of 2′-O-[2(2-N,N-dimethylamino-ethoxy)ethyl)]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH₂Cl₂ (2×200 mL) . The combined CH₂Cl₂ layers are washed with saturated NaHCO₃ solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH:CH₂Cl₂:Et₃N (20:1, v/v, with 1% triethylamine) gives the title compound.

[0192] 5′-O-Dimethoxytrityl-2′-O-[2(2-N,N-dimethylaminoethoxy)-ethyl)]-5-methyl uridine-3′-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

[0193] Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5′-O-dimethoxytrityl-2′-O-[2(2-N,N-dimethylaminoethoxy)ethyl)]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH₂Cl₂ (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

Example 2 Oligonucleotide synthesis

[0194] Unsubstituted and substituted phosphodiester (P═O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

[0195] Phosphorothioates (P═S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55° C. (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution.

[0196] Phosphinate oligonucleotides are prepared as described in U.S. Pat. No. 5,508,270, herein incorporated by reference.

[0197] Alkyl phosphonate oligonucleotides are prepared as described in U.S. Pat. No. 4,469,863, herein incorporated by reference.

[0198] 3′-Deoxy-3′-methylene phosphonate oligonucleotides are prepared as described in U.S. Pat. Nos. 5,610,289 or 5,625,050, herein incorporated by reference.

[0199] Phosphoramidite oligonucleotides are prepared as described in U.S. Pat. No. 5,256,775 or U.S. Pat. No. 5,366,878, herein incorporated by reference.

[0200] Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/U.S. Pat. No. 94/00902 and PCT/U.S. Pat. No. 93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

[0201] 3′-Deoxy-3′-amino phosphoramidate oligonucleotides are prepared as described in U.S. Pat. No. 5,476,925, herein incorporated by reference.

[0202] Phosphotriester oligonucleotides are prepared as described in U.S. Pat. No. 5,023,243, herein incorporated by reference.

[0203] Borano phosphate oligonucleotides are prepared as described in U.S. Pat. Nos. 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3 Oligonucleoside Synthesis

[0204] Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethyl-hydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P═O or P═S linkages are prepared as described in U.S. Pat. Nos. 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

[0205] Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Pat. Nos. 5,264,562 and 5,264,564, herein incorporated by reference.

[0206] Ethylene oxide linked oligonucleosides are prepared as described in U.S. Pat. No. 5,223,618, herein incorporated by reference.

Example 4 PNA Synthesis

[0207] Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, Bioorganic & Medicinal Chemistry, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Pat. Nos. 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5 Synthesis of Chimeric Oligonucleotides

[0208] Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the “gap” segment of linked nucleosides is positioned between 5′ and 3′ “wing” segments of linked nucleosides and a second “open end” type wherein the “gap” segment is located at either the 3′ or the 5′ terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as “gapmers” or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as “hemimers” or “wingmers”.

[0209] [2′-O-Me]--[2′-deoxy]--[2′-O-Me] Chimeric Phosphorothioate Oligonucleotides

[0210] Chimeric oligonucleotides having 2′-O-alkyl phosphorothioate and 2′-deoxy phosphorothioate oligo-nucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2′-deoxy-5′-dimethoxytrityl-3′-O-phosphor-amidite for the DNA portion and 5′-dimethoxytrityl-2′-O-methyl-3′-O-phosphoramidite for 5′ and 3′ wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2′-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2′ positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to ½ volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[0211] [2′-O-(2-Methoxyethyl)]--[2′-deoxy]--[2′-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

[0212] [2′-O-(2-methoxyethyl)]--[2′-deoxy]--[-2′-O-(methoxy-ethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2′-O-methyl chimeric oligonucleotide, with the substitution of 2′-O-(methoxyethyl) amidites for the 2′-O-methyl amidites.

[0213] [2′-O-(2-Methoxyethyl)Phosphodiester]--[2′-deoxy Phosphorothioate]--[2′-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

[0214] [2′-O-(2-methoxyethyl phosphodiester]--[2′-deoxy phosphorothioate]--[2′-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2′-O-methyl chimeric oligonucleotide with the substitution of 2′-O-(methoxyethyl) amidites for the 2′-O-methyl methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

[0215] Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to U.S. Pat. No. 5,623,065, herein incorporated by reference.

Example 6 Oligonucleotide Isolation

[0216] After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55° C. for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ³¹P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., J. Biol. Chem. 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7 Oligonucleotide Synthesis—96 Well Plate Format

[0217] Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, Calif., or Pharmacia, Piscataway, N.J.). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.

[0218] Oligonucleotides were cleaved from support and deprotected with concentrated NH₄OH at elevated temperature (55-60° C.) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8 Oligonucleotide Analysis—96 Well Plate Format

[0219] The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

Example 9 Cell culture and oligonucleotide treatment

[0220] The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 4 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, Ribonuclease protection assays, or RT-PCR.

[0221] T-24 cells:

[0222] The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, Calif.) supplemented with 10% fetal calf serum ((Invitrogen Corporation, Carlsbad, Calif.), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

[0223] For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

[0224] A549 cells:

[0225] The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, Calif.) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, Calif.), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

[0226] NHDF cells:

[0227] Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, Md.). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, Md.) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

[0228] HEK cells:

[0229] Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, Md.). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville, Md.) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

[0230] Treatment with antisense compounds:

[0231] When cells reached 70% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100 μL OPTI-MEM™-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, Calif.) and then treated with 130 μL of OPTI-MEM™-1 containing 3.75 μg/mL LIPOFECTIN™ (Invitrogen Corporation, Carlsbad, Calif.) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

[0232] The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, TCCGTCATCGCTCCTCAGGG, SEQ ID NO: 1, a 2′-O-methoxyethyl gapmer (2′-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, ATGCATTCTGCCCCCAAGGA, SEQ ID NO: 2, a 2′-O-methoxyethyl gapmer (2′-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

Example 10 Analysis of oligonucleotide inhibition of phospholipid scramblase 4 expression

[0233] Antisense modulation of phospholipid scramblase 4 expression can be assayed in a variety of ways known in the art. For example, phospholipid scramblase 4 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. The preferred method of RNA analysis of the present invention is the use of total cellular RNA as described in other examples herein. Methods of RNA isolation are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, Calif. and used according to manufacturer's instructions.

[0234] Protein levels of phospholipid scramblase 4 can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to phospholipid scramblase 4 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, Mich.), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

[0235] Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

Example 11 Poly(A)+ mRNA isolation

[0236] Poly(A)+ mRNA was isolated according to Miura et al., Clin. Chem., 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μL cold PBS. 60 μL lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μL of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine Calif.). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μL of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μL of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70° C. was added to each well, the plate was incubated on a 90° C. hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

[0237] Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12 Total RNA Isolation

[0238] Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia, Calif.) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μL cold PBS. 150 μL Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 150 μL of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 1 minute. 500 μL of Buffer RW1 was added to each well of the RNEASY 96™ plate and incubated for 15 minutes and the vacuum was again applied for 1 minute. An additional 500 μL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum was applied for 2 minutes. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 90 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 3 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 170 μL water into each well, incubating 1 minute, and then applying the vacuum for 3 minutes.

[0239] The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia Calif.). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13 Real-time Quantitative PCR Analysis of phospholipid scramblase 4 mRNA Levels

[0240] Quantitation of phospholipid scramblase 4 mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™7700 Sequence Detection System (PE-Applied Biosystems, Foster City, Calif.) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., FAM, obtained from either Operon Technologies Inc., Alameda, Calif. or Integrated DNA Technologies Inc., Coralville, Iowa) is attached to the 5′ end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, Calif. or Integrated DNA Technologies Inc., Coralville, Iowa) is attached to the 3′ end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3′ quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5′-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

[0241] Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be “multiplexed” with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only (“single-plexing”), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

[0242] PCR reagents were obtained from Invitrogen, Carlsbad, Calif.. RT-PCR reactions were carried out by adding 20 μL PCR cocktail (2.5× PCR buffer (-MgCl2), 6.6 mM MgCl2, 375 μM each of dATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNAse inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5× ROX dye) to 96 well plates containing 30 μL total RNA solution. The RT reaction was carried out by incubation for 30 minutes at 48° C. Following a 10 minute incubation at 95° C. to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95° C. for 15 seconds (denaturation) followed by 60° C. for 1.5 minutes (annealing/extension).

[0243] Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreenTM (Molecular Probes, Inc. Eugene, Oreg.). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreenTM RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreenTM are taught in Jones, L. J., et al, Analytical Biochemistry, 1998, 265, 368-374.

[0244] In this assay, 170 μL of RiboGreenTM working reagent (RiboGreenTM reagent diluted 1:350 in 10 mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30 μL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 480 nm and emission at 520 nm.

[0245] Probes and primers to human phospholipid scramblase 4 were designed to hybridize to a human phospholipid scramblase 4 sequence, using published sequence information (GenBank accession number NM_(—)020353.1, incorporated herein as SEQ ID NO: 3). For human phospholipid scramblase 4 the PCR primers were:

[0246] forward primer: GTGTACAGCATCCAAAATGAGAAGA (SEQ ID NO: 4)

[0247] reverse primer: GAATCTGAACCACAGCCATAGGTT (SEQ ID NO: 5) and

[0248] the PCR probe was: FAM-TGTGATGAGAGTTCGTGGGCCATGC-TAMRA (SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye. For human GAPDH the PCR primers were:

[0249] forward primer: GAAGGTGAAGGTCGGAGTC(SEQ ID NO: 7)

[0250] reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 8) and the

[0251] PCR probe was: 5′ JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA 3′ (SEQ ID NO: 9) where JOE (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye.

Example 14 Northern blot analysis of phospholipid scramblase 4 mRNA levels

[0252] Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST “B” Inc., Friendswood, Tex.). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, Ohio). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, N.J.) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST “B” Inc., Friendswood, Tex.). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, Calif.) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, Calif.) using manufacturer's recommendations for stringent conditions.

[0253] To detect human phospholipid scramblase 4, a human phospholipid scramblase 4 specific probe was prepared by PCR using the forward primer GTGTACAGCATCCAAAATGAGAAGA (SEQ ID NO: 4) and the reverse primer GAATCTGAACCACAGCCATAGGTT (SEQ ID NO: 5). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, Calif.).

[0254] Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, Calif.). Data was normalized to GAPDH levels in untreated controls.

Example 15 Antisense inhibition of human phospholipid scramblase 4 expression by chimeric phosphorothioate oligonucleotides having 2′-MOE wings and a deoxy gap

[0255] In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human phospholipid scramblase 4 RNA, using published sequences (GenBank accession number NM_(—)020353.1, representing the main mRNA of phospholipid scramblase 4 (PLSCR4), incorporated herein as SEQ ID NO: 3; GenBank accession number AA359989.1, representing a partial sequence of phospholipid scramblase 4, incorporated herein as SEQ ID NO: 10; GenBank accession number BG184242.1, representing a phospholipid scramblase 4 variant herein designated PLSCR4B, incorporated herein as SEQ ID NO: 11; GenBank accession number BG705538.1, representing a partial sequence of phospholipid scramblase 4, incorporated herein as SEQ ID NO: 12; GenBank accession number BG719151.1, representing a partial sequence of phospholipid scramblase 4, incorporated herein as SEQ ID NO: 13; and residues 610001-714000 of GenBank accession number NT_(—)005775, representing a partial genomic sequence of phospholipid scramblase 4, incorporated herein as SEQ ID NO: 14). The oligonucleotides are shown in Table 1. “Target site” indicates the first (5′-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human phospholipid scramblase 4 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, “N.D.” indicates “no data”. TABLE 1 Inhibition of human phospholipid scramblase 4 mRNA levels by chimeric phosphorothioate oligonucleotides having 2′ -MOE wings and a deoxy gap TARGET SEQ ID TARGET SEQ ID ISIS # REGION NO SITE SEQUENCE % INHIB NO 196283 5′ UTR 3 2 aggatttttcaagttataaa 0 15 196284 5′ UTR 3 59 tctagttgtactggcagagg 46 16 196285 5′ UTR 3 108 atccgcctgccccgcagaat 6 17 196286 Start 3 137 acacctgacattttgaagaa 20 18 Codon 196287 Coding 3 322 gttgctgtggactgtagtat 35 19 196288 Coding 3 350 actggctggtacaaagggaa 2 20 196289 Coding 3 430 ctggcatccatgttattgga 37 21 196290 Coding 3 490 tgttgtccaactgaactaag 19 22 196291 Coding 3 523 tttccagaggctcaaaatgc 27 23 196292 Coding 3 583 ccatctggtctgagttgttt 53 24 196293 Coding 3 608 tctgtgtcttcggttacaac 51 25 196294 Coding 3 624 attcctggtaaagtcatctg 30 26 196295 Coding 3 629 taggcattcctggtaaagtc 37 27 196296 Coding 3 634 tccgataggcattcctggta 40 28 196297 Coding 3 656 cggaggacgaagggccttag 33 29 196298 Coding 3 719 cagcaggtgcatctgaaggg 21 30 196299 Coding 3 726 gaagcaacagcaggtgcatc 26 31 196300 Coding 3 760 gcacctccagctcttgtctg 8 32 196301 Coding 3 794 gcaacaaagccaatggtgac 35 33 196302 Coding 3 806 ttccaatgttccgcaacaaa 16 34 196303 Coding 3 836 ttttggatgctgtacaccgc 52 35 196304 Coding 3 922 gggatttgacctcaaaaaca 6 36 196305 Coding 3 958 tccggataatactgccgatg 36 37 196306 Coding 3 1021 ctagtgggaagtgaatgtca 43 38 196307 Coding 3 1031 acatccaggtctagtgggaa 48 39 196308 Coding 3 1042 ctttcatcttcacatccagg 27 40 196309 Coding 3 1077 gaagtcaatgaggaagcaag 21 41 196310 Coding 3 1082 tacatgaagtcaatgaggaa 8 42 196311 Stop 3 1124 gtgtctctctatcttgaacg 38 43 Codon 196312 3′ UTR 3 1192 tgagtgctgactgtaagccc 60 44 196313 3′ UTR 3 1270 gcaagcccactctcagctgt 46 45 196314 3′ UTR 3 1292 cacacttttagattgtgttc 40 46 196315 3′ UTR 3 1350 atgagtcacagcttttcagg 55 47 196316 3′ UTR 3 1361 ttactgggttaatgagtcac 55 48 196317 3′ UTR 3 1476 ccaacaaagtctgctctaaa 24 49 196318 3′ UTR 3 1501 gggatagaagccaggttatt 17 50 196319 3′ UTR 3 1633 ttcttagtgcaagaaaacat 40 51 196320 3′ UTR 3 1640 tagtaccttcttagtgcaag 53 52 196321 3′ UTR 3 1785 gatcatccatgccagtgaat 17 53 196322 3′ UTR 3 1790 ctcctgatcatccatgccag 22 54 196323 3′ UTR 3 1879 tgtctctaagttgctcagag 39 55 196324 3′ UTR 3 1936 tgtacaaatgtattatgtat 16 56 196325 3′ UTR 3 1949 gttatgaattaaatgtacaa 0 57 196326 3′ UTR 3 1967 catctgtgaccaagagacgt 40 58 196327 3′ UTR 3 1985 cttattttatatataaggca 4 59 196328 3′ UTR 3 2126 ttcttaccatgagaacagca 24 60 196329 3′ UTR 3 2176 atagtgctacataaaatgtc 14 61 196330 3′ UTR 3 2201 ggaatttgtcgctttcactt 41 62 196331 3′ UTR 3 2224 gcaaagcagtattaagcagc 53 63 196332 3′ UTR 3 2249 gtatctatcatgtcaataaa 14 64 196333 3′ UTR 3 2328 atttactggcatgctgtaga 50 65 196334 3′ UTR 3 2464 atgcagtccatatgcaggta 66 66 196335 3′ UTR 3 2737 tattttagaaagcagcaact 21 67 196336 3′ UTR 3 2759 ctttcaaatataaggcaatt 10 68 196337 3′ UTR 3 2773 cgattgcaatggcactttca 50 69 196338 3′ UTR 3 2809 atcagacatcattataggaa 20 70 196339 3′ UTR 3 2913 atgatgcagcaggttttgga 43 71 196340 3′ UTR 3 2955 aaatatcacgtcttatgcta 35 72 196341 3′ UTR 3 2961 aattaaaaatatcacgtctt 21 73 196342 3′ UTR 3 3058 tagaaatcatgtgaattgta 11 74 196343 3′ UTR 3 3095 cgatcaattttacacaacaa 51 75 196344 3′ UTR 3 3128 acaaattccagagaatttgt 4 76 196345 Genomic 13 97 tttcaagttataaacaaagt 8 77 196346 Genomic 13 217 tccaattaatccgcctgccc 1 78 196347 Exon: 11 430 gcacctccagtttccagagg 18 79 Exon Junction 196348 Genomic 11 641 catggttggttaatatgagt 0 80 196349 Genomic 11 652 ccagatctttccatggttgg 40 81 196350 Exon: 10 214 ccaattaatcctgcgagtgg 4 82 Exon Junction 196351 Genomic 12 155 ccctgggcaggaaactgctc 42 83 196352 Genomic 12 233 gaaacccaatcaagcgagac 18 84 196353 Intron: 14 720 caagcgagacctgtcacgca 17 85 Exon Junction 196354 Exon: 14 801 gcgtttttacctgcgagtgg 47 86 Intron Junction 196355 Intron 2 14 4802 aatatcaggtgtctcctttt 31 87 196356 Intron 2 14 31277 ttaaattgctgatggctggg 0 88 196357 Intron 2 14 72992 tggtaagttctaggagagtc 22 89 196358 Intron 5 14 89936 tactcttgtgctttggagac 41 90 196359 Exon: 14 94409 ttatacatactttccagagg 31 91 Intron Junction 196360 Exon: 14 100320 gaaggcttacaatgaggaag 36 92 Intron Junction

[0256] As shown in Table 1, SEQ ID NOs 16, 19, 21, 24, 25, 26, 27, 28, 29, 33, 35, 37, 38, 39, 43, 44, 45, 46, 47, 48, 51, 52, 55, 58, 62, 63, 65, 66, 69, 71, 72, 75, 81, 83, 86, 87, 90, 91 and 92 demonstrated at least 30% inhibition of human phospholipid scramblase 4 expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as “active sites” and are therefore preferred sites for targeting by compounds of the present invention.

Example 16 Western blot analysis of phospholipid scramblase 4 protein levels

[0257] Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 μl/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to phospholipid scramblase 4 is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale Calif.).

Example 17 Targeting of individual oligonucleotides to specific variants of MHC class II transactivator

[0258] It is advantageous to selectively inhibit the expression of one or more variants of phospholipid scramblase 4. Consequently, in one embodiment of the present invention are oligonucleotides that selectively target, hybridize to, and specifically inhibit one or more, but fewer than all of the variants of phospholipid scramblase 4. A summary of the target sites of the variants is shown in Table 2 and includes Genbank accession number NM_(—)020353.1, representing the phospholipid scramblase 4 variant PLSCR4, incorporated herein as SEQ ID NO: 3; and Genbank accession number BG184242.1, representing the phospholipid scramblase 4 variant PLSCR4B, incorporated herein as SEQ ID NO: 11. TABLE 2 Targeting of individual oligonucleotides to specific variants of phospholipid scramblase 4 OLIGO SEQ VARIANT ISIS # ID NO. TARGET SITE VARIANT SEQ ID NO. 196283 15 2 PLSCR4 3 196284 16 59 PLSCR4 3 196285 17 108 PLSCR4 3 196292 24 583 PLSCR4 3 196293 25 608 PLSCR4 3 196294 26 624 PLSCR4 3 196296 28 634 PLSCR4 3 196297 29 656 PLSCR4 3 196298 30 719 PLSCR4 3 196299 31 726 PLSCR4 3 196300 32 760 PLSCR4 3 196301 33 794 PLSCR4 3 196302 34 806 PLSCR4 3 196304 36 922 PLSCR4 3 196305 37 958 PLSCR4 3 196306 38 1021 PLSCR4 3 196307 39 1031 PLSCR4 3 196308 40 1042 PLSCR4 3 196309 41 1077 PLSCR4 3 196310 42 1082 PLSCR4 3 196311 43 1124 PLSCR4 3 196312 44 1192 PLSCR4 3 196313 45 1270 PLSCR4 3 196314 46 1292 PLSCR4 3 196315 47 1350 PLSCR4 3 196316 48 1361 PLSCR4 3 196317 49 1476 PLSCR4 3 196318 50 1501 PLSCR4 3 196319 51 1633 PLSCR4 3 196320 52 1640 PLSCR4 3 196321 53 1785 PLSCR4 3 196322 54 1790 PLSCR4 3 196323 55 1879 PLSCR4 3 196324 56 1936 PLSCR4 3 196325 57 1949 PLSCR4 3 196326 58 1967 PLSCR4 3 196327 59 1985 PLSCR4 3 196328 60 2126 PLSCR4 3 196329 61 2176 PLSCR4 3 196330 62 2201 PLSCR4 3 196331 63 2224 PLSCR4 3 196332 64 2249 PLSCR4 3 196333 65 2328 PLSCR4 3 196334 66 2464 PLSCR4 3 196335 67 2737 PLSCR4 3 196336 68 2759 PLSCR4 3 196337 69 2773 PLSCR4 3 196338 70 2809 PLSCR4 3 196339 71 2913 PLSCR4 3 196340 72 2955 PLSCR4 3 196341 73 2961 PLSCR4 3 196342 74 3058 PLSCR4 3 196343 75 3095 PLSCR4 3 196344 76 3128 PLSCR4 3 196346 78 116 PLSCR4 3 196347 79 430 PLSCR4B 11 196348 80 641 PLSCR4B 11 196349 81 652 PLSCR4B 11

[0259]

1 92 1 20 DNA Artificial Sequence Antisense Oligonucleotide 1 tccgtcatcg ctcctcaggg 20 2 20 DNA Artificial Sequence Antisense Oligonucleotide 2 atgcattctg cccccaagga 20 3 3206 DNA Homo sapiens CDS (146)...(1135) 3 gtttataact tgaaaaatcc tctccgtctc ccttccctgc ctcctttcct ttccctttcc 60 tctgccagta caactagacc cggcgtctgg cgtccccggt gcccagcatt ctgcggggca 120 ggcggattaa ttggaattct tcaaa atg tca ggt gtg gta ccc aca gcc cct 172 Met Ser Gly Val Val Pro Thr Ala Pro 1 5 gaa cag cct gca ggt gaa atg gaa aat caa aca aaa cca cca gat cca 220 Glu Gln Pro Ala Gly Glu Met Glu Asn Gln Thr Lys Pro Pro Asp Pro 10 15 20 25 agg cct gat gct cct cct gaa tac agt tct cat ttt tta cca gga ccc 268 Arg Pro Asp Ala Pro Pro Glu Tyr Ser Ser His Phe Leu Pro Gly Pro 30 35 40 cct gga aca gct gtc cct cca cct act ggc tac cca gga ggc ttg cct 316 Pro Gly Thr Ala Val Pro Pro Pro Thr Gly Tyr Pro Gly Gly Leu Pro 45 50 55 atg gga tac tac agt cca cag caa ccc agt acc ttc cct ttg tac cag 364 Met Gly Tyr Tyr Ser Pro Gln Gln Pro Ser Thr Phe Pro Leu Tyr Gln 60 65 70 cca gtt ggt ggt atc cat cct gtc cgg tat cag cct ggc aaa tat cct 412 Pro Val Gly Gly Ile His Pro Val Arg Tyr Gln Pro Gly Lys Tyr Pro 75 80 85 atg cca aat cag tct gtt cca ata aca tgg atg cca ggg cca act cct 460 Met Pro Asn Gln Ser Val Pro Ile Thr Trp Met Pro Gly Pro Thr Pro 90 95 100 105 atg gca aac tgc cct cct ggt ctg gaa tac tta gtt cag ttg gac aac 508 Met Ala Asn Cys Pro Pro Gly Leu Glu Tyr Leu Val Gln Leu Asp Asn 110 115 120 ata cat gtt ctt cag cat ttt gag cct ctg gaa atg atg aca tgt ttt 556 Ile His Val Leu Gln His Phe Glu Pro Leu Glu Met Met Thr Cys Phe 125 130 135 gaa act aat aat aga tat gat att aaa aac aac tca gac cag atg gtt 604 Glu Thr Asn Asn Arg Tyr Asp Ile Lys Asn Asn Ser Asp Gln Met Val 140 145 150 tac gtt gta acc gaa gac aca gat gac ttt acc agg aat gcc tat cgg 652 Tyr Val Val Thr Glu Asp Thr Asp Asp Phe Thr Arg Asn Ala Tyr Arg 155 160 165 aca cta agg ccc ttc gtc ctc cgg gtc act gat tgt atg ggc cga gaa 700 Thr Leu Arg Pro Phe Val Leu Arg Val Thr Asp Cys Met Gly Arg Glu 170 175 180 185 atc atg aca atg cag aga ccc ttc aga tgc acc tgc tgt tgc ttc tgt 748 Ile Met Thr Met Gln Arg Pro Phe Arg Cys Thr Cys Cys Cys Phe Cys 190 195 200 tgc ccc tct gcc aga caa gag ctg gag gtg cag tgt cct cct ggt gtc 796 Cys Pro Ser Ala Arg Gln Glu Leu Glu Val Gln Cys Pro Pro Gly Val 205 210 215 acc att ggc ttt gtt gcg gaa cat tgg aac ctg tgc agg gcg gtg tac 844 Thr Ile Gly Phe Val Ala Glu His Trp Asn Leu Cys Arg Ala Val Tyr 220 225 230 agc atc caa aat gag aag aaa gaa aat gtg atg aga gtt cgt ggg cca 892 Ser Ile Gln Asn Glu Lys Lys Glu Asn Val Met Arg Val Arg Gly Pro 235 240 245 tgc tca acc tat ggc tgt ggt tca gat tct gtt ttt gag gtc aaa tcc 940 Cys Ser Thr Tyr Gly Cys Gly Ser Asp Ser Val Phe Glu Val Lys Ser 250 255 260 265 ctt gat ggc ata tcc aac atc ggc agt att atc cgg aag tgg aat ggt 988 Leu Asp Gly Ile Ser Asn Ile Gly Ser Ile Ile Arg Lys Trp Asn Gly 270 275 280 ttg tta tca gca atg gca gat gct gac cat ttt gac att cac ttc cca 1036 Leu Leu Ser Ala Met Ala Asp Ala Asp His Phe Asp Ile His Phe Pro 285 290 295 cta gac ctg gat gtg aag atg aaa gcc atg att ttt gga gct tgc ttc 1084 Leu Asp Leu Asp Val Lys Met Lys Ala Met Ile Phe Gly Ala Cys Phe 300 305 310 ctc att gac ttc atg tat ttt gaa aga tct cca cca caa cgt tca aga 1132 Leu Ile Asp Phe Met Tyr Phe Glu Arg Ser Pro Pro Gln Arg Ser Arg 315 320 325 tag agagacacag caagccatca actatggtta attttgaaaa atggaaaagt 1185 tggattgggc ttacagtcag cactcagtta tttgcaagtg tatttctttg ctttgtagag 1245 tatttttatt gggtgttaac tttgacagct gagagtgggc ttgcaagaac acaatctaaa 1305 agtgtgtttc aattgagtat ctctctagta gaataggagt tcatcctgaa aagctgtgac 1365 tcattaaccc agtaaacata tacaaagtaa gcttaaaaca ctataaacat gagataaggg 1425 aaaatgaatc cagagttctc atattaatag gtagtgaaac aataaggctt tttagagcag 1485 actttgttgg cataaaataa cctggcttct atccctaacc ctttcctacc tttcctctcc 1545 gtcaacatgt cctcatactg aagacaaact tgtttcaatg atagtcttca tttttaaaaa 1605 caaaaaggca ggcagacaga aataatgatg ttttcttgca ctaagaaggt actacttgta 1665 cacatatatc aaaacctcat tctgcaaagt ttttgaaggt ttcaatggga aatttgattt 1725 tattacaaaa taaaacattt tttaatgtta aagtttatat attccatgct tgttttctca 1785 ttcactggca tggatgatca ggagctgcct atatatgaag gcagaatcag actatcagga 1845 aaggagctgg ccagggccac agccagtcaa gatctctgag caacttagag acattggtgt 1905 cattatatga agcttgcatt taatacattt atacataata catttgtaca tttaattcat 1965 aacgtctctt ggtcacagat gccttatata taaaataagt tgccagatct ctaagattgc 2025 ctagtacacc tttgtatctc atttgatgtg atacccagaa gagatcattg ttttttgttt 2085 ttgtttttgt ttttttcaag aagatccttc gtgatcacca tgctgttctc atggtaagaa 2145 ctggagttat gtttttaaat ttgaaaatat gacattttat gtagcactat ataaaaagtg 2205 aaagcgacaa attccaccgc tgcttaatac tgctttgctt ctttttattg acatgataga 2265 tacatatgta tctacacaga gtaataataa taaaacacag taaacattct atttctctat 2325 ggtctacagc atgccagtaa ataatatgta ggaccaataa taaattatca attacacatt 2385 tttgtgttaa ctaattaaaa gcatagtgta taagtgagta cactctaatt aacttgcttc 2445 tgttgcactt tagttttcta cctgcatatg gactgcattt ttttttttaa cacagtcagt 2505 atgtagaatg ggatgtattc ttctgctgct gcttattaaa taaagaaagc ctgagtgttc 2565 ttagatgggg ttattctgag atgagggtct tagcctacag ttctttttga aatgaaaggt 2625 gctttgtttt ttaattatat tcatcttttc agggtaaatt tgtttttctg agtttctcgt 2685 aatgctcatt tttacatgct gctactagct ttttttttta aaaaaagtaa aagttgctgc 2745 tttctaaaat attaattgcc ttatatttga aagtgccatt gcaatcgtaa gtagactatg 2805 tatttcctat aatgatgtct gatatttaaa taggaaatca gacaaacaat attcagaaag 2865 tttaagcata taaacttttt atttttaact tgcctagatc cctgtattcc aaaacctgct 2925 gcatcataat aaatatatct atatatattt agcataagac gtgatatttt taatttcttt 2985 tttaaaaaat tatatttgtc tcttagagtt aaaattttct ttatataata ttgtcatatg 3045 tcatagtttt aatacaattc acatgatttc tatgtttctt aatgatattt tgttgtgtaa 3105 aattgatcgg attgattaaa aaacaaattc tctggaattt gtgcgttcat gctttttcgt 3165 attctttatg gcttttaaat aaatatacaa tggttaatag t 3206 4 25 DNA Artificial Sequence PCR Primer 4 gtgtacagca tccaaaatga gaaga 25 5 24 DNA Artificial Sequence PCR Primer 5 gaatctgaac cacagccata ggtt 24 6 25 DNA Artificial Sequence PCR Probe 6 tgtgatgaga gttcgtgggc catgc 25 7 19 DNA Artificial Sequence PCR Primer 7 gaaggtgaag gtcggagtc 19 8 20 DNA Artificial Sequence PCR Primer 8 gaagatggtg atgggatttc 20 9 20 DNA Artificial Sequence PCR Probe 9 caagcttccc gttctcagcc 20 10 280 DNA Homo sapiens exonexon junction (223)...(224) exon 2exon 3 10 cttccgcgcg cttactttgt ttataacttg aaaaatcctc tccgtctccc ttccctgcct 60 cctttccttt ccctttcctc tgccagtaca actagacccg gcgtctggcg tccccggtgc 120 ccagcattct gcggggcagg cggtctcgct tgattgggtt tctcatgggt ctctggcgtt 180 tntacggcgc ggctctcacg gactcaggcc aggccactcg caggattaat tggaattctt 240 caaaatgtca ggtgtggtac ccacagcccc tgaacagcct 280 11 815 DNA Homo sapiens unsure 477 unknown 11 tctaacttac caccgctaca ggattaattg gaattcttca aaatgtcagg tgtggtaccc 60 acagcccctg aacagcctgc aggtgaaatg gaaaatcaaa caaaaccacc agatccaagg 120 cctgatgctc ctcctgaata caattctcat tttttaccag gaccccctgg aacagctgtc 180 cctccaccta ctggctaccc aggaggcttg cctatgggat actacagtcc acagcaaccc 240 agtaccttcc ctttgtacca gccagttggt ggtatccatc ctgtccggta tcagcctggc 300 aaatatccta tgccaaatca gtctgttcca ataacatgga tgccagggcc aactcctatg 360 gcaaactgcc ctcctggtct ggaatactta gttcagttgg acaacataca tgttcttcag 420 cattttgagc ctctggaaac tggaggtgca gtgtcctcct ggtgtcacca ttggctntgt 480 tgcggaacat tggaacctgt gcagggcggt gtacagcatc caaaatgaga agaaagaaaa 540 tgtgatgaga gttcgtgggc catgctcaac ctatggctgt ggttcagatt ctggttttga 600 ggtgaaacta tgtaaaaata gtgtttctga tatttttcct actcatatta accaaccatg 660 gaaagatctg ggtgtgacct ttttttttat gtgagtgaat acctagtgtt aggaagagta 720 attacccagt tgacatcaaa ggatttaagg ttattggagt aattggggtt gccaaatgaa 780 ggctttttta tactccggac ctgataaaat aaaag 815 12 799 DNA Homo sapiens 12 agcgggcggg gtgcctgcgg gcaggcgcgg aggttgcgcg ggtcctgcgc tagcagttcc 60 cggacactgc gctcgcgtcg catcctcagg tggttgcaga agtttcgtgg tgtcgggcgc 120 gcgtctgcac tgcagacgca gagggtttgg gagcgagcag tttcctgccc agggatgggg 180 gtcctggctg cacttcacgg gggcgtgcct ttcgtttcgc tctgcgtgac aggtctcgct 240 tgattgggtt tctcatgggt ctctggcgtt tctacggcgc ggctctcacg gactcaggcc 300 aggccactgg caggattaat tggaattctt caaaatgtca ggtgtggtac ccacagaccc 360 tgaacagcct gcaggtgaaa tggaaaatca aacaaagaca ccagatccaa ggcctgatgc 420 tcctcctgaa tacaattctc attttttacc aggaccccct ggaacagctg tccctccacc 480 tactggctaa ccaggaggct tgcctatggg atactacagt ccacagcaac cagtaacttc 540 cctttgtacc agccagttgg tggtatccat cctgtccggt atcagcctgg caaatatcct 600 atgccaaatc agtctgttcc aataacatgg atgccagggc aaatcctatg gcaaaatgcc 660 tcctggtctg gaatacttag ttcagtatgg acaacataca tgttcttcag gcatattgag 720 cctctggaaa tgatgcaaat gttttgaaac taattcaaac catctgatat tagaaacaac 780 tcagacacaa cagataagc 799 13 791 DNA Homo sapiens 13 agcggcgaga cggggaagcc gcgcgcgggg aaggagggtc caggcgtgcc ggacccgccc 60 ccagaacccg cgcctagccc tcccttccgc gcgcttactt tgtttataac ttgaaaaatc 120 ctctccgtct cccttccctg cctcctttcc tttccctttc ctctgccagt acaactagac 180 ccggcgtctg gcgtccccgg tgcccagcat tctgcggggc aggcggatta attggaattc 240 ttcaaaatgt caggtgtggt acccacagcc cctgaacagc ctgcaggtga aatggaaaat 300 caaacaaaac caccagatcc aaggcctgat gctcctcctg aatacaattc tcatttttta 360 ccaggacccc ctggaacagc tgtccctcca cctactggct acccaggagg cttgcctatg 420 ggatactaca gtccacagca acccagtacc ttccctttgt accagccagt tggtggtatc 480 catcctgtcc ggtatcagcc tggcaaatat cctatgccaa atcagtctgt tccaataaca 540 tggatgccag gccaactcct atggcaaact gccctcctgg tctggaatac ttagttcagt 600 tggacaacat acatgttctt cagcattttg agcctctgga aatgatgaca tgttttgaaa 660 ctaataatag atatgatatt aaaaacaact cagaccagat ggtttacatg gtaaccgaag 720 acacagatga ctttaccagg aaagcctatc ggacactaag ggccttcgtc ctccgggtca 780 ctgattgtct c 791 14 104000 DNA Homo sapiens unsure 14992 unknown 14 ctgcccctct gattggaagt gaccgtgggc tggcttttat cttttctttc acctcttatt 60 agagtagtga caacttattt tcttcatttc ttcctccccc tcggctttta ggtttcagcg 120 gacttcaggg tgccccacct cttccaggaa gacgctcccc cgggctggcg gctctcccag 180 cgcggggcgg ggtccgagac ggggaagccg cgcggggaag gagggtccag gcgtgccgga 240 cccgccccca gaacccgcgc ctagccctcc cttccgcgcg cttactttgt ttataacttg 300 aaaaatcctc tccgtctccc ttccctgcct cctttccttt ccctttcctc tgccagtaca 360 actagacccg gcgtctggcg tccccggtgc ccagcattct gcggggcagg cggtgagtgg 420 ggctggacag gcgggcgcag agcaggacag ggtggcgggc gcccgggctg cggggccgag 480 ggcgtcgtca ggggaggccg aggccgcggt ctgcgggcag gcgcggaggt tgcgcggcgt 540 cctgcgctag cagttcccgg acactgcgct cgcgtcgcat cctcaggtgg ttgcagaagt 600 tccgtggtgt cgggcgcgcg tctgcactgc agacgcagag ggtttgggag cgagcagttt 660 cctgcccagg gatgggggtc ctggctgcac ttcacggggg cggccctttc gtttcgctct 720 gcgtgacagg tctcgcttga ttgggtttct catgggtctc tggcgtttct acggcgcggc 780 tctcacggac tcaggccagg ccactcgcag gtaaaaacgc tatttatagt aactttttaa 840 ttgctcagcg agtggaggcg gtgacaggag agaatccctc tctcttattt ccaattctgg 900 caaactgggg cgatttgggg ctgtgcttga tttgttttta aaaacgttca tatttaaaga 960 cttaggattt tattttgtgg ccttatcttc tcttaggatc tacaatttag tttttaattt 1020 tatactgcat ttagaatgga gccaccaaaa taagtacttg tgaagatata atgcaccaaa 1080 cttgatactg cttaaagggg aatagattgc ctaatttaaa ttgcattctc ctgtaatagt 1140 aatagaacac aacctccatc tgtctatctg ctctcatgga tagctgtgaa atactagcag 1200 catttccatt aaatttgaaa aagacaagaa tgctaatcat tacactctgt gacatggttg 1260 tgaattctat gggcgagtga caacaggtag gggaacatat tatcacttta tgcatgatgt 1320 gagtgtatac cttaatgtcc ataggaaaca ctgaaatttg atgggaagca taagtgaatt 1380 tatcaaagtt tccaattgca tcatacttaa tttatagaag tcagttgatg tttatacata 1440 aactagataa tacagtaaaa taaagtaaaa ttcagtttgg catgaaataa cacacaattg 1500 agaaattatt tttaagaaga tataaaaagg tatgtatgag aatccaataa aatacataac 1560 attcttctag gtaaagatat catttctcta aaacaacgta taagtagaat cctaactgaa 1620 tatttttgtt actgttttta actgtactgt ttagctcatg tggaagaaca aacatattaa 1680 cgttatgtat aatatattac aaataataaa atacaaaata tataattatg tcttatttta 1740 tatattatat atgattttaa catttaatat tatacataca cacatatata tagtggagac 1800 ttcttcatat aataaaaggt gttacaaaac tgtggtgatt aaaagacagt gcagtagacc 1860 tactaccaga tgtgtaaatg aaactgaaga gacatggaag aataaaagga aagctggcat 1920 ttgataagca tacattttaa atcactgggt gggaagaaga aataacattt aattgaatgt 1980 acttggacaa gcaggaattt gtttgggaaa cctaataata aaactggaac ttttcctcac 2040 tgttaataga caaatgtagt ctagatggct tactagttta aatctaaaca tatgcagcct 2100 aaaaagggaa aaagaaagcc tgaatagata tttgtgcaca ttgcatgtgg gaaaagcatt 2160 tctaagcata atacaaaaac ctagacccat ttagggacat gatttttatt aacatttgca 2220 tcccccaaaa aagatacaaa ctgcggacat tgttaataga aaaaaaaaga taattttgct 2280 aatataccta gaaatcttat taatgacctt caaaatcaat gacccagtta aggataaaaa 2340 gagtcaactc aaagcaaaag aaatgcaaat aataagcaga gtgaatactg ttagccacac 2400 taattatcca aaacatatat gaagtaagac atcaattttt gcattaattt tacaaatttt 2460 gaaagtctga taactttagg tgttgttgaa aatgcagtga ggaaaatata attttacaaa 2520 cttttagtgg aaatgtgaat tggtgaagct gttttagggt taaagctgtt cagatttaca 2580 aatgttcatt tacttaactg gaatttatcc agcaaaacat gctcccaagt gtacaaataa 2640 aaatctctgt caaagatgtt taaagtagga ttgtttacaa tgtagaaaac atggatacag 2700 ctctgtagcc attgattggg aattggttac ataatgtatg gtatattcaa aggtggaata 2760 atatacagtt taaaacattg tagctctaaa tgttctaact tggaaatatg tccaaaacat 2820 aaagttaaaa cacaaaatga aacaacaagt tgaaacactg tgtgtgtcgt gtgtgtgtct 2880 gtgtgtgtgt agtgtagtaa ttatattttt gtaaataatt tggaatatag gctgaattat 2940 attgtgagta gtgatgtttt acacacagcc gaattatatt attatgagta gtgatgttgt 3000 tttacacatt tctataatgt atgcgtgtgt ataaggaaaa attgatagtg atagtaattt 3060 atacagaaca ttgccttctt gaatatatta gctgtcattt actacagaag aaatatattt 3120 cacaaaacct ttcatattgt ctcatttttt ttcttttata agtgtcctct ttcagctgct 3180 tcctttaaaa tccccttcct taatattgat gtttatgatg tttattgcaa gaacagcagt 3240 gaagaatttt gcttgaggga tttcacaacc agttaacttt tataaacaaa aaatacagca 3300 atgttcatac tcatatgttc accagcattg tgctaaaatt catttttata gtactcattc 3360 ttcaggatga aagagataga tatgctagtc cttaaaaaga aaaacatcta aagttggaaa 3420 aaaattgttt ttaattgcat ggtaaggctg ggtggcggtc gcacgcccgt tatcacagta 3480 ctttgagagg caggggtggg cagattgttt tagcccagga gtttgagagc agcctgggaa 3540 acatggcgat accccacctc taaaaaaatt taaaaattag ccaggcatgg tggcacccac 3600 ctgtagtgcc agctgctcag gaggctgagg taggacaatt gattgagcct gggaggtcaa 3660 ggctgcagtg agccattatc atgccactgc actccagcat gggcaacaga aagagaccct 3720 gcctcaaaaa taaaactgca tgacaaaaat gcagtgaaga caaatgataa gttttgaaaa 3780 gataatttta atataaaatt ttaatacctt tcatataaag aagacaaatg aaaagctaac 3840 aaaaatgaac aaatgacaaa caggcagttc acagaaatag agttgcaaat tgctttcaaa 3900 caaataataa aagtggctca gcctcctcat tatgagatat atggaaaata aaactcaatt 3960 tttttttttt atatatcaga ttgactacta caaaaatgtt gataaaatac tgtattagga 4020 atgtaacttt ttgtctgggg tctaaattga ttcaaattct ttagagtgca gtttgatagt 4080 atctttaaaa atgtacaaaa ctttgatcca tcagttctgc ttccaataat ttaatgcaca 4140 gatccacagg aagaaaatat ttttttcagc atttttggta atagcctaaa tttggaaacg 4200 atttaacttg ttgtcattag gcagccagtt aaatacatta tgttgcagcc attaaaaaga 4260 atgaggttat atggactgaa atgtaattaa catcaagaca ttttaataaa tgaaaagaaa 4320 aagacacaga aaagtatata gatgattgcc attttataaa aactgtgtgt attagtttat 4380 atatgcttag aaaatctatt ggaggaaaaa aaatctaatg tctgtggttg ccttttcaaa 4440 tgggaaatgg gaattggagt aggtgggatt tttttgtata aatgtattgt gtaaatgtat 4500 gcactgccga ctccttgaat tatatttgtg tttgtttgca cataacatct gttttttaaa 4560 agtctgtttt cataaatgta aagtttctta tcaaagtgac ttaactgtat gcaacatgac 4620 atcttgtttt actacaattt taaatactaa aagactagct gtaaaatgac acaatgaggc 4680 gttcttggta atcatagttg gcatggtaat gtttccttaa tgtcttatat aaacatcatg 4740 agaatattgt tctgatattt ttctactcta aataacaaaa acatttccct tttgaaagct 4800 aaaaaggaga cacctgatat tctctttaaa caatttgaac taaattaata tatttaataa 4860 aggttatgta tggactgtgg ctatcaattt gctttcattt aatcttatct tttattttat 4920 attaaagcca aatagctaac ctccaagatc cttcacactt gctaaaaaga atgaaatatt 4980 ctaccataca ctttttcttt tgaaggagtc atgatgttaa taaaataata aatatattga 5040 tataggttat aaaaacaaca caataaaaat cttaggtttt gcccttgtaa tttgttgaac 5100 attaatcact ccctaagttt cttctagaat tgattttatg caaagataca attaaataca 5160 tatatgttaa catgtaatta taatgaagat actgtgtatc tatgggacat tcctgctgca 5220 gcatatttta tcaacatgga cctaggttta tcttttgtgc aagcctggaa ttcgtttctc 5280 taatttcagc ccatgtgaca gaaacttact aagtttacaa gatgtctaca gaaatgactg 5340 aatccttcag tcattggact ttaatccact catattgagc ccactgaact atccagttcc 5400 ctatagccaa gaaacccata aaagtaatta acacagtcca ccataggagc caagaaattt 5460 ggcttaaagt ctataaagag gattgtactt ggaaaggtgt gcataatatt tcctctttga 5520 tgaacatgca ggtcttttta gttacagatt cactacaaga gagtacattg tcaggtttta 5580 aaaattattt taaaaactca gtttatataa tttattatac atttattgta gaaaatttaa 5640 agaggaaatg tttatatctt agcatgtttc ctccagtttc catatttttt aaaaacattg 5700 ctatcattat aattatccag attatatgtt taacatttga atgtaaacat ttaatgattt 5760 ttacaaaact gttactatat ttttaaagga aaattatttt atcataatgt ttcatgataa 5820 tgtgtttact taacaattgt gcttgatatt tatgtagttt acaatcacta ctattttcgt 5880 tttgcattcc ttctgtgaaa atgagaatgt atcacttaaa aatattatat ggcatatttt 5940 ggatttattt tgaatttggt atagaggaaa tttacttggg tttacaaatg agatttgaga 6000 aaaaatagat atgtcttata ttggtaaact gaacatttga ttgaatgtat tatgattcct 6060 acagcagata ggtttttatc tgaatggggt aaaatttcat agatctgtaa ctgagggggt 6120 gtgtgttggg gccaggaggg gatatattaa aatcatctgg gaaatggctt ccattttctt 6180 tccttatcca tagaagcaat gatcctttta agctttatca tgagactgca acaattcggt 6240 aacatcttca tgcttcactt ctaactctta gttctcttgc tattctctca catctgcagg 6300 tacttcatcc aatgaagtct tgaaccacgc aaaatcatcc aggagggttg gaatcaactt 6360 cttccaagct cctgttaata tttatatttt gacttcctcc catgaataac aaaagttctt 6420 agtggtatct aaaatggtga atccttttta gaaagttttc aatttacgtt gcctagattc 6480 atcagaggaa tctaggccta gcttttggcc tgtctttgct ttcagcatgc cttcctcatt 6540 aagcttaatc ttttccagct ttttgactta aagtgagaga tgcacgaacc ttcttttcac 6600 ttgaatattt agaggcattt gtaggcttat taattggcct aatttcaata ttgttttgtc 6660 tcagggaata gggaggtcct agaataaggg gagagatggg agaatagttg ctctgtggag 6720 cagtcacaac aacacttact aagttcacca tcttatatag gcatggttca tggggtccca 6780 aaacaattat aatagtaaca tcaaagatca ctgatcatag atcaccataa cagattgtta 6840 tgaaaaagtc tgaaatattg tgagaattac caaaatttga caaagagaca aactgagaag 6900 ttgctgttct gcaaaatggc actgatagac tccttgatac aaggatgcca caaaccctca 6960 atttgtttaa aaaaatggag tatctgtgaa tcacagtata gcaaagcaca gtaaaacaag 7020 gcatgcatgt acataatgag gtatcttgag aatgggaccc aagtaaacat gaaattcatg 7080 ttccattatg ttttaaacat atagcctgaa gataatttta tacaatattt ttgataatgt 7140 tgtgtatgaa acgtttacgt acgttgaacc atcagaaagc aaaggtatca gtatctcaat 7200 cacccatgtg gacaatctgt ggttatttga cgtcaccatc attcctgact ctaaattcat 7260 tatgctactg ataagtaatc attttcttac attactcaca aataagtgct taacagtaaa 7320 aaataggatg tatcattagt acagtgaaaa gagaatgcgt tcagggtaac taagcagcac 7380 agtagtatct ccagaatgcc tgtgtcggaa agccaccaat aagcaatggc aggctttcat 7440 tctttaccta caatgctgta ttttgattac aaggttatca ttcactgaat tttattattt 7500 taagtgagaa gaaatatcag aagtagccaa gtgaccagca agtgttttct ctacaaatga 7560 ggaagcattc tgatggatga cttttcagaa tgtttcctct ggagtccgct gtctcattaa 7620 caatggtttt tgtcttagaa gtctctgttg attttacaga ctgacacaat ttcttattct 7680 gtgatgaatg aatgctctta gagtccttca gtaaacccat cacatatttt caccatgtca 7740 tctataggca ctttgcagtt ttaacagtgt cctcatcatc tttcacttgt gacatcatgt 7800 tggtgctgaa agttttggat ttttgagcat ttcagatttt ggacttttgg attagggttg 7860 cttagtctat acagcatttt atgtgcccga actctgcatg aatattataa tcttttctta 7920 aagttagaga ttggttcatc ctttttgttc atttctttgt tttcaagaat aaatgacaac 7980 acagtttttg ttttgctttc tatttttttg tttttcaaga gttttggagc atagtcagga 8040 tcatgatgat aagaaagaga tgtatatatg taacaaacct gcatgttgtg cacatgtacc 8100 ctaaaactta aagtataata aaaaaaaaga tgtatacagt tggtagagca tattgttagc 8160 aggagtttga gaagaggggt ttcagtcaat tgagagatcc ccatggaaga agcaggatga 8220 aatacagata acagaactaa ttcttacaaa ttttttttct gaaaatggtc caagtgtcaa 8280 ttaggaactt tccaggtttg atttgaaacc cccaccacag aatttgtttt tcctccctga 8340 gagattgatg ggttactgtt ttgggattaa agcctttggg ggctttctct ggtggagaaa 8400 tagttcagac aaaaggtagt ggatccatta gatggctaat ataaaagtgg acaatgtatt 8460 ttccagttgc atgagtgttt accataaagg cagacatctt ggggcatagg gttctttatt 8520 ttgggatcct cttgggccct gtagccttta caactgtaaa gacataaacc tgtttgcctt 8580 tcgtaaggaa ttttcccact gtagccattc taagttactt ttgctaaggt tctcccattc 8640 gtctcgaaaa gcacaggttc tgggtctctg gtttttatac atgaagttgg ctagaattcc 8700 agagggcgaa gctctagcaa cctttgacca gataaaccca tgattctatg tcttttatta 8760 acctttccta cctactaact gagttgagtt tatgtctgac ccagtcaaat acctgaggcc 8820 tccctactgg gcccagtcct gttgttggca tgactttgaa acccagtgta gatcaaaaat 8880 gctcaaactc agctcaaatc agaagttcat gaagcttaga ttcaaaaatc tcacccatga 8940 ccccagttgc tgcgaaagag cagtgagtac actgggcatg ctgggtacct taacttggtc 9000 actcagtgct cctgggatca ctggaagttt gcttcaagat ctgacttctc atgtgaaact 9060 cttaaaagaa aaactttagg caaattcagc agagtttatc tgagcgaaaa acgattcatg 9120 aatcaggcag ccctcagaac cagaagagtt tcagagagct ccaccgagca acatgggcag 9180 gcagtattca taaacagagg aaagaagtga cgtacataaa tcagttgatt ggatccagcc 9240 tggtatttgc tttatttggt catggtgtga tgaggcattt gccttcaacg gacatggtct 9300 gatcagttga cagcccgtga ttggctgaag ctccactacc atcattggct gagactcagc 9360 tacttgttac aagaatacaa cctcaaatca agttgcagtc tgctatttac agaggcagct 9420 ttaggcccaa tttaatttat caggttatga tttagattac gtagaaatgt gttgttttat 9480 ttttatgtgg ttagagaatt tcctgttatc ttgcggttag taattcctag ctcattacat 9540 tatggtcgga gaacaagctg tattatttta atttttttgt aatattttaa gatttgtttt 9600 atgagccaga atgtggtctg tctgggtgaa tgttccgtac gttgaaaata atggttattc 9660 taatgctgtt gggtgggtgt cctacaaatg tcagtgttgg ttgatgatgc tgtctagttg 9720 tgccaatatc attgctgatt tttcctctgc ttgttcttgt agattactaa gaatggagtg 9780 taaaagtcct caactgtaac tgtggatttc tctttatttt tttcaatttt gccagttttt 9840 ccttcatgta ttttgaagct ccattgttag gatcagtcat gcttaggatt gctgtatctt 9900 gttaagaaat tgtctcttac ttttaagtga tagcccttct tatctctggt aattttcttt 9960 gctctgaaat ctacttgtga gatattagta taaccactcc agctttcttt ttctctgtaa 10020 tgactttgtt gagacataat tcacatacca taaaattcac ccattcaaag tgtacagttg 10080 agtgattttt agtatattca gagttgtgaa gctatcacca caatctaatg ttagaataat 10140 ttcataattc caaaaagaaa cccatgccca ataacagtca tttcccatct tcttgaagcc 10200 acaaatctac tttatgcctt tataaacttg cctattctgg atagttcaca tcagtagaat 10260 catgtactat atggtttttt tggtgactga cttctttcta gtagtgtaat gttttcaagg 10320 ttcatccagg atatagcatg tatagccata caaaattact ttgtatggct gagtcatatt 10380 tcattgtagg gatatttaaa aattgatcag tttaccgatt gatggatatt tgaattgttt 10440 ctatttgttg gctattatgt gtaatgctat tatgaacatg tttttgtgaa ggcatttatt 10500 ttcatttctc ttaggtatat acctagaaag aaattactag aggacatggt taactgtatt 10560 aaccatatga aactctatgt ttaatctttt gaggaactgc cagactgatt ttcaaagcag 10620 ctttaacatt ttacattcct cagcgacata tgaaggtttc gatatctaca tatctctcct 10680 aaaacgtgtt gttatatttt ttattatagt catcttacta ggtgtgaaga gtatctaatt 10740 gtagttttgt tgttattttt caagagacag gatcttgctc tgtcacccag gccagtatgc 10800 agacacagtc atagctcagt gcagcctcga actcctggtc tcaagaaatc ctcccacatc 10860 agcctctcct gtagctggga ctacgggtac atgccacctt gctcagctaa tgtttatttt 10920 ttcgtagaga cggggtctca tgatgttacc cgggtttcta actcctaacc ttaaggaatc 10980 ctcccacctt ggcctcccaa agtgttgaga ttacaggcat gagccactat gaccggcctt 11040 aatgccttaa ttagttttga tccgcatttt ttttaatgat cagtgatatt gagaatattt 11100 ttatgtgctt attggctatt catatatctt ctttggagaa atgtgcaaat tctttggcca 11160 tttttcaatt gagatgtctt tatttttgag ttggagtatt ctttattttg gacaaaagtc 11220 tctcagataa atggtttgaa aatattttat ctcattctgt gggttctgtt ttcattttct 11280 tgatgatgtc ctttgaatta caaacctttt aaatttttat gagtccaatt tatttattta 11340 tttatttttg ttgcttttac tattgatgtc atatcaatga aaccattgcc taacccaatg 11400 tcatgaagat ttactcctgc gttttcttct aacatttatt agctttatct tttgcattta 11460 agtatttttt ttttcttttt ttgagataga gtttcactct tgttgcccag gctggagtgc 11520 aatggtgcaa tctcggctca gagcaacccc cacctcccgg gttcaagtga ttctcctgcc 11580 tcagcctccc aagtagctgg gattacaggc atgtgccacc atgcccagct gtttttgtat 11640 ttttagtaga agtggggttt ctccgtgttg gtcaggctgg tctcgaactc ccaacctcag 11700 gtgattctcc tgccttggcc tcccaaagtg ctgggattac aggcattagc caccgcatct 11760 ggcctgcatt taagtttata atatactttg attaattatt tgtattgggt attgtagggg 11820 tccaagtttt tttttttttt ttttttgtat gtggatgtac aattgtctca gcactatttg 11880 ttgaaaagac atttccttcc cctgttggta tccttgtcaa aaatcaatta cccataaatg 11940 caaagatttg tttctggatt ctcatttctg ttcctttggt ctatatgtct attctttgga 12000 ccaatgccat actgttttga ttgcagtaca tttgtagtaa gttttgaaag caggaagtct 12060 gagttttcca tttttcattt gcttccaaga ttgttttggc ctttatggga cccttttatt 12120 tctataagaa ctttgtattc agcttgttag tttctggaaa aaggcaactt gtattttgat 12180 agtgattttg tttcatctgt agataaattt ggggagtatt gctattttaa caatattaag 12240 atgaacttgg gatatctttt atttagatct tctttaattc tttcaacatt tcatggtttt 12300 cagtgtacaa gccttgcact ttttaattaa atttatttct aggtgtttta ttatttttgg 12360 tactattata aatgtaattg atttcctgca ttgttcattg ccagggtata gaaatacaat 12420 tgatctttgt ataatggtct tgtatcctgc tgcattgatg aacttgttta tgcttccttt 12480 ttaatgaatt ccttagaaac tttgatatga ctttaaaaat gtcacattat ttctatttca 12540 gatggcttta tttctttttt ctaacctaat cactctgggt agaacatcca gtacaatgtt 12600 gaaaagaaat agtaacagta catactcttg tcttgttttg gtcttaaggg aaagcattta 12660 gtctttctct gttgagtatg acattagctg tggagtgctt cacaagtttc ttacgagatc 12720 aagaaagttc tatatttcta gattgttgag tatttattgt ttttatcaat aaagagtagt 12780 ggattctttt gaatattttt tctgtcatct attgagatta catagttttt gtcctttatt 12840 ttattaccat gatatattca ttgattgagg ttttttttgt ttgataaacc attttattac 12900 tacaataaat cccacttggt catggtgtat tgtggtatat tgtggattca gttttcaagt 12960 attttgttga gaatttttgt gtcagtattc ttcatggtta ttagtgtagt tttgttgtgt 13020 tgtctttacc taattttgat ataagggtca tactgaaata aaataagttt tagaagagtt 13080 tgcgaagggt tgatattcat tccttattaa gtatttggta gaatgcacaa gtaaatcatc 13140 tgtacctggg tttttttttt tgtgggaagt ttttttggtt actaatttag cctcttatta 13200 cagttctatt caggtttcct gtttcttctt gagtcagttt tggtagtgtc tgtcttctag 13260 gaatttgtcc atttcatcta ctgtatctaa ttggcatatg gtagtttgta gtattcccct 13320 ataatccttt tttcttttca atgtaaggtt agtattaata tggctctttt cattcattat 13380 tttggtaatt tgaatctttt ctctttttct ttattagtgt atccaaaagt ttgtcagttt 13440 tgatcttttc aaagcaacaa tttttagctt ttttgatttt cttttttatt ctctatttta 13500 tttattccta ctctaatctt tatttctttc ctttttcttg ctttggtttt aatttgctct 13560 ttaagacata ttttacagag aaagattatg ttatttattt aagagcttta ttctttaaaa 13620 ttatttttat ttacaactat aaatttgcct caaaacattg ctttggctgt acttcataag 13680 tttgtggcct tttgtctttt cattgtgaat tttcattgtg atttttttgc caacccattg 13740 cttattaaag agacttgttt aatatccaca tattttgaat ttcctcaact tttttctatt 13800 gttgatttat aatttagttt tccattgtgt tcagataata ttttatatga tttcagtttt 13860 taaaaattta ttgaggctca tgttatagcc taatgaatgt tatatcttgg agaatgtttc 13920 atatgcactt gaaaatcagg tattctgcta ttgtcagtta cagtgttaca tagataatta 13980 tagatctaat tggttcataa tgtatgtgta tttcccatca atttcatcag tttttgattg 14040 tgtattttca ggctgtattg tgatgtgcac ataagtatgt aattgttata tcttcctgat 14100 agattaattt tttcttctct ttatgaaata ttcttcttag tcttcagtaa tagtttttgt 14160 cttaaagttt tatttgtata agattagtat agccactgca gctcttcttt ggttaacaca 14220 aagtacacct ctttcctttt tcgacctgtt tgtctttata aattgtgtct cttgtatatg 14280 acgtatagtt ggatcatgtt ttctctcttt tttttctttt ctttttttaa tccattctgc 14340 cagtctctac cttttgattg gattgtttaa tccatttaca tttaaggtaa ttactggtaa 14400 ggtaggaact atatcagatg ttttactact tgttttctat atgtcttaca ttctttcttc 14460 ttattagtgt atacatggta tatctttctt agcctttctt ctttaaccct tttctctttc 14520 atctttctct accttatcat ttcatttgaa gttagtttct tttagagagc atgtaattga 14580 gtctgtatta gtccattttc acgctgctga taaagacata cctgagatgg ggcaatttac 14640 aaaagaaagc ggtttaacgg tcttacggtt ccacatgact ggggagacct cacaatcatg 14700 gtgaaggcaa ggaggagcaa gtcacatctt atgtggatgg tggcaggcca agagaagagc 14760 ttgtgcaggg aaacttcccc ttatgaaacc atcaaatctc ataagactta ctcattatca 14820 gaaaagcagc acagaaaaga cctgccccca cgattcagtt acctcccact ggtccctccc 14880 acaacacctg gaattcaata tgaaatttcg gtgggacaca gccaaacaat atcagagtca 14940 tttaaaaaaa tatgcattta actattctgt aacctcagct gtttgttata cnnnnnnnnn 15000 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 15060 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn naaaaaaaag agggggcccc gaccccctcc 15120 gctaaaacca agctttggca ataaacaacc tgggcccccg gtgccttccg cccggaaaga 15180 aagcttcctg gaccccaccg gaggccaaag ggaacaccgg gcctcccggg gagcccggcg 15240 aacccattaa acccggacag cccggagagg ccaattaacc ccctttcctt aaaaaatacc 15300 ccagcccaag gggctcccgg aaaagccggc gaacccaatt aaaccccttt ccttaaaaaa 15360 taccccagcc caaagaatcc cttatagcaa tgcaagaaca ccctaacata ctgttttact 15420 actttatatc aacatgtatt tcaccttgtc atgtatttct atgggctggt tttttttttt 15480 tttttttttt tggatgatga gtcatgattt tctttttctt acaatggata ttactttttt 15540 attatgcaca gggcattgca aataatatat ctgagttatg tcttcttcct ctaaggagaa 15600 agcattctct ggcaggcatt tgagggctga tcacctttaa catccggagc cattggttta 15660 tactttaagg catgactatt gaatacctga agattttact aggctcctct atcctttgtg 15720 ttactcagat tccaaacagt atttcatttg ctgtatacag caattgaaat ctctgtccag 15780 tcctttcagc tgctgccttc tcctttctgc tggcatcatt ggagcgtccc caatagacac 15840 acagttccac ggtcagtcaa ggatttgagg acttttaatt ggcaggtatt aatattattg 15900 tctctgtgtc tccctacttt ctgggattac tcttcattta taagcaccct ggtagcctga 15960 aatctctaca ccgatatcac aactcagtaa ttctgatgca tcctacttga gttctagcta 16020 cgttacatct gagaactggg agtaccacag ggaaagtgtc tataagcgtg ggtctcactc 16080 agtcattgta attcccttct tcactagttg aattaagaca tttttgcatc accacaaaaa 16140 aatacctgag gctgggtaat ttaaaagaat agtgatttag ttggctcgca gttctgcagc 16200 ttatacagga agcacctaaa tctggtctgc ttctggggag gactcaggga gttcttactc 16260 atggaagaag gcaaaggagg agtaggcatg tcacatggga aaagggaaag gtcccagact 16320 cttttaaagt ctttaagttc tcacatgaat taattgagca aaaagtcagt tatcagtaag 16380 gggctggtct aaaccattca tcagggaccc atcctcatca tgtaatcacc tcccaccagg 16440 ccccacctct aatattggga atcacatttc agcaggagat tttgagggga caaatatcca 16500 aaccatatca ttctactcct tgcccctcaa aacttatgtc cttttcaaat tttaaaatac 16560 aatattgcct tcacaatagt tccccaaagt tataactttt tccagtatta ctcaaaagtc 16620 ccaaattcca agtcacaagt ccaaagtttc atatggagtt gttttttttt tccacctatg 16680 acagtgagat taaaatcaag ttatttacct acaagatact gtggtggtac aggcattggg 16740 taaacattcc cattccaaaa gggagaaatt ggccaaacga aaggggcaat aggccccaca 16800 caagtctgca tcccaacaga gcagtcattg aatctcaaag ctccaaaatc tcctttgact 16860 ccatgtccca catccagggc acactgatgc aagtagtggg ctcccaacac cttgggcagc 16920 tccacccctg tgcattccag gatgtagccc ccatggctac tctcataggt tggagttggt 16980 tgcctgtttt ggttccagga tgaggttgca agctgtcagt ggctctacca ttctggggtc 17040 tgaaggctgg cagccccctc cccacagctc cattaggtag tgccctcgtg gggactctgt 17100 gttggggctc caaccccaca tttcccacag ctccattagg tagtgccctc gtggggcctc 17160 tgtgttgggg ctccaacccc acatttcccc tctgtgctgt cctagtagag attctctgtg 17220 aggactctgc ccctgtagca ggctcctgcc cgggcagcca agctttctta tacatcctct 17280 gaaatcgagt ggaaagctgc caagtcttct tcaaacttgc ataccatggg cctgcatact 17340 taacaccaca tggatgctgc caagacttat ggcttatccc ctccaaagca atggctcaag 17400 ctatgccaga ggctctttga actctagcag ctggagaggc caggatttgg ggaacaatgt 17460 ccagaggttg cacagggcag cagggccatg agcctgctcc actaaacaat tttttctgcc 17520 tgggcctctg aacctttgat gggagggtct accatagaga tttctcaaat gcctgctaga 17580 tcttttcctc attgtcttgg atattagcac ttggttccct tttagtcatg ctaatctctc 17640 taacaagttg ctgctctgca acctgcatat atttctctct tgaaaatgcg tttccctttt 17700 tagccacatg gccaggttct gaattttcca aatgtttaaa ctttgcttcc cttttatatt 17760 taagttccaa ctttaaatca cttctttgct ccagtacctg atggtaaact gttagaaaca 17820 gccagaccac atcttgaatg ctttgctgct tagaaatttc ttccaccaga tagcctccta 17880 ggtcattact cttgagttca aacttccaca gaaccctaag tcatggacac actgcagcta 17940 agttctttgc gagggcgtaa cgggggctac cttcactcct gttcccaata aattccttat 18000 ttccatctga gacctcctca gtctggactt cactgtccat attttaatca gcattttgat 18060 cacagccatt tcaccattta agaagttcca aacttcccct catctttctg tcttgttctg 18120 aaccctctaa actcttccag cctctgccca ttacctagtt ccaaagccat ttccacattt 18180 tcaggtatct ttatagcaat actgcactcc tgggaccaat agtctgtatc aacatgatgt 18240 ttttcgtgtt gctccaaaga catatctgaa gctggctgaa ttataaagaa aagagattta 18300 attggctcat agttctgcag gctgtacagg aaacatggtg cctgcatctt cttggctgct 18360 ggtgaggcct ccagagcctt ttctcatggc aaaaggcaaa gcgggggcag acacatcaca 18420 tggtgaatga gggaacaaga gagagaaggg ggaagtcccg tactctttta aacaaccaga 18480 tctcatgtga aataactgag taagtacaca cttatcaagg agatggtgct aaaccgttca 18540 tgaggaggtg ggacctaccc tcgacccacc ctcatgatcc aatcatcacc gactaagccc 18600 tactttcaac attgggaatc gcatttcaac atgagatttg gagaggacag atatccagac 18660 aatattacca gtcagatgcc ttacaatttc tgtcagcttt tgattgttct ccagtgcctt 18720 caaatagttt ttattttata ttttcccaga gtttattatt gttatctagg gaaagattat 18780 tgcaatccaa gctaacttat catcattgga gctccaactc tcacaaattc ataacttttg 18840 aaagcaattt attttcagac atgccaaact gttagaaatt ttttttatta aactaaatgt 18900 acatgtatcc tttatcccaa aagagaatat ttttcttact tatttaatat aataacgctg 18960 taaattgttg taaatagcta ttaacttttc cttaagtatt ttcttcctaa gaccaaacag 19020 ccttatttcc ttttgctgtc tctatttgtc attattgcag atcccttaca ttaagactac 19080 cttccttagg tttattcatt gccttctaat atttgatctg atgtttagat aatacaataa 19140 tatatcaata ggtctctatt aatgaggcct aattgcatta gttttattgg catattattt 19200 actcctagta ttataagtaa tactatattt gtggttcatt aaaccctaac attattacct 19260 tagagtcagt cttttcattg tgtactagaa agaatattat cattgttaat atctgataga 19320 tgagctttta tttcctgagc tcaattcttt agtccaataa gttctatatg caaaggataa 19380 gagatatgga aaccaaataa ttttaataaa aaagtaggca aacgtgttaa gaaatgagcc 19440 cacggctgat gttgtgggtg gaggtagagg agtatagtga gagaaaggct ctttctagca 19500 cctgaagtaa tggcttggtg gttttaccag taaacaatat aaagcaaatt gtccactgtt 19560 ttcaatacta ccctcatgat tttttgattt aaagtgcttc attggtttca caatttttat 19620 accttttcac ataggccaag atgataaata aatttgccct ctgaccaatc agtgtgagaa 19680 aaatatttga aaaatgggaa acatttctat ttgtgtgcag cattagatag gaacgggaca 19740 ccagcaacaa tgtgtttcag gatatagttt ctcattatca gatgctcttc acagatggat 19800 ttgacataaa tgttatggga gttaagaaca caatcagatg agccatgttt aggaggctct 19860 catctaacca gctttttaaa actgcagata tggttattgt gtggacagct gatttttgat 19920 tttagaaata gaaactcaca ctgtgcctat ataattttat cttccttatt aagcccattt 19980 ggcttctcag ccttgtgact aaaatcagat gtagcatatt aaggttaata attgaatctg 20040 tattatgttt acctatcatg ttagccattt tcttagattt tgtcacatgg aatttgataa 20100 tctttttctt tatgtctaaa tttatgtcac tgaaacaaat gttgggttag ataaagaatc 20160 taataggtca tttctgagat taacctctag gatgacagaa attcagtaat caataccttc 20220 tgtaattgtt caaccagcta aaaatccatt tagactttcc ttttacataa tccacatttt 20280 aaaatgtctt gctcacagca atgaatatta aaatctctgc ttaatgtgtt aaaaacagtg 20340 tttattatga catgctcatg atctctctac tccaccagtc aggagggaag gggaaatgag 20400 tccattttat aagatttgat tgagaacaca atactgcctt tgttaaatgc tcaaatgcta 20460 ttatttacaa cttctgtact ataaatttgc ctgaaactga cattacaatg cgttgttagt 20520 tgagttgtgt cccccaaaaa gatattttga tatgatttta tttagaaatt gtctgtatag 20580 atgtaatcaa aataaaagaa aaccaatacc gtattagggt gcaccctaat ccaataactg 20640 tggccttata agaagagaga aatttggata cagagacaga cacacagaga gaacccatgt 20700 gacaataaag acagagatta gagtgatgcg tctagataag gagcaccaag gattgccagc 20760 aaccactaga gtctaagaga gaggcatgaa acaaattctt tctgagtctg caagaaggaa 20820 ataaccctac caacatatat atatatattt tcagttttct ggccttcaca actgagagaa 20880 aataaaattc cgttgtttta aatgatctcg tgtgtggtaa ttttttaagg caatactagg 20940 aaactattac aaaatgtgtg agtgtttctg tgtgtaattt ctacaagtca atattttctt 21000 ttcttgaaaa ttgggacaca attcgctttt tactagtttt ctgaatcttc acacattctg 21060 tgatgttgaa aagaaaattg agagtgattt caatacaata ttttcatgat ttttgtcccc 21120 atggctatag ttgatatgat tttaaaagct tgaactcatt tatgctatct gggtcaaatt 21180 gaccttgata catggagtag aaagtgagtt gcatctccaa gaacacaaga ataaagaatg 21240 taaaagagca actgaagtat ttgggggaac atacggaact tctatcaatt atcatttaaa 21300 tacatcgaga agcatattta gaaatgattg cttacaaatg gaaaaggatc ttaaatcttt 21360 ctgaagtaaa attgctctaa aaacacaatg gttaaatttt gttggaaaaa actttatata 21420 tacttacata tagatatata cgccatgctt atatgtatgc atacactaga tatgcttaca 21480 tgtgattaca taagcatggg gaaaaatgga agaacaaact acttttataa atatgggtta 21540 tctggggtgt ggcagtagtg gaaagaggaa aaaaatgaga aaactgtggc ttgagaggat 21600 aagtaacttg acccaacaag tgatggagct gagatctgaa ccaaagtctg tattgaatct 21660 aaagcttact gtcataaact ttgtttaaaa tgttatgata ttcaattcaa tgtagaaaga 21720 gacagtaaaa caatcttttt caaaagcgtg ctctgttcct tgaaatttaa ttatagggta 21780 tctctttttt cctttcacaa agcatattaa ccaacttttc tgtctattca tagagatata 21840 tttaaatctt actttttaat ttaacaatat tttatcttag gtatacttca gacagattaa 21900 tacaaatata tctgtgaaat gtctaaaact attttaaatt tagagtattt atactttact 21960 aatggctagg ccatgtgatc attacgtatt tatatatttt tacaaaatcc taaaatggtt 22020 aatgcagttc aacaaaaatt tgaggaacta gaaaattttt gaggctggca ttcccaaaag 22080 caaaaatgag aaaaaggaaa tatttcttga agtcaggcaa gtaatttaac tatatatcga 22140 tgaaaagagt attttaaatt caaattttgt acacggcagc ctcgtatgtc acaatctgca 22200 taattattat aacatcaggg catttaattc aatagtgtga atgtttaagt tgtgattaaa 22260 gacacacaag tttgccattg tccttaaatg tcgataaata acaaattctt tttgtatagt 22320 gtctatatgc aaagtgaatt atttgctgat ttaaagaatt ttggctgaat cagatctact 22380 gacattttat gtatatattt aggaatgtga gttattcaag tatgtgtcag tgatttaaaa 22440 taatgaatgt taaaaaattt actaaagtct taaacatgta atgaaaagag tctatttttt 22500 ctacaaaatt gctcaagact tctgaaatac aaagctgata atgtcacttc caggttaaag 22560 tctttcattt ttcagggaag atttttcatt ttaaagccta cagttttcaa gaaaactctt 22620 aatatgtatt gtagaacata cagccctaat tttcttgcat ttgcttaatt tttttttttt 22680 gcttcaccat gtagcacttc cctgttttcc atgttctagt gatatgctag atactatatc 22740 tatctatcta tatacatata tctgtatctg tatctatata aattcaccat tgtattatgt 22800 tggttcatga cactgtgagg tttatgactt cataaatatt ttgccactgc tttatcctca 22860 tttctccatc tggctacatt ccattcattc tcccagactc attttaaata tcacccactt 22920 tgggaatcct tccatgacct ctccattctg atttactgag tactttgagc tggttctata 22980 ctaggtgctg gagattcagt agaaaataag acagggtttc tgccctccta gaacttacat 23040 tcttgtcaga tcagagccaa taaacaacga agtggattgc aaaataattt tagagcatga 23100 aaagtagttt ggaagtaata aagcaaggtg atatggaaga tggtgaggtg ggactacatt 23160 acaaatagta ttcaggaaag gcatcttggt cactggagaa agtaacattc atgccaaatg 23220 attagaaaaa aacaactagg caaacatatg gtgtttacta gtattccaga aatagagaac 23280 aactagcata gagatcctga gggaggaata ttgtatgctg acagaacaaa acaatacaaa 23340 acaaaacaaa aataggtggt gccggagcag gagagagagt ggcatgagaa taatatgtag 23400 ttcatgaatt cattttattt ttatttcaac tccttttata tgtttctcca tgcaactcct 23460 tgcctagccc ttcctaattc tgttgtattt acccataaaa ctaattgctg gcataggaat 23520 tcccaaagtg atattactct ctgcaaatta cttttgtaat tgtggcctgt atatttaaat 23580 ttaaactggg tctggatata taatgattta tattcaatat atatttcaac tagatatttt 23640 ctgaaatgtt attattacac ataataaggc catgatacaa ttataagaga tgcaaataat 23700 ttcagctgca tccacagggt gttttgcaag gaggaacaat ctagaactag aaacctaaca 23760 aatttgaata aggtttgaaa ctaaatttat acagagaaga atatcagcca gttttcataa 23820 tttggaaagc tagtaaattc tagctttgga gcttaacatg atgagggggt tgaaacacac 23880 ataaaaacag cattatgtta tttcattcaa cagatatttt taaagtactt atctaccctg 23940 agctatctgt ttggattcct tgggaataaa aataaggaac aaatagtgaa ataaagcatc 24000 catttgaaag cacaaaacaa ccccaaaaac atgttattta cttgcatctg taaaacgcaa 24060 aaggaataac ataaactgac tcagaagcct gtggtctctg tcttatatct gtgaagccat 24120 gtgtaaaaga aactctgggg tgggtacagg tgacagacat tctcctcatg accttaatga 24180 tgtaattact gcctacctat cacaggatgc tattcacact cattagcagt cccagtatct 24240 tatctcttcc atattaatac tttttcacct acctattagg atgcagaaat tgaaaaaata 24300 ctttataact agaaacaaag aaatccttga cctgtgaaag gaaaactaaa aaagagttgt 24360 aattactgtt acctgtcatt tctcagtaat accttaatct tgctacactt tgggtagaga 24420 aggaaagagg aagggcaagg aatggagggt cagagtgaga cagggtagcc tgaagaatgt 24480 ttaagttttt ccagctgtat atagttgtta agtgtctaca gggctatgtt tacatagaaa 24540 tgtaattata gaacacaatt ttaggaaagc aagtctcatt gatgagactt aagttagtgc 24600 atggatgtat taattggact ttgtgagaaa gactttggag ggaataaaat atgattttac 24660 agtggagctg agataagaaa tgtatattaa tagaaagaat tgagatattc taatgcatga 24720 gaagtaaaac aatgccacaa aagcagaaac acaacagttt aataaaagta gatccaaaat 24780 tgctcatgct actcagctca gttagaatgg acttcatctg tcagatgcat caaaagataa 24840 aaacaagggc agcaggttta atggaaagaa taacaaattg tgcaccagaa agtctgtact 24900 gatttttttc attaacttgg aagaagttcg agaaaagcca agcatagtgc ctgagacata 24960 actagcccta aattatttgc agaattaagg aatgaatcca agtaaagaag taaggaggag 25020 cagccatagc taaaatggga cctcttgttt gtgtagagtt tgctatgaaa taagcaacca 25080 ggttacatta atttcaacta tataaagtat tcgaactaaa aagaacagta agtgaatggt 25140 actacctaaa ttttttctta aatttatttc ttaaatttta tgtactgtct tgataatatt 25200 ttttaaaatt acagttatta caagtttaaa aacaaacaag caaaaaagga atacagagat 25260 tcaagtttct gtttgaacca agacaagcca ttgaatcttc attcttatct actgttggca 25320 taataatgcc aactgtaatg cttcaaagaa tctttttgat gatcaaaaga gataagactg 25380 agttccatga gagtagcagt ctttacttcc gaatcctcaa ggattattac agtcctggca 25440 cagtaggtga ttaataagta cttactgtac attgagcaat tgaatactta ttcaaatgaa 25500 gctttcttaa taactttgta aacaatactt ttttctttga tctttctagt ttgccagttt 25560 gattaatgat ttgttttact ttttcatacc tggccatcat ttctgaactg atagaaacaa 25620 cagtttctgc aaattttcac aaaacatttc tcccaatagg aaagcacatt aaaacattct 25680 ttgctctaaa ctttgaatac attcttcttc taggctattt gtaaacagtg aatctagaat 25740 gaaagaatta ttcacctttt caacaatgtg ttctctatct cttgaagaaa aaaaatgaaa 25800 gttttgcaaa taattataaa gtttctgtaa cattaaatgg catcaaaaga aaaatttcag 25860 ctaatggaga gcaagacaga gttaagagag agggaagaga aagatgagat aaatgtggtg 25920 atacaaacaa ttaggttgag gtaaatagac acaatattgg caaaacccaa aggctaagga 25980 gggtacactg aaagaacatt ttggtcagag aagtaaaatt tgtataacca tacttgttta 26040 gttctaaaca aatcttggga tctgagtgaa caaattttga ttgctataat tatggcagat 26100 tacacagaat tgatatatac tgtacaaaaa caaccaatta atctagcaaa ccaacaagaa 26160 gtgcaaaaat aacacttcaa gaagaaagcc actaactgtg actctgactt caaggtataa 26220 caagtatgta ggaccacctg ctaagtaggt actaagcatg agtaagtgtg tatctgacca 26280 cctgctaagc tacacaggtg gtcagaaaca cagtcacagt gggcctccac agtgaatcct 26340 gtgtgaatat aaggaaaatg gacaacagca tctcagaatg gaagcatagt gatattttat 26400 tatagtttgg atatttcatt atcgtttgga ttatattatt tggatttcct atacctatgt 26460 ttactctgtg accaagaaaa tttctggaca taacaagcac aatctaaact atgtgaagat 26520 gctttttaca aatatatttc ttccgcaaca gcagatctag aaagacaata agataacaaa 26580 gctgagtgat atagctgctt tttttttaat ttggacattg agaattaagt aacaagttaa 26640 ataaaggtgg tttacagaaa taaaattaaa aataaattat gtcaaaacca ggatgaatat 26700 tctagctatg aaatgtatgt aaaaatctgg atcaaatgcc agaagaaaaa tgcaaaagct 26760 catcaagaat gagaaaagca atgcaaattt ggcccagggt ttgaaggatg tgggggaagg 26820 gagccaaaga agttttcaag aaaatctgac taaatcaaca ctttgaagat tgtacttttg 26880 atgaaaaaaa aagataaaaa tttcataaat tcctcatgtc tactttccaa tatagaagat 26940 ttatcagttt ttcctacttt aaaaatacag atggagatgc tagaaatatc atgtcatgaa 27000 catctggaaa tgctgatccc atttaggaag caactgtggg cattgatctc tgatggaaga 27060 agcctgggaa atatttcaat ttcttatact caatgttgaa aagcatggaa ctgacactgc 27120 tattaaaccc atgccattac atatacactc agccatctgt atccatgggt ttcgcatctg 27180 tggaatcaac caattttggg ttgaaaatat tcttttaaaa gattgcatct gtactgaaca 27240 tggacagact ttcttctatt gtcattattc tcaaaacaat acagtataat aactatttac 27300 atagcattac attgtatttg gtattataag taatttagag atgatttaaa gtacacagga 27360 ggatgtgtgt acattatgtg caaatactat gccattgtac ataaaggact tgagcatgtg 27420 tgaaacctgg aggaggttct ggaaccaatt ttccacggat accaagggtc tttcgtattt 27480 taacagtgga actaaaggcc tttacctttt ttcctctttt taaagatgac tctggtaaaa 27540 aagaattgta tttcaagaat atgctatgaa tttctttttg aactatctca tcaaaatgta 27600 aaatggcatt aaactggtat atttctgctt ttttaaaata tgatttgctt tgccatgtct 27660 ctgggtgaca ctcatgatgt gttctaaaat tctggcagac aaactacatt aacccagagt 27720 aatttaatgg atagatactg aaattgtctt tcaagcccca cattgcaaat gcacttgggg 27780 ctcagcaact atctagaaac atggttctca aaactggctg tcctggagac taatgtggca 27840 agattttgaa aaatactagt gtgtgagttc catactgaga gattctggtt taattgctac 27900 agcatggggc tcaaaaacaa aggactgggt ccagctctag tatttggcaa caaccaagtt 27960 aattatctct ctccatctct tacctttata tattacattt tttattgttg ttgtttgttc 28020 attaattaaa ggctgttttc tgctttggat ttcacatcac agaaaatagt ccctgaaccc 28080 atgaaccaat tgactgtgta tagaaaagat gatcatcttg taaaagcata aatgcttttg 28140 tagtaacatg tagacaaaga tatagggtat ggtagatcac cagtttccag aaaaggttca 28200 gagaaggtaa tattagtgtt cagtaataga gaaactatct tgaatcttta acttcttatg 28260 ttgacatgtg aaacagaaca cttcaacaaa acttctctaa ttacattttt gatttgatag 28320 gtaaactgaa tttttactaa tgaaactctt atgtttactt taagctgact aaattgtatt 28380 tattattttt aatgaataca tttgtttctt ctgctatgca catacaccca ccactctgtg 28440 ccaggcatta ggctcctgat cctgtttggc tgttgaatag cctgatgaag ggcatgggga 28500 ggcagtagag gagtggggag gaggggacgt gggagtgtta ggtgatggta aagagacatg 28560 actttctttt ctgatgacct ggtacagcat ggaccaagcc caaatctttt ctaagttcaa 28620 agagtggacc tgctgatttt taagcaagaa tttcatcagc tttgttattg atgtctctat 28680 gactctgaat ctaatcccct tccaccctat gttcttgaaa ctagttcttc tttatttttc 28740 acccatcatt acaaatgcag tcaagtttgt atttttaagg cttctgaagg tacaacttgt 28800 ctagttagaa aaaattaata attggttttc tttgctacca caaatacttt gtcctctaca 28860 tctcttcatt catcccgctg ctaatgggct ttgtcaaaga agagagggct ttagcagtat 28920 ccctttcaca attgcagctt cctgagaaca ttggaaaaat actcaccttg gcttcagtgt 28980 ggcctatgct gagatatggt agcagtagtc atgtcccagg agattagcac tcccagcaag 29040 tccctgcttc tcagaacaac tgggtttcgc tatgatgaac agtatgcact ggtaaaaaga 29100 atcacagccc tttgaagata acaacacttt gaaactttga gcaagtttgg cacaccttca 29160 ctctttcctc cctccatcaa tttttactta agaaacgtca actgtttttg aagcattttt 29220 gtttaaaaag tcagtgttat tgacttaatg tttgtgtcct ttcaacccac ccaaattcat 29280 atgttgaaat tctaactccc aatatgacgg tgttaggagc tggggccttt gggaggtaat 29340 taagtcatga gggtggagct gcacaaatgg gattagtgtc cttagaagaa gagacaagaa 29400 aacttcttct gcctctgttc tctgccacgt gaggacacaa agagaagaca agcatctgta 29460 aaccaagaag acgacctttg ccaagaacct gaccatgttg aaaccctgat cttggacttc 29520 cagccttaag agttgtgaga aataaatgtt ggttttttta aacctctcag tctatggtac 29580 tgtattatag tagtccagac taaaacaggt acccgtccca cctttccccc caaaacagga 29640 taattgctct cttccacaac tgggatagaa ataaactgta ttatcatgac agtttacaaa 29700 gaagcaactt tacttcttga tgagaaagac atcagtcact gtattagtca ggcttctcta 29760 gagggacaga attaacagga tatatatatt ttatatatta tatataaacg ggagcttact 29820 aagtattaac tcacatgatc acaaggtccc acaatgagct gtctgcaagc tgaggagcaa 29880 ggacagccag tccgagtccc aaactgaaga acttggagtc caatgtttga gagcagaaag 29940 catccagcac gggagaaaga tgtgggctag gagtctaggc cagtctagct ttttcacatt 30000 tttctgcgtg ctttatattt gctggcagct gattagatgg tgcccaccca gattaagggt 30060 gggtctgcct tccccagccc actgactcaa atgttaatct cctttggcaa caccctcaca 30120 gacacaccca ggatcagtac tttgcatccc tcaattcaat caagttgaca gtattaacca 30180 tcgcaatcac tttttagtga tcagcataat taatatagtc caaccatttg atatatacac 30240 acacatactg atttggtata tcttaaatta aatttctaac tctatttctt agcaaaactg 30300 tcttggcaca gaaatagttg ggtaaatctc acatgttatt aaaagtaatt aatgaaaaca 30360 ttttcattta ggtttattaa aaaacaataa ttaatgataa cacactggcc tttacaaact 30420 ccttttgaca tacttatctt taatatttat taaggccaac ataagtaaac aaattttatc 30480 aagtaaagat gtgtaaacat aaattgtgag aggttaaata agtttatgag cttgtggaat 30540 gttgttgaat gaatttatga atgttgttat agagattcaa cctacatatt ctgactttaa 30600 gtccagttcc cttttcacta cataatgtga tgtccattaa aaagaacaac accttaaata 30660 ggaaactgct aatgttcatg caaaataaac acaaataaaa aaataaaaat gagtccatta 30720 gcttcatgcc cagtatgatt cagctatctc atgcagctga taaacaaatt gataccaact 30780 taatctatgt tagtaaatgt ctagtgtcca agaaaagaag ctcacatctt tttactatat 30840 tctgcaatgc taagaacgtg tctggaatat catttagttc ctgggccttg tcttaaatga 30900 agttgtaaaa agttaaaaat atcttaaaga atggccattc tagcaagaga gcatgtggat 30960 atggcttcat ttgaaaaaca gctgaaatgg gggatatgga cgtgtttagc ccagaaaaat 31020 aaagatttag caaggaggat gagggggtta gttgtcatga agtacttgaa gaactattcg 31080 aaagtaactt tgcatgtcaa tgtgtcagag ctaagaacaa ggaatgtaat ttttaggcga 31140 ggacaacagt ttccatttaa tatactactt tctaactatt agaactcttc agaagcttta 31200 aagggctacc tcatgcagac acaaagtgct cctgtgaaat acgttgtaca gaaggctcca 31260 gactgcatgg ttcctaccca gccatcagca atttaaccag agaagggaag aatggagggg 31320 ttcagttttt ggcgcaagag atcatacgca atagcgtaat catggaaaga gcttgtctac 31380 aaatcgttat gatgatgtag gtaagttata tcaatcatga aatttcacat ttgagaggct 31440 gagtacagta catttactct ctttctccct cttctttttg agtagttgaa attagtataa 31500 cacatttcat tatttcaaaa taccctttgg tgttcaagag acagactaaa aggcagaggt 31560 ttcagttaat gtcctcagtt tagaagccac atctttaagg cagagagtga cctggagcta 31620 aaattgtaac tcttatcctg cagcattcag gttagaatag acagctgttc cttcacaact 31680 ctctctgctg aaacccttat gatgctgact aaagcacatt ttcaattgct caacaggtca 31740 actggaactg gggattttgt aacatagctt tacatctttg caaaggcttt atattcttta 31800 ggttggatat tttcactctt tggggtggtt ctgtaaacag agtagatgtt aggtctcctg 31860 gatttggagt cagacaagac cagctctttc ccttgacatg tgtgtgccct gtatatgtcc 31920 tcttctggaa tagtaaaata tcagtaatgt ttactacact cagttgttct gagaatggag 31980 ataaccatat atatatgaag agtttagcac aatacatggt aaatattaag tgctggaaaa 32040 atatcaaatg ttgattttta aaattatacg tatgctgctt gtttcaagca agtgtgaatc 32100 cacaatcaag ggtagctctg tgaaagagcc caactgcagc ttctttgtac ccagccaaga 32160 cttttgggat tgctattttg ccagttgtct acattaaact atggtttctt gaagaatatc 32220 atcatcacac aaagttcatt gtttaaaaaa atgaaataaa tacgcgtcat aaatgttatc 32280 tattggaata tagaaatatc ttcattttaa ttggtgactt tttattttat tattttcttt 32340 gagatatgag aaggtggaaa tgaagagagc actgtggaat caaacgaagg tgtatgtata 32400 tatgtctata cttacatgtg tgtgtggggc agggagagag gtctgtgtgt gtgtatagtt 32460 ttggtttttg tagcaggagt ctttagaaag gtggtgactg caaggtcacc ctgcccttca 32520 tcactaactc atatgtgtct gctagtccta agtaaaatgg atattaatgt ccatgggtgt 32580 ctgtgtgcaa gtgaggcact gtgttctatg gtggctatgg tgtgagcaac tgatgcagaa 32640 ccatggactc agactggatg agaccctgaa agccaggatt cacatactga agccaagaag 32700 aaactgaagc atacacagat ccttcctaca gagcataggc gaataggagt atttgcatat 32760 ttgactgcat catgaggagt tttcttcagg tatctccgag aaaaacagct ggcttgcttg 32820 tttttattct atcatcagtc ttttcagagt agaacccgaa gtcctcatat cgacctgcat 32880 gatttggtag ctctgacctc atctcccatt cctctcttat tctcttgctt ttactccagc 32940 cacactggca tctttctgtt tcttaaactt caagactact cacctatctc aggatctctg 33000 caattattgt accctctttc tcaaataata tgcgattttc tcatttaaaa tgcatatatt 33060 tatgaatgca tttattaaat ttattttctg cttctcccaa ccaatattat ctccaatagt 33120 catagaaaat aatagagtaa aaaaacctgc ccacagcgga gacaatttta gaatttaaaa 33180 ataaatttag taaaaaatgt attaggcctt catgaaggag actaaaatat caataaatac 33240 tgtaaaatct aggtcatgta ggcaatgctt ttagatgaga atacccaaga tattaaaaat 33300 caacacatag taattaacat attactttaa tctgcaaaac ccctaacttt taaaaaattg 33360 actaaaagga tcatcaaata tatgggggaa aataaatgcc caagaataat taaaaaatat 33420 tggaagtgta attttacata caaaatttta ccttttacac agtaacaggg ccactaaata 33480 ttattttaca atgactcaat acaaaaataa ttttacaaac catgtccatt agctttaaaa 33540 acttaatttc tttgtcagca acttagtgct ctatactcac aaatatatga aaattatcaa 33600 aagttttgct aatccacgtt gctatgatta ggatgtttcc tgctgttacc tctatttcac 33660 atatagtcca tagctcccta taagaataat ggagatttat agtgagtaaa tatgtaatat 33720 taatggtatg gaagaatatc acaaatataa caaggtatgt tgttttgaaa cctcttccta 33780 aatattaatt atttgtacca cacacctata ttcttaattc aaacatttgt gtaatgaata 33840 gctacataag gagtgaaaaa aaagttttgt taaactattt tttacttttt ctggtctgac 33900 tttcatagta tttctttctt ttctaattat actatgatga atgtaaaatc ttagagaaat 33960 aggactagta gaaatctgtt gtctacagac ccaaaaataa acaatgcaaa attatagagc 34020 atttaaaaaa taagtctgtt acttccagcg aatatataga attagtttgt tttcaatgtt 34080 tgtatatctt tttttctgag taaataaata ttaccttctg aatgtaatga tttctggact 34140 aatgttacaa aaacaacaaa aaacaaaaca aaatcctcca ttcatttccc attcattgaa 34200 tttagtcagc tgtttcctaa cctaatccat tgaccttgtt atggtcacaa tgaaaatatc 34260 aatatttttc ctagctgggc ataatggttc acacctgtaa tcccagcatt ttgggagacc 34320 gaggagggca gatcacttga agtcaggaat ttgagaccag tctgggcaac atgctgaaac 34380 tccatctcta ctaaaactac aaaaaaaatt tagccaagtg tggtggcatg cgcctgtagt 34440 cccagctggg gagggtgagg caagataatt cattgagcct gggaggcgga ggttgcagca 34500 agctgagatc gtgccactgc actctagcat gagcgacaga gtgagtgaga ctctgtctca 34560 aaaaacacaa cacaactaaa caaagcactc aatatatttc ctgattgtga aaatgattta 34620 tgaaaattca aacagcacag aaaagaggga gttggtctgc caggtgaaaa cacacacact 34680 tgaacctttt cttgaatata gaacatgata gaaagttcag tttattctta atttcaagat 34740 tgtatttgtc taatacaaaa catacaagcc cattctggca gtatgtgaaa gttggacatg 34800 acaacctggt cgagtcgact ccatttcaat taaccaccct gtaccagcat attgtgccaa 34860 cctttgggcc ctgggcagac agatgttgca tttgtggatt gagaacatgc acaagaaagt 34920 atctgcttcc ttctatgtcc cttctctttt gtcctggcag tccctctgtc ccttctatcc 34980 ctttgaaatg tctacctcct gtatcttgaa cttgttgcct tttgttttcc tcccttagcc 35040 aaaattaagg cctatctctc ccatccaaaa taattcatct attgtatcca cttctcccta 35100 cattcaaaat ttcatcttat ttcttctctt cttccctacc aagattatta ttgtatttaa 35160 tctcccattc atttctcagc tatttacaat ctggcttgct ctcttatttt tctgcggaaa 35220 tgattctgac atagttctcc agtgacctct aaatttccaa actcagtgga aacaattcag 35280 actttatttt actcttcctg gctctctgtt ccctgacatc atacccttct ggttctcata 35340 cttttggaat tctttgcctc tttcatgaca tcttttctac acaaccctta aatgtttatg 35400 ttctccagga tgcattactt ggcaaacccc tactggataa tctcatcttt ttaaatgttt 35460 tcagtgatta cccagtatta aaaattccca gacctctcat tcccacatat atgtctgtcc 35520 tcagctacag actcacaaat ccagccagct actggacatt tccttctggt tatcacatga 35580 cattctaaat tcaacagttt cagaaacaaa ctgattttat tccagatata ttaatgtatg 35640 ttctttgtct tgattggcag cactgtaatc cacttagcta gaaaccagga ttcttccccc 35700 aaacttctct gtactttact aaccacttct aatcaattct tatatatgta tagattttgt 35760 ctcccaaata tttctcaaat tattttcctc ttttatcatc ttaataccac taaggtattt 35820 aaactgtctt catcttatag acagtcataa tgatataatc aaaatacaat tctaaccact 35880 tagtaccctg aataaatcct tcagtgtctc actggcacct acaggataaa gcccaacctc 35940 ttagaatgta tatgcggccc ctctgcttgt ctgtcacctt ctctctcaac atttcctaac 36000 actgtgttca tcaaaaccca gttgctagca aatgccccat gccccatgct gcttgtcgta 36060 tctctttctt ttctcatgtc atctcctctt tctcgaatcc ccttctactt gtagtcccta 36120 tttctgccct ttacctgtgt aactcctatt ataagacttg gcttaggcct tgctcccaaa 36180 gcttttctga ccctttcttt ttttgctatc tgatatggta tggctatatc tccacccaaa 36240 tctcattttg aattccccac gtgttgtggg aaggacctgg tgggaggtaa ttgaatcatg 36300 gaggcaggtc tttcccgtgc tgttctcatg atcgtgaata agtctcataa ggcagagttt 36360 tataacttta taaggtggag tgtccctgca caagcacact ctttttttag cctgccacca 36420 tccacgtaag atgtggcttg ttcctgcttg ccttccgctg tgattgtgag accttcccag 36480 ccacctggaa ctgtgagtcc aattaaaccc ctttctttta taaattgccc agtctcagta 36540 tgtctttatc agccgtgtga aaacggacta ataaatacac tatctttcct tcatctcatt 36600 gggttaaata atatttctat gggttcacca gtggctctcc ctatcatcat tctcacatgg 36660 tatgtacaat cagctttgta ggtatatgta tgtgtttatc ttccctataa actatagtaa 36720 agatgacatc tatgttggta actataaaac cccagttctt agcatagtgg ctaagatata 36780 gtggttgaat tcaatatata actttttctt tttgaaaata aagataaggt ctcactgtgt 36840 tgcccaggct ggtgttgaac tcctggcctc aagtgatcct cctacctcgg cctctcaaag 36900 tgctgggatt acagacatga gcaatcatgc ccagcctcaa tacctatctt ggcattgtat 36960 cttttactag aattctggaa gattcactta gtgagtgtta attaaataaa aagtagcaca 37020 gacattgttg ccaaggacat attgtttgtt ccatttttct aattttcacc ttgttttaat 37080 tatattaaaa tccaagaata tttttaatta catcctgaaa gctaacaatc actaaacaca 37140 tatttcttaa attaaatctt ccaatggcaa ttggtatagt atttttttcc ccattactat 37200 tgtacacatc caaagaggga ggtaaaacta ttgttttatt taaccatgtt tatacattcc 37260 tatcctttgc actaaggggg ttttcaacaa aattagaatg tttttggata taggaacaaa 37320 taagttaaat gttattacat ctacccctaa attagccatg agccagacat ggtctaataa 37380 tatccattag atgtttattt tacattttaa tatttatttt gttatgctag gtgtaagcca 37440 agccttaagt gattaattta aatctttgga taaatcaaga tgtgactgag cttcatattg 37500 gtaaaagaaa ataaagatgt attgtcaact acaatacata tacatataaa aataattata 37560 aaacaagaat acttttcaat aaagatttaa agaaaggcct gacatggtgg ctcatgccta 37620 taatctcagc gctttgggtg tttcaggcag aagtatcacc tgatgccaag agtttgagac 37680 caacctaggc aatgtaggga gacccctctc tctatataaa aaaaagttaa aaattagcca 37740 ggcaaggttt agcatgtctg tagtcccagt tacttgggat gctaagagag gaggattgct 37800 ttagcccagg agtttgaggt tttagtgagc tatgattgct atgattgcac cactgtattc 37860 tggcttgaga gacagactga gaccttgtct ctaaaaaaaa aaaaaaaaaa aaaaaaaaaa 37920 aaannnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 37980 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnaaaaaaa aaaaaaaaaa 38040 aaaggtttaa agaaaatatt ttatatgaat cctattaata agttcataag atataatact 38100 ttggaaatgc cttttatatt cctgggtaac tccaaatacc tcagaataga aaataagttt 38160 acattcacat accagaggat actgttcaga tcaagaaact aatttaatcc ctctgtcact 38220 ttctcaaatc tatgatatct taatctcaca acttttgact gctaatagcc atggctgaga 38280 tttgtatttc agcttctctc agttctatgt atccacaaag attttgagtt taaaggtctt 38340 gagactacta ggttcacaga ttactgccac attctgtctt cttgatttat catttatctc 38400 aactaaccat atacttgtaa aaaataacag ctttattgat acataattta tatagtataa 38460 agttcacctt ttcacactgt aaatacagtg gtttttgtta tattcacaga attgtgcaag 38520 ctttaccatt gagtaatagt aactggccca agacacacaa tagtctggct gtcatcccag 38580 accattccaa ctcttatgtt cctggcctgc taattcttaa attccatttc catctgtttc 38640 ctgacttttg atcctttatt tttcatttaa cacttgcttc tgccctggag acttggcatt 38700 tgtctcttgt ctctaattaa tgacagtctt ctaaggactt tgacttagaa ttgttcacca 38760 gagctttcat tttggtcacc tctggaagtt cttctgcctt acttgttttc taagaatcta 38820 cccatggata ttgccactct agtcagatga ttgttttccc atcaggaagt cattcaaaca 38880 ttttgcttcc agtttttgtt tctttggact cagtcttgat gaagctatag acacatggat 38940 gaactcagac tctctcttga agatgaagga aaagtagagg tctcgtttgg gagaaattta 39000 gggcatgtcc tcaggaattg ggaattactg caaagccaag caaattaaga tacaagatac 39060 atcgcagtga ggtacagata atttgcctgg gactcctgat tctagatcgc ccctcaggag 39120 ttcacacggt gattctcagc ataggacaaa ccaagtcata gaattcatat tggacatggc 39180 agaatgtgtg caagggagca tttgtaggtg ccactttgat acagacattg ttagcattga 39240 aaggacaatg cacagagata ttaggcctcc tgcaatacat agagcagtcc tgcacaaaaa 39300 gtgtgttggt gactttgatg attttgaatc cctaatgggt gacatgaaaa aatatgtcat 39360 aaactgtcat ctgatggatt taagattatt gatttatccc atcatctccc tgcatttctg 39420 ttgcctttgc gctaccccac cagtgacttg ggtcacaacc ttggctctgc ttacctgcgg 39480 atgcctgcac aacaacctga ctcccagtgg agagattctt ccctttccct gcctcaggga 39540 aagaactggt tatttgaccc agaatggcta tgtttggaca gcattcctag cagtaggaaa 39600 gggttcctga gccagtatgt gagtttcaat acagctagag ggtaagaaaa tggactctgg 39660 ccccaggata tctggatttg aacttgagct ttacaactca ctaaagggga gatgacttcc 39720 aggaagttat caaacttcct tttgcctccg tttcttccac agtaaaaaag gggtaatatt 39780 agtacctgtc ctagaggttt gttatggaat gaaatgtgtc aatacataaa aagtgcttgt 39840 gagaggctct gtaagtaata tgttagcttc ccctccaccc tcaagaagcc tgcatcactg 39900 atgatttatc ttggaatagg aaagtcaaat gacaattaat gctgatcact agatttgtga 39960 ccttggtaat ttcacttcac ccatctttat gtttctctct ggtaaataag gttaagaatt 40020 cctggggaca ttttgctaag tgaaataaga cagcgacaga agatcaatga cctgattcca 40080 cttatatgag gtaactaaaa tagtcaactc atagtagcag agattagaat ggttgccagg 40140 ggctagatgg agggggaaat agggagttgc tattcaatgg gcataacgtt tcaattttgt 40200 aagatggatg ttagatctgc tgtataaaat tgtgcttaaa gtttacaata ctgtattaaa 40260 acttacacat ttgtttagaa ggtagatctc attaactgtt cttgccacag tttttttgta 40320 aagctacaat tttgcctcag ttattccaca atgacttact aagatttctc ttccaaagac 40380 cgggagcagc acacagcagc aagcatcacg taatgtacgt aagaactcac aggcagaggg 40440 tcagcaggaa tgagggtctc ttgtttttgt aatatgctag agagttgtga ttggaccatg 40500 gagctgggtc ctggcagaga tattctgccc ctcgctgctt tttttgtttt ttttttttaa 40560 tggaataagc ataacaatga tcttgctcag ggtaatagac actttcagtt ttggggccag 40620 tttcttaatg atgtacttta aaaagccagt tctctagcac tggaagacaa tgaaaaaagt 40680 tgccaggcca cccagagaga gagcttcaca gtccaaaatt agcactcctg cttttctgta 40740 taagactgaa agacaaaaca taaataaatg aatctttaaa attattaagc atggtgtaat 40800 ttaaatggat gtacctatga gtatcaaaaa ctaattttga atgattataa tgaagaatac 40860 aatatacaac atatataatg cattatatta tgttcttaat cctaaattta taacttttac 40920 ttaaatatta aaaacatcta aaagtatttt taatcatgaa tcaaactttt gattagtagc 40980 tcacaactga gaatgcgata aaattgatag ccaagggggc aagaaaaaaa aactccaaaa 41040 gactgtttta attagtatac agttgttcct tggaatccat gggtgattgg ttccagaatc 41100 cctaccaaaa tctatggatg ctcaagctcc tcatataaaa aagttgtagc acaataaatt 41160 ctcatcatca ttgataagtt cttggaaact gcaactttaa gtaaaacaat gtataacaaa 41220 atctatttaa tcataggcta attgacataa ataagaatta agttcttatg gcatatttct 41280 tgtcacaaaa acatcaccaa acttctaatt aaagaccaaa acacttctga tattcaacag 41340 tgaaataaat gtgagctata tataccttta agaaaggctc aaaaaaacaa atcagataaa 41400 tgtttatcca actactccag ttcaggatcc cgggtagctg gagcctatcc cagcagccca 41460 gggccaaggc tgacaccatt ccattgctgg gagcaattag gcacacacac ccacactcac 41520 ttagaatggg accattttga catgccagtt aaactaacat gcacatcttt ggaacgtgag 41580 aggaaatcag aatgcctgca gaaaacccac acagacatgg agagaacgtg caaactcaac 41640 acagacgtgg tccaggccaa gaattgattt tttttctctt caatgttaca acaaaacaac 41700 attcatgctg tacttgcata taacctatgc acatcctccc atgtacttta aatcatctct 41760 agattattta taatgcctaa tacaatttaa atgccatata aatagttgta ttactgcatt 41820 gattagggaa tcatgacaaa aaaatctaca tgttcagtac aaagtcaatc atccatttta 41880 atttttctga ttattttcga tccatggttg gttgaatcca cagatgagga acccgtggat 41940 atgaacagcc atctgtaatt aatactctaa aacaaatacc aaaattttaa agccacaaat 42000 ttttatacat tcttatttta taacacataa cattatttgt aaattcataa gaatagaact 42060 tacaagtata atttatatgt gatgttggca tgtgaatgaa agtttaattt gcataactat 42120 atttcagtaa tgaaactcaa aataacttgt cccaaatcca atagttgata tgtgatagag 42180 ctaggattct gacctgaact tgctatattc taatgcctat ggtatccagt actagacaga 42240 ataggagaga tttagctggc ttcaatattt aaagtgacat taccttctgg acagggctgg 42300 ctttgtgggc ctaggagttg tgcagttgca tgtggcttaa tgtgttacat cttcatcttg 42360 aagatattaa tattttttta aaaggggctc agcattttta gtctgccctg ggctcactga 42420 attatgtagc cagtcctgtt tttggaaaag atacagacaa ctctttaaat agtctctgtg 42480 tttgtaatca gtgtgataaa aatatagagt aagcaaccag caaagttgtt cctggacaac 42540 cctgggatca gcatgctcac ttgctgaagt gctctccatc catggtgatg tcttctggag 42600 ttctccaaaa gaagataccc cactgggtct ttctgtagct gtctagaatg ctctttgtta 42660 ggcttgagca cacctcctag caagccacag gacatggaac aaatatgact tctaaaatcc 42720 tcaaaggata ctttgaacct tctcagaatt tatcttcaaa atgagagaca agtgggaatt 42780 gatagaagaa gggaagaaga gagagaatga agaaggcagg gagaaaaaga gagagaggga 42840 gagggagtga gaataacaat gtctatagac tttgttatag aaaaagaatg tatttatatc 42900 ctacctgtaa agattgtatt gctctctcat ttcatttcta taatggcgta tatgaagttc 42960 tttaattccg cccatcacct ggtagaggtt tatatgtatt gctcctctac taacttcttt 43020 aagtagtgga atattgcctt gatcatcttc ttgggccacc aaaattttgg aaaattttga 43080 tgaagtgttt ggtgaagtta aacaaaatga aatgacagag tctgcctgta ttcaatgact 43140 ttggcattta tatatttcca ttaaaattat gtgcttttca ggtgagttac gtgaagtttc 43200 ctaaaactaa aactaaatga atctccaaaa tagatgcgta agtccttcat tacctaaaag 43260 caatgtttcc acttagtttc tgcctctaag ctttactatc ccaatgcaat ttagctaatg 43320 ctttagctaa agagaaagta agcgactgat taaattaatg tcttagtaga agattaagtg 43380 acctactatt agcgtaaatc cttcttcaat agcatttgac aaaactgctg ctaattatct 43440 agccaactac aaatgttctt gccaggtagt agaatcatga ggttcttttt gccttttcat 43500 tttctttttc tttttttttt ttagttggat tttatttttt ctggaatatg tcacatttta 43560 aataagagtg tctcttgaaa gacaatgtga ttggggccat actcctcaca gaaaaagacg 43620 attttttttt tttttagttg aggatatacg attttcaaga gcaataatag caccagtgtt 43680 caaatccatc aatcaaaacc ctgtgaatgc taaagaaaat ttaaagagga aacagtaata 43740 ccaatcttac accaatactt tcaaagaaaa atcatgattc ccaacctgtt ttatgaggtc 43800 agaacagggg tgtgctgtag tcagtttgca caggctaaca aaagtcaatt acaaatatct 43860 cttcccaact ctgcatttca catgtaataa ccaccattgt ataacaaaca gaactaagca 43920 aattataatg ccaacaaata tagttatagt tcagtgagac aatattaaaa atttgggaaa 43980 aactttgaaa aaaagaaaaa attggaaatc tcaagaaaaa taaaatctcc tgtgttctct 44040 ttgatcaaat ttactttgaa gtctgtgctc aacttgacta atgaaataaa tgtgcaaatg 44100 ataactaatg agaccaatat actgactttt cccaaataca tggaaaagtt gaaatacatt 44160 atagttaacc tccatgcacc tgtcacctac aacaaaacat caatagtttt ttaagggtcc 44220 caattgtttt ttttaaagct ggtccaatgt gcagctaagt ttgagaatca ctgcgttaaa 44280 ttatagtgtt tctcacactt cagtgacaat ttaaattaca cagattggtg ttggttattc 44340 tttaacttat tggagagcag ctgtggggag tgggcttaac taggagctgg tatgtctggc 44400 cacattccaa tgcttcaaag gagtatcttt ctccttgagc acagtgttta tagataagag 44460 caggtcacat tctgatcatg ggaacatgat ggcaataagg aggctttcct actcagaggc 44520 ctcctgtggc tttccacaac ttattgttcc atatttttat ggccagttta tacaagcacc 44580 ccataagcct ttttcccaac acagattgct atgtcccatt tccagagttt ctgatccagt 44640 aggtctagag ttggacccat gaatttgcct tttgtagaag ttcccagatg atgttaatgt 44700 cactgactca aagccacatt tgagtaacac tctgctctgg aaagggagat aagagataaa 44760 ggaaaacaag gggataattg agtaggcaat gtcctttggg aggctggaag caaccagtgc 44820 accagtggtt tggttgtctt tgtgacagga agaaaggaag acactttttt ctttgtgaca 44880 agtaaaaaaa gaaagtatga atgtaaattc aaataagttt attggtggat ggattaacag 44940 gaagttaagg aaggtctgca cagatgattt caaacatctt aggctaacac tggggatcta 45000 gaatggtcaa gtatatctga tacatacata gtcatgaagt cataatctac aacatttatt 45060 catgtggtgg caaaattaca ttccagacca ctctatacat tatcacactg ataatatatg 45120 taaacaggac ctatttgacc aggaagtgtg tgctgttgta aacacattta ttttagcatt 45180 cttttttttt tttttttttg cataaaaacc aagaaagcag tactccctta ctagtgttcc 45240 caacatctgc acaatagcaa agatgactct tgcttagaag taaggaatac ctttggacag 45300 tgattcaaga gacatgtggg ttataaacct atggaatcta aattaaatga acctaatcaa 45360 aacaagaaaa ctcctctgtt tatatattat ttgaaatatt gacaattttt caaaattatc 45420 gtgcaagctt tgcatgtgaa acagatgtca actggttcaa ttgcactgcc ctttgcaccg 45480 ggaatgatga tccttatgaa ggctgtggaa ctctttggag aacttgtact gctatgaaat 45540 gttccattga atgacatact gcagttttaa aaaatccatt gtcctgttga caatgatgaa 45600 ctgtttgtag gctgttccat tatgaataaa atggctataa acattcttct acaagttatt 45660 ttgtggaaat gtgttttcat ttctcttgag tgtaaaatgg ctataaacat tcttctacaa 45720 atgattttgt ggatatgcgt tttcatttct cttgagtgaa tacttaggag ttgaattact 45780 atgtcaaaaa ttaatgtatg tttggtttga taagaaattg ccagagtttt tccaatgtgg 45840 ttgtaccata ttatactccc ttcagcaatg taggagagtt agaactggtc tacattctcc 45900 ccaaagctta gtgatgtcat tgtttttcat tttagccatt ctggtgacat atgtgggtat 45960 cttcttctaa ctttaatttt tgtgtggacc aaatgacatt gagcagtttt ttgtgtactt 46020 tattggctat ttgtatctct tcctttgtca gatatctgta aaaatatttt gctcactttt 46080 aattaatttt gtcttttaac tgtttggtta taataagttt ttatatgtat actgaggata 46140 gaagtcgttt gtcagatata tgtttgcaaa tacttcttgc tagtttttcc attctttttt 46200 tgtctttcaa tgacaaattt ttaattttgt gaagtccaat ttatgacttt tttctgttat 46260 gattactgct ttctaattct gtctaggaaa cttttgctta gcctcattac aaaggtttgt 46320 ttgtaatgtt tatgtctgta tgtttatttt gctaaaagta ttacatagtg tttgaagtta 46380 atgattccca taaagctatc cagttgttct cgaactgtta ttgaaaaaac tttctatttc 46440 cattggattc ctttggcatc tttttcaaaa cttgatttac catcaatgtg tgcttatatt 46500 tctggacttt attctattgt gctgatctgt ttatcaatac ctatgccagt accatattat 46560 cttgattact atagctttac agtaaatatt agggttagat aatgtaagtc ttccaaattt 46620 gttctttttt ttctttcaaa attgctttag ctattctagg tcctttgtat ttccatacaa 46680 attttagaat caaattttac aaaatcccct gctgggattc tgtttgggat tgcattgtat 46740 ctatagatca atttggggtg gattgttgtc ttaaaaatat taggtcttca aattgatgaa 46800 ctttatcaaa tgaaccccat gtatttaggt cctttttatt taacatttca tcaatatatt 46860 atagttttca atgtgaatgt cgtttatatc tttgtgtcaa atttatttca aaatatttta 46920 tgtttttaat gccattataa gtaaaattat ttctctgagt tttaaatttt tctctgtcaa 46980 tatatgaaaa tacaattgag ttttaaattt taatcctgta tcctgtgaac ttatttatta 47040 ttttcagtat ctttattgta ttttccttac aattttctgt taaaaattat gtcatctata 47100 tatagacata gttttattca tttcttttat aactttagtc ttctaaatat ttttaatccc 47160 ttactgcaat tagcaaggac cttcagtaga atattcaaaa taaatggtag aagtgggtat 47220 ccttggcttt tttcagatct cagaggaaca gttctcagtg tttctgcatt aagcagattt 47280 ttcatagacg ccctttgtca ggttgagaaa gtttcttact attcctagtt tgctgagaat 47340 tgttatcatg aataaatttt tataagttat tttcataatt ttttaagtga ttgcattgtt 47400 tctgtctttt attttgttaa tatggtgact tacattggtt ggcttgtgaa tgttaaacca 47460 gccatgcatt cttagaataa gtcctttaat tgagatgtat tcttatatat atagtaaaat 47520 tgctagtatt gtgttaaagt cttttttgtt cctttgttta tataattttc cttttttagt 47580 aatatctttg ttaggttttg aaattaaagt tataccggca tcgtaaaacc aattataaag 47640 tgcatcttcc ttttatattt tgtcaaagag tttttgtaat atcggtacta tttatttatt 47700 tcatttgcta gttaataaac ttggcctgga gatttccata tggataggat tttgacagca 47760 aactgaatag tgtgtcagat acaggaccat ttagttttct gttttacctt gcatcaattt 47820 ttggcaagtt gcatattgtg ctttcagtaa atttatttat tttatcttat ttattcaatt 47880 cctaataact ataatttatt ttttctccat ttttcttctt ggtaagtcta gctaggctta 47940 ttaattttat ggatgttttg tatagaggtt tatatttcat tgagttcttt gcttatattt 48000 attttctttc ttatatatac atttggttta ttctgatttt ttaatgattt attagatgca 48060 acgctaatga ttcattttag aacattattc ttctttggtt taaggaagaa attttccttt 48120 aagaactact ccagatgcag ccacaaattg tgatatgttg tgcactttca ttattattct 48180 ttgcaaattc tcttttgata tcttattttg tccatagatt atttattaaa tgtgttgttt 48240 aatttccaaa tatttaaaaa tattttatta tcactaattt ataacttaat tccatagtaa 48300 ttacacagca tactctgtat gattcaaatt ctttattttt ttttatactt tacgttttag 48360 ggtacatgtg tacaatgtgc aggttacata tgtacatagg tatacatgtg ccatgttggt 48420 gtgctgcacc cgttaactcg tcatttacat taggtatatc tcttaatgct atccctcctc 48480 catcccccca ccccaactca cgacaggccc cggtgtgtga tgttccccac gctgtgtcca 48540 agtgttctaa ttgttcagtt cccaccagtg agtgagaaca tgtgtttggt tttccgtcct 48600 tgcaatagtt tgcccagaat gatggtttct agcttcatcc atgcccctac aaaggacagg 48660 aactcatcat tttttatggc tgcatagtat tccatggtgt atatgtgcca cattttctta 48720 atccagtcta tcgttgatgg acatttgggt tggttccaag tctttgctat tgtgaagagt 48780 gctgcaataa acatacgtgt gcatgtgtct ttatagcagc atgatttttt ataatccttt 48840 gggtatatac ccagtaatgg aatggctggg tcaaatggta tttctagttc tagatccttg 48900 aggaatcgcc acactgtctt ccacaatggt tgaactagtt tacagtccca ccaacagtgt 48960 aaaagcattc ctatttctct acatcctctc cagcacctat tgtttcctga ctttttaatg 49020 atcgccttcc taactggtgt gagatggtat ctcattgtgg ttttgatttg catttctctg 49080 atggccagtg attatgggca tttttttcat atgtctgttg gctgcataaa tgtcttcttt 49140 tgagaagtgt ctgttcatag cctttgccca ttttttgatg gggttgttgg attttttctt 49200 gtaaatttgt ttgagttctt tgtagagtct ggatattagc cctgtgtcag atgagtagat 49260 tgtaaaaatt ttctcccatt ctgtaggttg cctgttcact ttgatggtag tttcttttgt 49320 tgtgcagaag ctctttagtt taattagatc ccatttgtca attttggctt tggttgccat 49380 tgcttttggt gttttggtca tgaagtcctt gcccatacct atgtcctgaa tggtattgcc 49440 taggttttct tctagggttt ttatggtttt aggtctaaca tttatgtctt taatgcatct 49500 ttaatttttg tgtaaggtgt aaggaaggga tcctgtttca gctttctaca tatggctagc 49560 cagttttccc agcaccattt attaaatagg gaatcctttc cccattgctt gtttttgtca 49620 ggtttgtcaa agagcagatg gttgtagatg tgtggtatta tttccgaggg ctccattctg 49680 atccattggt ctatatgtct gttttggtac cagtaccatg ctgttttggt tactgtagcc 49740 ttgtagtata gtttgaagac aggtagcgtg atgcctccag ctttgttctt ttggcttagg 49800 attgtcttgg caatgcaggc tcttttttgg ttccatatga actttaaagt agttttttcc 49860 aattctgtga agaaagtcat tggtagcttg atggggatgg cattgaatct ataaattacc 49920 ttgggcagta tggcattttc atgatattga ttcttcctat ccacgagcat tgaatgttct 49980 tccatttgtt tgtgtcctct tttatttggt tgagcagtcg tttgtagttc tccttgaaga 50040 ggtccttcac atcccttgtg agttgaattt ctaggtattt tattctcttt gaagcaattg 50100 tgaatgggag ttcacccatg atttggctct ctgtttgtct gttattggtg tataagaatg 50160 cttgtgattt ttgcacattg attttgtatc ctgagacttt gctgaagttg cttatcagct 50220 taaggagatt ttgggctgag atgatggagt tttctaaata aacaatcatg tcatctgcaa 50280 acacggacaa tttgacttcc tcttttccta atttaatagt ctttatttct ttctcttgct 50340 ggattgccct ggccagaact tccaacacta tgttgaatag gagtggtgag agagaacatc 50400 cctgtcttgt gccagttttc aaagggaatg cttctagttt ttgcccattc agtatgatat 50460 tggctgtggg tttgccataa atagctctta ttattttgag atatgtccca tcaatatcta 50520 gtttattgag agtttttagc atgaagggct gttgaatttt gtcgaaggcc ttttctgcat 50580 ctattgagat aatcatgtgg tttttgtctt tgttttgttt atatgatgga ttatgtttat 50640 tgatttgcat atgttgaacc agccttgcat cccagggatg aagctgactt gatcatggtg 50700 gataagcttt ttgatgtgct gctggattct gtttgccagt attttattga ggatttttgc 50760 atcgatgttc atcagggata ttggtctaaa attctctttt tttgttgtgt ctctgccagg 50820 ctttggtatc aggatgatgt tggcctcata aaatgagtta gagaggattc cctctttctc 50880 tactgattgg aatagtttca gaaggaatgg taccagctcc tctttgtacc agtggtagac 50940 tttggctgtg aatccatctg gtcctggact ttttttggtt ggtaggctat tacttattgc 51000 ctcaatttca taacctatta tcgttctatt cagggattca acttcttcct ggtttagtct 51060 taggagggtg tatgtgtcca ggaattaatc tatttcttct agattttcta gtttatttgc 51120 gcagaggtgt ttacagtatt ctctgatggt agtttttatt tctgtgggat cagtcatgat 51180 atctccttta tcatttttta ttgtgtctgt ttgattcttc tctcttttct tcttcattag 51240 tcttgctaac agtgtatcaa ttttgttgat cttttcaaaa aatcagctcc tggattcatt 51300 gattttttga agggtttttt tgtgtctcta tctccctcag ttctgctctg atcttattat 51360 ttcttgcctt ctgctagctt ttgaatgtgt ttgctcttgc ttctctagtt cttttaattg 51420 tgatgttagg gtgtcaattt tagatctttc ctgctttctc ttgtgggcat ttagtgctat 51480 aaatttccct ctacacactg ctttgaatgt gtcccagaga ttctggtatg ctgtgtcttt 51540 gatctcattg gtttgaaaga acatctttat ttctgctttc atttcgttat gtagccagta 51600 gtcattcagg agcaggttgt tcagtttcca tgtagttgag cagttttgag tgtttcttaa 51660 tcctgagttc tagtttgatc gcactgtggt ctgagagaca gtttgttata atttctgtcc 51720 ttttacactt gctgaggagt gctttacttc caactatgtg gtcaattttg gaataagtgc 51780 ggtgtggtgc tgagaagaat gtgtattctg ttgatttggg gtggagagtt ctgtagatgt 51840 ctattaggtc tgcttggtgc agagctgagt tcaattcctg ggtatccttg ttaactttct 51900 gtctcgttga tctgtctaat gttgacagtt gggtgttaaa gtctcccatt attattgtgt 51960 gggagcctaa gtctctttgt aggtctccaa ggacttgctc tatgcatctg ggtgctcctg 52020 tattgggttc atatatattt aggatagtta gctcttcttg ttgaattgat ccctttacca 52080 ttaataatgg ccttctttgt ctctcttgat ctttgtttgt ttaaagtctg ttttatcaga 52140 gagtaggatt ccaacccctg ctttgttttg ctttccattt gcttggtaga ccttcctcca 52200 tctctttatt ttgagcttat gtgtgtccct gcacatgaga tgggtttcct gaatacagca 52260 cactgatggg tcttgactct ctatcaaatt tgccagtgtg tgtcttttaa ttggagcatt 52320 tagccaattt acatttaggg ttaatattgt tatgtgtgaa tttgatcctg tcattatgat 52380 gttagctggt tattttgctc gttagttgat gcagtttctt cctagcattg atggtcttta 52440 caatttggca tgtttttgca gtggcagcta ccacgttgtt cctttccatg tttagtgctt 52500 ccttcaggag ctcttgtaag gcaggcctgg tggtgacaaa atctctcagc atttgtttgt 52560 ctgtaaagga ttttatttct ccttcactta tgaagcttaa tttggctgga tatgaactac 52620 tgggttgaaa attcttttct ttaagaatgt tgaatattgg cccccactct cttctggctt 52680 gtagaatttc tgccgagaga tctgctgtta gtctgatggg cttccctttg tgggtaacct 52740 gacctttctc tctggctgcc cttaactttt gttcattcat ttcaactttg gtgaatctga 52800 caactatgtg tattggagtt gctcttctcg aggagtatct ttgtggaatt ctctgtattt 52860 cctgaatttg aatgctggcc tgccttgcta ggttggggaa gttctcctgg ataatatcct 52920 gcagagtgtt tttcaacttg gttccattct ccccatcact ttcaggtaca ccaattagat 52980 gtagatttgg tcttttcaca tagtcccata tttcttggag gcattgttca tttcttttta 53040 ctcttttttt ctctaaactt ctcttcttgc ttcatttcat tcatttgatc ttcaatcact 53100 gatacctttt cttccacttg atgaaattgg ctaccgaagc ttgtgcatga gtcacatagt 53160 tcttgtgcca tggttttcag cccatccggt catttaagga cttctctatg ctgtttattc 53220 tagttagcca ttcgtctaat cttttttcaa ggatttagct tctttccgat gggttcgaac 53280 atactccttt agctcggaga tgtttgttat taccgatcat ctgaagcctt cttctcccaa 53340 cttgtcaaag tcattctcca tccagctttg ttccattgct ggcgaggagc tgcgttcctt 53400 tggaggtgaa gaggtgttct gatttttaga attttcagct tttctgctct gctttctccc 53460 catctttgtg gttgtatcta cctttggtct ttgataatgg tgacgtacag atggggtttt 53520 ggtgtagatg tcctttctgt ttgttagttt tccttctaac agtcaggacc ctcagctgca 53580 ggtctgtcag agtttgctgg aggtccactc cagaggctgt ttgcctaggt atcaccagca 53640 gaggctgcag aacagcaaat attgcaaaat ggcagatgtt gctgcctgat ccttcctctg 53700 gaagtttctt ctcagagggg cacccggctg tatgaggtgt cagtcagtcc ctactgggag 53760 gtgtctccca gttaggctat tcgggggtca gggaccattt gaggaggcag tctgtccgtt 53820 ctcagatctc aaactctgtg ctaggagaac cactactctc ttccaagctg tcagaaaggg 53880 atgtttaagt ttgcagaatt ttctgctgca ttttgttcag ctatgccctg accccagagg 53940 tggcatctac agaggcaggc aggctccttg agctgcgctg ggttccacca gttggagctt 54000 cctggctgct ttgtttacct actcaagtct cagcaatggc tgccgcccct cccccagcct 54060 cgctgccgcc cctcccccag cctcgctgcc gccttgcagt tccatctcag actgctgtgc 54120 tagcagtgag tgaggctctg tgggcatggg accctctgaa ccatgtgtgg gatataatat 54180 cctggtgtgc cattttctaa ggctgttgga aaaatgcagt attagggtgg gagtgtccca 54240 attttccagg taccatctgt catggcttcc ctttactagg aaaggcaatt ccctgacccc 54300 ttgcactttc tggatgaggt catgctgcac cctgctctgt gggctgcacc cactgtctga 54360 caagtcctgg tgagatgaac ccagtacctc agttggaaat gcagaaatca cccgtcttct 54420 gtgttgctca cgctgggagc tgcagactgg agctgtccct attcggccat cttggaacct 54480 ccctcttgat tcaaattctt ttaaatttat gaaaacttgt tttaatgcct agtatgtggt 54540 ttatcttagt gaacatactg tttgtaactg aaaataacat gtattctata gttcttgggt 54600 gtggtgttct ataaatatct attagcttag gttcattaat aacattcaga tcttctaaga 54660 gcttagagga aatgttttca gttttccccc attcagtatg atactagctg tgggtctgtc 54720 atacaggttt tttttttttt tttttttatg ttgaggcatg tcacttctat acctagtttt 54780 ttgagggttt ttatgatgaa gggatgttga attttatcaa gtgcttttca gcatctactt 54840 aaattatcat atggcttttg tccttcattc tactgatatg atgtatcatg ttgattgatt 54900 tgtttttgtt gaaccattct tgcatcactg ggataaatcc cccttggtca tgatgaacga 54960 tctttataat gtattgttca atgtggtttg ctagtatttt attgagaact tttgcattaa 55020 tattcatcag atatattagc ctatagtttt ctttttttgg tatgtctgtc tggttttaat 55080 attaaggtaa caatggcctt gtaaatgaat ttggaagtat ttttttatcc tcttttttaa 55140 aaaatagttt gggtaggatt ggtattagtt cttctttaaa tgtttggtag aattcagcag 55200 tgaatcagtt gggtctcagg cttttcttta ttgagagact ttttaattta atggctttaa 55260 tctcattaat tgttattggt ttgttcaggt tttggatttc ttcatggttc agtcttggtg 55320 tgttgcatgt gtctagaaat gtatccatat cttgcacatt ttccaattta ttggcatata 55380 gtcgctctta atagccacca attatccttt gtatttctgc agtatcaaat gtaatgtctc 55440 ccttttcatc tcttatttta tttattttgg tcttctccct tattttcttc attagtctta 55500 taaaaggttt gtgaattttg ttgatatttt caaaaaaaca aattttttgt ttcactgata 55560 ttttgtattg tttattcatt tcaaattcat ttatttctgc tctaatcttt attatttatt 55620 ttcttctact aactttatga tcagtttgct cttgcttttc tagttcttta acatgtatca 55680 ttatttatca agtttttctt cttttttatg tcatcactta tagctataaa tttccctttt 55740 ggtactactt ttgctgtatc ccataggttt ggaatagtat gtttccatta ttatttgttt 55800 gaagaaattt ttcagttttc tttttaattt attcattgac ccactggtca ttcaggagca 55860 tatttattct tcctgtgttt gtatagtttc cagtattctt cgatttctag ttttattgca 55920 ttgtgttcag agaagatgct tgatattatt tcaatttttt gaatgtttta agatctgttt 55980 tgtgatgtaa catgtagtct atccttgaga ataatccata tgctgaggag aagaatctgt 56040 attctgcagc ctttggaaga aatgttatgt aaatatttat tgagtccatt tgttctacag 56100 tactgcttac ataattttta gtgggttttt tttttctgga ttatagtata aatccttaat 56160 gttttacagc atattagagg tagtattata ccaattatta taaaagtaga aagactgaaa 56220 tatatgggtc catttactct atgcacaatc attgtgttac agtttttatg tatagcacat 56280 ctttacatgt tataaaccct gttgtttata attgtactat aatttttgct ttaaaaatta 56340 aaaggaatta agattaaaaa aagtctttat ttcttcatag gcatagaagt ttgcagttgg 56400 tctaattttg cttcagcctg aaaagctttc tttagcatta cttgtagtcc aggtacggtg 56460 gtggcaaatt ctttatttta atttacctca aattatcttt atattacctt caatgtttaa 56520 gcatattttc acttgataag gaagtctaga tgcacagttg ttctttgttt gggtattgaa 56580 ttttgaccac aatctctgta ttctgggtac tttttacatg caattggcaa ttattttctc 56640 ctaatctgtg gcttatcttt tcattcacat cagaggacct tttgcagagt aaaaaaaagt 56700 tttaaatttt gttgcggtca aattattttt tccttttatg tattgtggtt ttgttatcaa 56760 gtttataaag tctttgctta atcctagatc atgaagattt tctcctattt ttttcttaaa 56820 ttgttataat tttatgtttt acatttatat atctgacatg tttgcatata acttttttgt 56880 gtaaagtgtg aggttaagcc atgtaaaatt ttgccttgga tgtctaatta cttccacacc 56940 atttgttgaa aagtcaattt ttccttcatc gaattgcttt tgtacctttg tcaaaaatca 57000 gttgaacaag tttgtgcagg tctatttttc taccctttcc cattgacctc tatgtctatg 57060 cctctatcaa tatcacacag tgctcattat tgtaactctt agatgttact attcggtata 57120 ctgagatctc tcttaacttt tttttcattt ttaaaaatta ttctagggcc tgtgccccta 57180 gaataaattt tatgataatt ttatgataag taaattttct gataagctct aggtctacag 57240 aaaacaattt tgaggatttt acaggaatta cattaaactt agaaatcaat ttgggaagaa 57300 ttattgttat atttctatct tccttcattc ctttattcct tcattccttt aaccagaatt 57360 ttataatttt cagcgtacag attctgtaca tgtttaagtg aatgagagaa acaattctac 57420 ctaaaattaa gactttttaa tgaataccta agtatttaat tttctttgga gtgattataa 57480 atgttacggc actttaaaat ttgttttcta cctgctcatt gttagtagaa atgctattga 57540 ttttcatgcc ttgatatgtg tcatgtggcc tggctaacct catttactag ttttagaagt 57600 tttgtttatt tggtttgtag atttcttggg attttccatg taaacacatg tcagtgtttt 57660 gaatctgtgg gcttatatat tttgccagat ttggaaagtt ttaaacatca ttatttttta 57720 atgctctttc aacctacctc tctaatgtca taaatgttgg atggtttatt attctacagg 57780 tccttgagac tctattcata tgtttttttc agtctatttt ctctccgtta ttcagattgg 57840 aataactgct tcctatctgt aaatcagtat tcagattgga acttaacgat tctattctct 57900 gccatctcca ttctactact gagccaatct agcaagcttt aaaaatttat cttacgttat 57960 ttttcagatc tatcatttcg atttgtttcc tttaactaaa ttctatttct gttttgctat 58020 ttttcatctg tttcaggaca atttgtaact gcttgttgaa tcatttttct gttggttgct 58080 ttaaaatcac ttaacatgta attaaaagtg ttacatggat gttaaacctc ctgcatattt 58140 gtatttacat aatttttatt tatgtaaacg taaatcttac ctttgtaatt acatagcaaa 58200 ttacatatta ttaattttac acatctttta aataatcact ttatatatgg acatgcatac 58260 acagaataaa tttactgttt aaatttccaa aattatttcc ccaacaaaca gtagatttca 58320 tttactaaga caatggtttt caagagtggt cctcagagca gcagcattaa tattatattt 58380 gaaatactta gaaatacaat atttttggct ctaccctaag catattgcat gggaaactct 58440 gaggatgggc ccagcaattt gtagttgaac aatgctccag gtgattctga tgtacaatta 58500 agtttgacaa tcactgctgt gggagatcct tagcttaagg gttagctgta atgaatatgt 58560 ttcttctatt tctgttaatt caaaattgaa atagaattat gttttaagta ttttttaaaa 58620 ggcaatgcaa ttgaatagct tctgaaaaat tgaataatac aggtctgata taaacctgaa 58680 atatcaagtt aacaatagac tttcatttta aaaagaaaaa gtaatataat aataatacat 58740 ttgtaatgct tgctctctat atgccaggtg taattataag cactttacac ataataaata 58800 tttaattctc acaatttata taggtaagta gtttttccat tttacagatg gaaaaactgg 58860 gtatagggag gttaaacaac ttgcccaaaa catggacctg gtaagagaaa ggtgacgtac 58920 agagctaata attggcagag ctggaatgta actctaattg agtgttttca tattccccac 58980 tttgatcacg atgaaatact tctgcttata ataaattgtt ttaagttctt aatttgtatt 59040 aataagatgt ttgcctctaa aaagtagtgc atagggaaga caacactatt tgtatatggt 59100 tgcaaatgga gacttttgtg tctaatcacg ccaaactaca atttaggatt tggccagcaa 59160 agtagtttgt ttgtctgatt gtttttgaga gacattagac tgggcatcac tgtcagttcc 59220 tctgccttcc cccgtcactt cctgatatct tacactgccc tgtgcatttt tcttactttc 59280 aaagtctcag gtggcagata agtcatgagc ctgagttaac tggttcagtt cactaattaa 59340 tatgagtcct aaaacaaagc tctcaaagat atacaagcac acagatggga gatttagcat 59400 gggggttact ttattccaat ttggctccta cccacatgag gagtttctct gtgggagctt 59460 gacattattt tctcaagaaa gcagagggtg atattgtata cataatagtg aattaaaaaa 59520 caagcaggaa atcagccaga gctgcttgag acatgagatc ttcggggtat atacttacta 59580 ttgagcctca aattggaaat tgacccaatg aacacaattt atccaaatca gaatcaagtt 59640 atttttttct ctttaatgat ctgcattaac taagaccttc tgttcccctt ccacctaacc 59700 tataggtgac tgaaactcct ggtaaacaga aaggacaagg aaagcaatct aattaaaggc 59760 tgctatggct gctctaatca cagttaccag gaaataaact tccatctttt cccaggtctc 59820 ctttttccca cttggtggaa aatgaacagg ctagaatgaa catgcatgac atgatttatt 59880 aactacactg gttccgactt gagtcagcag caggagaaac aagaagttta caaactcttt 59940 tgagtatgca ggtcaaaaaa ctttacgtat cgcaaattcc ttctttgctc tttctccctt 60000 aatccatgga acaaactcct cccaaggaga aacaattagt tcatatttgg ctacacttct 60060 aaatactctt ggcctcagtt ctcaaagatt ttccataata acaccagcag ggtgtggttg 60120 atgcctcaat tgcagggtct gtaggagcag ggcttgcata gatttagctg taactgagac 60180 cttactccag attggccata ctctcactac attattaacc ttgaactgat atgaaatcta 60240 ggacacacac ttcttggatt ctgcccctgc ctcaggccat ttgtactgct ataataaaat 60300 acctgagaca aggtaattta taataatcag aaatttgttt cttccatttc taaaggctgg 60360 gagaatcaag tcctttcaga atggcattaa tccattcata agggtggagc cttcattacc 60420 taaacacatt ctatattctt gtgaataatt catttaatat tttttactcc tgaggaaaat 60480 gaataactct tatacaatag agatctcacc cgcataccaa tactgtttgt aaaatattaa 60540 tgttttagac tccgtttata tgggacataa ctttaaaaca aaacatgttc catgaatcag 60600 acatttgtta gacctactta aattaaagat acttcatcaa ttcctccaat tttttcccaa 60660 cctttttcta ctaaaagctt gaatattcaa tgatatagaa atatgcccca ggagaggcag 60720 aacaacatgg caaaatagaa aactccacag atcatccatg gctgcaagga caccaagtta 60780 acaacatctt cataagaacc aaaagtcagg tgagcattca cagtatctgg ttttaacttc 60840 atatagctga aagaggcact gaagagatag gaaaaaagcc ccaaatctcc agtgctaccc 60900 tcttccccta cccatggcag cagtggtgtg gtgcagagag catctctgtg ctccaggtga 60960 gggagaacat ggcaatgtga ggcattgaac tcagtgttgt cttgttagag cagaaaggaa 61020 aaccagacta aactcagctg atgctggccc atggagggag catttaaacc agccctagtc 61080 agatgggaat taccagtcac aatggtctga acttgagtgc tcacagacct caccaccaag 61140 gactatagca ctctgtgcct ccaagtaaac ttgaaaggta gtctaggcca taaggactgc 61200 aactcttagg tgagtcccag tgctgaacta ggcccagaga gactgcactg aggggacatg 61260 tgactaacca gcttgggcag ccaagggagt gctggcatca cccctcccct aaccccaggc 61320 tgcacagctc atggctccaa aacagacccc ttccttctgc ttgaggagaa cagaggagag 61380 agtggggagg gctttgtctt gcatctagga taccagccca gccacagcag gatagggtac 61440 cagtcagagt catgagcccg gattccaggc cctagctcct agacaacatt tgtagacaca 61500 ctctggccag aagggaaccc actgcaatga aggaaaggac ccagtcctgg cagcattaat 61560 cacctactaa ctgaagggtc cttggatgct gaataacctg tagctatgcc caggtattac 61620 atcgagggcc ttgggtgagc ctctgagact tgctggcttc aggtgagact cacacattac 61680 tagctgtggt ggctatgagg aaaaactcct tctgcttgag aaaagcagaa aaaaaaagta 61740 aaggtttttt gggttttttt ttccacctta ggtgccagca cagccacaga ggggtagagt 61800 gccaagtggg cacttggggt ccccaattcc aggacttgac ccttggatgg catttctggc 61860 cagccatggg ccagagagga gtccactgtc ctgaagggtg agtcccaggc caggcagcat 61920 ttaagacaag ctgacttaag agtctttggg gcttaaaaga acattagtgg taggctggca 61980 gtagtcctgg gcctggggta gcacagtggc tatggggtaa gtctcctctg cctttggaaa 62040 aggaagggaa gtgtgtgaag gactgcgtct tgtggtttga gtgccagctt ggctgcaata 62100 caatagaaca ccaggtagac ttacatatat ggattttgac tatagtccct gactcctggc 62160 cagcacttct gaatctaacc agagcctggg ggacctcaca gccctgaagg gaagaacaca 62220 ggcctgactg acattcccac ctgtggattg tggagcccta gtcagagagt agtttagcag 62280 accttgggtg aggcccagca ctgtgctggc atcaagtctg acccagcaca gtcatagtag 62340 tggtggtcac aggggtgctt gtgtcactcc atccccagcc ttaggtggct cagaacagag 62400 gtagagactc tatatgtttg ggagaaagta atagaagaga acaagagtct ctacctgatt 62460 ttccagggaa ttcttctgga tctcttagac catcagggtg gtacttccac aagtcagcaa 62520 gaaccacaaa tttactgggc ttgtggtgct ccctaaagat aaagcttaca tcataacacc 62580 caagttcttt taaatatctg gaaagccttc ccaagaaaga tggctacaaa taagcccata 62640 tagagcaggc tacagtaaat acctaacatc aatgctcaga caccgaagaa catctactag 62700 catcagcatc acccaggaaa gcattgacct caccaaatga actcaataag ctgccaggga 62760 ccaattttgg acgaacagag atatgacacc ttttagacag agatttcaaa atagctgtgt 62820 tgaggaaact caaagaaatt caatattaca tagagaagga attcagaatt ccatcacata 62880 aatttaacaa agagattgaa acaatgaaat agaatcaatc ataaattcta gatctgaaaa 62940 atacaactgg catactgaaa aatgcttcag attcctttat tagcagaatg gatcaagcag 63000 aaaaaatagt gagcttgaag acaggctatc tgaaaacaca cagtcagaga caaaagaaaa 63060 aataatgaaa accaatgaag tttgcctgca gcttctaaaa aatagcttca aaagggcaaa 63120 tctaagagtt attggactaa aagaggaagt agagaaagag acaggggtgg aaagtttctt 63180 taaagtgata ataacagaga gcttcccaaa catggagaaa gatatcaata tccaagtaca 63240 aggttataga acaccgagca gaataaactc gaagaagact acctcaaggc atttaataat 63300 caaactccca aaggtaaagg ataaagaaag ggttctaaaa acagcaagag tgaagaaaaa 63360 aataacaaat gatggtgctc caatatgtct gacaacagac ttttcagtgg gaaccttaca 63420 ggccaggaga gagtggcatg acatatttaa agtactaaaa taaaataact tttaacccag 63480 aatagtttat ccagtgaaaa catccttcaa acatgaagga gaaataaaaa ctttcccaga 63540 caaaaagctg agggatttca tcaatgccag acctgtccta caagaaatgc taaagggaat 63600 atttcaaaca gaaagaaaag aatattaatg agcaataaat aatcacctga agttacaaaa 63660 ctcattagta atagtaagta aacagaaaaa tacagcatat tataacactg taactgtggt 63720 atataaacta cttttatcct aagtagaagg actaaaccat gaaccaatag taataaagag 63780 ctacaaccat ttttcaagac atagtcagta cagtaagata tgaatataaa taatgaaaag 63840 ttaaaaagtt gggggataaa gttaaggcat agagttttta ttagttttgt ttttacttgt 63900 ttgtttatgc aaataatatt aagttgttat cagattaaaa taatgggtta taagatagta 63960 tttgcaagtc tcatggtaac ctaaagccaa aaaacataca atggatacag gaaaagaaag 64020 aggaagaaac taaatcatgt taccagagaa aattaccttc actaaacgaa gacacgaagg 64080 aaagacagaa ggaagagaag accacacaac aaccagaaaa caaataacaa aatggcagga 64140 gtacttctta tcaataataa ctgcaatgta aatggactaa actctttaaa caaaagatac 64200 agactggcta aatgcatgga aaaaacaaga cctatttatc tgttgcctac aggaaaagca 64260 cttcacctat aaagacacac atagactgaa aataaaggga tggaaaaaga tattccatgt 64320 caatggaaac caaaagagag caggagtcac tatacatata tcagacaaaa tagatttcaa 64380 gacaaaaaat ttaagaagat acaaagaaca tcactatata atgacaaagg ggtcaattca 64440 gcaagaggat ataacaattt taaatatata tgcactcaac atgggaacac ccagatatat 64500 aaaggaaata tttttagagc taaagagaaa gataggcccc ccaaaaataa tagctgaaga 64560 cattttacat ttaacattga acagatcttc cagacaaaaa atcaacaaag aaacatcaga 64620 tttgatctgc actatagacc aaatgaatct aatagatatt tatggaacat ttcatccaag 64680 acctgtagaa tacacattat tttccttagc gcatggatca ttttcaagga tagacgatat 64740 actaggtcac aaagcaagtc ttaaaacgtt taaaaacatg aaataatatc aagcatcttc 64800 tctgatcacc atggaataaa actagaaatt aatagcaaga gaaattttgg aaactataca 64860 aatacatgga aattttaaac tatgcttctg aatggccaga gagtcaataa aagtcctagc 64920 tagagcattc agacaacata aagacaggaa gggcatccta aatggaaagg aatatcaaat 64980 tatccttgtt tgcagatatg atcttatttt aggaaaaaac ctataagact tcacaggaaa 65040 attattagaa ctgataaaca aactgagtaa agttgcagga tacaaaatca aagtgcaaaa 65100 atcagtagca tttctatatg gcaacaggga acaaggtgaa aaagaaatca aaaagtaatc 65160 ctatatacaa tagccacatg taaaattaaa tacctaggag ttaacttaac caaagaagta 65220 aaagacctcc acaatgaaaa ctctaaaaca ctgatgaaag aaactgaaga gaaacacgaa 65280 aaaatgagaa aatattttat gttgatgaat tggaaaaata aatattgtta aaatgttcat 65340 actaccccaa tcaatctaca gattcaatgt aatctctatc aaaataccaa tgacattctt 65400 cacagaaata taaaaaagaa atcctgaagt ttacagaaat gacaaaagac ccagaatagc 65460 caaagctatc ttgagcaaaa agaaaaaaat tggaggaatc acatcacctg atttcaaatt 65520 atactacaga gttatagtaa ccaaaacagc acagtagagg cataaaaaca gatacataga 65580 cttatgtaac acaataaaga accaagaagc aaatcttcac acctgcagtg aattaatttt 65640 tgacaaagtt gccaagaata tacactgggg aaaagatagt cccttcaata aatggtgctg 65700 ggaaaactga atattcatag cagaaaaatg aaactagaca catatctccc accatataca 65760 aaagtaaagt aaaaatggag taaacacttg aatctaacac ctcaaactat gaaactgctg 65820 caagaaaaca ttgggaaaaa ctccaggaca tttgtattag tctgttctca tgctgctata 65880 aagaactacc cgagactggg taatttataa aggaaacagg tttgattgac tcacagttct 65940 gcatggctgg ggatgcctca gaaaacttat aataatggca gaatgggaag caaacacgta 66000 gtttttcaca taatggcagg aaggagaagt gctgagcaaa ggtgggggaa agccatttat 66060 aacgccatca gatcttgtga gaactcagtc gctatcatga gaacagcatg agggtaatca 66120 cctcaataat taaattacct cccattgggt acctcccaag acatgtgggg attatgggaa 66180 ctacaattca agatgagatt tgggtgggga catagtcaaa ccatatcatt cagcccctgg 66240 accctcccaa acctcatgtc ttcacatttc aaaacacaat catgcctttc caactgtccc 66300 ccaaagcctt aactcattcc agcattaact caaaagtcca agtccaaagt ctcatctgag 66360 acaaagcaag tccctttggc ctatgagcct gtaaaatcaa gagtaagtta attacttcct 66420 agatacaatg gttacaggca ttgggtgaat acatctgttc caaatgggag agattggtaa 66480 aaacaaaaag gctacagccc tatgcaagtc tgaaatccaa tagggcagtc attaaacctg 66540 aaagtttcaa aatgatttct ttagactcca tgtctctcat ccaagtaaca ctgatgtaag 66600 aggtggactt tcatggcctt gggaagctct acccctgttg ctttgcatgg tacaggcttc 66660 ctctcaactg ctttcatggg ctggcattga ctgtagcttt tccaggtgca tggtgcaagc 66720 tatcagtgga tctaccattc tggggtctgg aggacagtgg ccctcttctc acagctccaa 66780 taggcagtgc tccagtggga actctacgtg gggactctga ccctaccttt cccttgcaca 66840 ctgccatagc agaggttctc catgagggtc ctacctctgt agcaaacttc tgcctggaca 66900 ttcaggcatt tccacacacc ctctgaaatc taggtcaccc aaatctcaan nnnnnnnnnn 66960 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 67020 nnnnnnnnnn nnnnnnnnnn nnnnnnnnna cagggggggt aaagtgtggt cggtacgaac 67080 cccgggggcg gactcttacg catggtcccc tacaaaacca tgcagagtta cagacggcag 67140 gacagagttt aaaaaaaacg cgggtaacga cccacattga ccttgggctc tccatcagta 67200 tgtcttacta gtgaaatagt agtaataatg caagtttatt gaggattttt tatatggcag 67260 gcactgtttt aagtgctata caaatgtaat tgttttagtc ttcacagtat ttctatgagg 67320 ttgatccagc catcatcatc cccatgatta acaggataac ctaagaacag accagtcatt 67380 caggattaca cagccatcag agaaagatct gagatttgaa cccactctgg accactgtcc 67440 atactgtctg aagtgtgtca gaatacacta tttaatagtc acacaatctt ctgcttttct 67500 ccaggtattc ttaaaggaag attaagatgg acaaagaata taatctccta tcagttacat 67560 aataaacaca aaagggatat catggtagct ggtgtaggac tttgcaggag cgagctattt 67620 ttcttgcctc tgctaagaag cagaaggaat tgctcattga cctgctttct gttctcttct 67680 ctcagggtta aaggcactgg agacagacag gacccagagt tttagaatgc atatgctgct 67740 tccaagcctt gtgcctgcag attctcactg cccagagcct cccttgtgga gaggccagga 67800 tagcttccag taaatactct actctaagag ctaatcctgt tgagttttgt gattgaattt 67860 ccaaatatcc ctggtgtgag ttctagaatt tgtggtttta tcaggttctg agagtttgtc 67920 actgtttaca gtggtgaaat tgaaaagctt gcatataaca cagctgcgct tgttgggtgc 67980 tgcggtgata tccatataat agcatataat aagatacagc actcttgctg taggatgcaa 68040 tttaagataa cagggctgcc ttgcaaggca gcaaacctca atctcagcaa ccttgtcctg 68100 tctagcccat gtctcctttc tctcttaatt acattccagg cagcccagat tcccctgtat 68160 gcatatcatg cccccaaaat accaaggcct ctgcaattaa cagctctcca gactttgtaa 68220 tactaacctg ttatggagac acagctcagt tttccagtct ggtttctgac agatatgaag 68280 ccaaaaatca attttttcaa gatacggcac tttttgctgt tgctaagtga tagggaaatc 68340 tgaagcagtt cactgaatat taaaggagga ttaagttaac aacattcatg cttctactaa 68400 ctggaaatta tcctgccttg cacaatattt tggctaaaac tatattgtaa aattttataa 68460 gaaagggaat agaatatagg gtggtgagaa aaaaatacta gcagctcaaa ggagatggaa 68520 ggtaaacaga cttcgagtat ctgaaacttg tgaggcaata tgtagctagt tttcttttct 68580 ttaaactcat tgagattagt tgctttgtaa tactttaaat atttctaaaa ttttatttat 68640 tttttcaagt tatcattcaa ttacttgaat tagatttgaa tgcttaataa tgcctggcat 68700 ggttgagaac tgttactttt ctttacattg aattagtctc agacatgcct gatcataagg 68760 atcacctgga actgtgttaa aagtagagat ttccaggcct ggaccccaga ggtgctactt 68820 caggtttgga gtccagaatt ctatattttt tccaagtttt attttgaaat taaatattta 68880 aaaattaata ttcaaatgta tttctgcact gagattcagc agttgttaaa agtttgccac 68940 tatagatagc tagatagatg ataggcggac agacacatag atataataat ttggcctctt 69000 ttcactaaga cattaaataa tctgttgtaa ttagtttcca ctctggctcc ttgatagttt 69060 gcaatcccaa gaacttaaca tataatcaaa caacagacca ttagttagaa gaaggtcaca 69120 ctcaacatat aactgtcaaa tggttcttgt ttattgtgaa ataatgcaat gcatataaat 69180 atgcatattt aaacatgtac atacctttta aaaactaatg acaagacatt agccttgttc 69240 ttatcaccct aatagaattt taatgttggc aggaacttag ggttccttgt gggccacagc 69300 taaacagcca cccctcatca cttctttaca cataaccctt ttctgaaatt ttgtgttttt 69360 aattccctag catttcttta aagctttcct ctatatattt atcagatgaa gtattttgtt 69420 tagaattcct gctactgaac attcttacgt ggaatcatac tgcgaggtga cagtgtgctg 69480 gcagtcctca gagccctcgc tctcggcacc tcctctgcct gggctcccac ttcggcggca 69540 tttgaggagc ccttcagccc accactgcac tgtgggagcc cctttctggg ctggccaagg 69600 ctggagccca ctccctcagc ttgcagggag gtgtggaggg agaggcgcca gcggcaaccg 69660 cgtgcggcgc ttgcgggcca gctggagttc cgggtgggcg tcggcttggc gggccccaca 69720 ctcggagcag tcggccagcc tgctggcccc gggcaatgag ggacttagct cctgggccag 69780 tggctgcgga gggtgtagtg agtcctccag cagtgccagc ccaccggtgc tgtgctcgat 69840 ttctcaccaa gccttagctg ccttcctgcg gggcggggct cgggacctgc tgcctgccat 69900 gcctgagcct cccaccccct ccatgggctc ctgtgcggcc cgagcctccc cgacgagcac 69960 caccccctgc tccaccgcac ccagtcccat cgaccaccca agggctgagg agtgcaagcg 70020 catggcacgg gactggcagg cagctccacc tgcagccctg ctgcgggatc cactaggtga 70080 agccagctgt gctcctgagt ctggtgggga agtggagagt ctttatgtct agctcaggga 70140 ttataaatac accaatcagc accctgtgtt tagctgaagg tttgtgagtg caccaatgga 70200 cactctgtaa ctagctgctc tggtggggcc ttggagaacc tttatgtcta gctcagggat 70260 tgtaaataca ccaatcagca ccctgtgttt agctcaaggt ttgtgagtgc accaatggac 70320 actctgtatc tagctgcttt ggtggggcct tggagaacct ttatgtctat ctcagggatt 70380 gtaaatacac caattggcac tctgtattta gctcaagcgt ttgtaaatac accaatcagc 70440 accctgtgtt tagctcaagg tttgtgagtg caccaatcga cactctgtat ctagctgctc 70500 tggtggggcc ttggagaacc tttgtgtcca tactctgtat ctaactaatc tgatggggac 70560 gtggagaacc tttgtgtcca tactctgtat ctaactaatc tgatggggac gtggagaacc 70620 tttgtatcta gcgcagggat tgtaaatgca ccaatcagta ccctgtcaaa acaggccact 70680 cggctctacc aatcagcagg gtgtgggtgg ggccagataa gagaataaaa gcaggctgcc 70740 cgagccagca ttggcaaccc gctcgggtcc ccttccacac tgtggaagct ttttttcttt 70800 tgctgtttgc aataaatctt gctgctgctc actgtttggg tccacactgc ttttatgagc 70860 tgtaacactc accgcgaagg tctgcagctt cactcctgag ccagcgagac cacgaaccca 70920 ccagaaggaa gaaactccga atacatcgga acataagaag gaacaaactc cagatgcgcc 70980 accttaagag ctgtaacact caccgcgagg gtccgcggct tcgttcttga agtcagtgag 71040 accaagaacc caccaattct ggacacaata ctacatgtat tctccagtga tttgcttttt 71100 ctgttgtgct ataattttga gatacatctc tgtccacgtg cacagctata atttgttttc 71160 actacaggat attattgtat catgtgaatg taccagaatt tatttattca gtctaccatt 71220 gatggacatt aggcaagttt tcattctttt aaatatgaat agtgttatca agaacattct 71280 tgtctatatc ctgtgtgcat gtgcaagagt cacttccagg tacataacta ggagtgtcta 71340 aatttctaga aagctgtagt cattttcctt aacaacaggg attaccatca ttaaggaata 71400 tgactaaccc cttgaactcc ttttactggc ccagaattgg gtctgacttt ttggtatgcc 71460 ccagaataaa taaataaata aataaatatt tattatttat aattattata tatttgtatt 71520 attttatatt taaatattaa tatatttaaa atataaatgt aaaaatatat aatatatatt 71580 aaatatatat ttaaaacatt tttacataat atatattata taaaagtaaa tatatatgtt 71640 ttaaaatata tttatatgta ttttttaagc ttggagacac atagggcacc gtacaacaaa 71700 ctccagctcc agaggtgagt ggagatggtc caagactggt taaactttca cccgtcttgg 71760 caagacaatc atttcagctg ggaatctgca tactggctcg taccatggca gttttcattg 71820 agtcagctca gtgtccatat tgatgactca ctaatacgtt gtttgaatgc ttttttgacc 71880 tactctaact tgatactttt ttactccact tggacaacgc aaatgactgt attcttatga 71940 acatgatcac atattgaaaa gtacataggc ttaggattta gaagcacttg cctttagcag 72000 ggttggccat ttacacatta gagagttgtt ataatcagag atatgtgaaa agaattgggc 72060 cctttgccta acacttgata agcattcagt aaattatagc ctttgttgat actctttttg 72120 ttatttgtca ttactcagaa ctcagaaatt cagatatatt gaaattccct tctcaaataa 72180 tagccttttt tttgcctgac tgaattcaga aaaatttacc ttcaccctca ttccttgttt 72240 caaatctcgt ctcaacttct agtcttcttc tttgagttat tctcataatg ttcccataca 72300 tatttttaat ttaaatgttt aacttctttt agtctcttct taaacatgcc ccagtctaaa 72360 ctttcaattc ttaccctcct ccatccccac tattccccca ctatcctcct ctctagtttt 72420 gttaatagga tcaccgtcaa ctcagttacc ttgggctatg actcagaacc ctcttccact 72480 cctctcttta ccttagtcca tcagcgactc ctggaggccc tgcttccaaa ccgtatcatg 72540 cctctgaaca ctcctaacct gcagtgtcac ctcccccatc taagctggtg tcagctctca 72600 cctcggattg ctgctgccat ccctcactgc tccctgcttc tactcttgct ctcattgtat 72660 gatgtcggtc agatctgatc actccaccga ctgaatcctc cagacttccc agttgcaaat 72720 accaaaaatg ccaaacccct tgccatggcc ttcagatgag atcagacctt tatctgcatg 72780 tcttacctca gttcgcttca ctcactgtgg cccagtcact cctaaaccac tttctctttt 72840 cctcccttca gtatcccatg ctcactgcca tctctgaccc tttgcactaa tttcctatct 72900 tcctggaact ctcttcccac aattgtagtg tgatgtttat ttttcatagt tgaaacagct 72960 caaaggtcac ttcctgagac aggctttccc tgactctcct agaacttacc atccgtgttt 73020 ctcttaagct tgttacattg ttttcctcat aactgtacta tctaacgtta aactttaaca 73080 tttcttgact ttttttaaat ctcattctac tacaatataa actgcagcac agtaggtggc 73140 agagtgtctg tctgcttcat tgctgtactc tcaacatctg tattagtgcc tcgtacataa 73200 taggtgctca ataagtattt ttttaattaa tgaagggaca aatgtaaggt aactggaggt 73260 taaaaaaatt acagaaatcc ttacctgtgt tactgagtag caatactatt tattatgtat 73320 gtattttaaa ggcattaaca ttttttattt ttcaggatta attggaattc ttcaaaatgt 73380 caggtaagtt tttgtgaata aatttgaata tgctttattt tcaaatgtga attttgtgat 73440 tattttccct aaagggggac tttatttcga tttttttttg tttaacattt ggcaaatata 73500 aatacgtgtg tgtgtttgca tatatatatg tatgtatata tttgttattt atgtatatag 73560 acattcctat cattgtcaga aaaagattaa aaagggactt acagtgggac acatatctac 73620 tgaataatct ttgaagtttg tggggaaaat taggtaataa aaaaagcaag atttgcaaag 73680 cagttctgca aagagaggtt gtagtaataa agagcctgtg gcaaggtcct gccttggtag 73740 aggaggatga aagtaggcct tgtattttct agtaacttac ataaagagag aaaaaccaca 73800 tttatgggat ttttgtttgc taggagataa aagtcaactg gttgtttagg aaactcagct 73860 tttttttgta gtaagcagag agagaaatta gtctctaatc tcaataagaa gacaaggtac 73920 aacatcatga aactgacttc agtacctccc ttgcagcaat tactgtgacc tagattgctt 73980 ttagaaagaa tacagtgaaa atgtgagtca ctggagatgt agactaaact attgctaatt 74040 cagttgtgtg tgacaccact gtttattaaa ccattatttg tttatggtgt tatgttgtga 74100 atctttttag acagcacttt ccaaaaataa ttaggaaaaa aaatcaactt cactctataa 74160 atgcttgtgt tctccatatt atgtaaaggg aaaaataatt tttgctatta tgccaggaat 74220 ttactttgta gataagagtt agcatcgggg cagttgaacc actagtatga aagctcattg 74280 ctttgatcac aagcataata taattgttta gttctatttt taaatctatg ttcagtttga 74340 aaattcatga aatttattaa tagtgtctaa tatatgatga attctttctt taaaaaatat 74400 aggagtgtat tttccagttg attatatttc ttgatgcatt cccataagaa aggaaaaaga 74460 atacattttg tcattatatt attgtttcct ttgtaagtca tgttccctgt cttcccctga 74520 aggttggtac ccacagcccc tgaacagcct gcaggtgaaa tggaaaatca aacaaaacca 74580 ccagatccaa ggcctgatgc tcctcgctga atacaattct cattttttac caggtgggtt 74640 aaatattcat aaaagatatt ctcctttgtt aaagaccata ctaatgatta aaagtgcttt 74700 ttaagcgaac aaattaattg actgatttaa taagtaaata aatattggat gccaataggg 74760 tgccacatag tttactatat gtcagttaga atatattcct gtagccatag gatttacagg 74820 cttttagatg gaagttgtgc aaatattgat gacattctct ccattctata tggagatatg 74880 aagagagtgt tgtaaggaca cagaagacag tatttgacat tgccagggat ttgaggaaag 74940 ccctgactaa ggaggtcaag ttttgctgtc atgataaaaa tttcacaagc aaagaaaagg 75000 gggaaaggac tatccttagc agaaagaatc atatgtccgt aagtacaggg tcatgaaaat 75060 ctggtatgag gcatgcatga gacacatgga agatgtgcag agaaatggaa gtgaatggcc 75120 atgggtgctg attaaggagc ttatctttct ggcaaatatt tttgtaagtc tgagtgcact 75180 actggtgatg tcttgggaga atgaatactt tatacagtgc tagtgtgaat ttgagatatt 75240 atgattgtta gaaaacaatt tggccaagtt taaaatttta aaaattaaaa gtgcccttac 75300 ttttggccaa ggaaatagtt agtattgtct ttaaacacat tttaatgact tacataatga 75360 tgtagacact gtagtaatat ttttttaaaa tacatattta agcgtatatt tagaagtaga 75420 aaccattgtg ttatgctctg aagggggaaa agaaaccctg ctatgtacaa gataatggca 75480 caagataatg gcaaaagttt tttttttgag atggagtttc agtcttgttg cccaggctgg 75540 agtgcaatgg tgcgatcttg gctcaccaca acctccacct cccaggttca agtgattctc 75600 ctgcatcagc tttcggagta gctgggatca caggcatgca ccaccacgcc cggctaattt 75660 ttgtttttta ttttttgttc tttgtttttt gtttgtagag acaaggtttt tccatgttgg 75720 tcaggctggt ctcgaagtcc cgacctcagg tgatccacct gcctcagtgt cccaaagtgc 75780 tgggattaca ggtgtgagcc accgtgcccg gccaaaggtt ttttttggct ctaggcatat 75840 gatccataca gctcaggtgg cttctgcacc tacagtgttt tctgaaagca tcaggatttc 75900 cttttttctc ttcctaatgt gtatgtgtgt tatgaggata aaatgcatta taacatactg 75960 cattaatagc gcaacctttc ctaaatccaa ggtattaaaa attaaattat taaattataa 76020 tcatgcttta tctatcgttt ctctatatgt cacttcagtg acttccaaca tgatatacaa 76080 gatctatctt atatttacca attactctat atccaaaaac ctagacccta ctagaacaga 76140 aacttcacca tttctgagaa aaaccttggt tatacatcat gttctcatct gataaagcgt 76200 atgtctattc ttctgtatat caataattca gcaagagagt aggctacatc cttcaaatta 76260 aatgacaagg taagttgtaa aaatattata gtgcagacca cacaactaat gaattttcag 76320 ttataaaata tagcaaaatt tcgctctgat cgccacctgg tggctggact ataaacttac 76380 gaagactgac aaaaattgtc tctgtgactc aaattaagaa tcttgaaatc tgtacttgaa 76440 ttatgtagtg ttaatgaatt tatcccaatt tctttacata attccaattt gcattatggt 76500 gttggatatg tgttcccaca aaaataattt tatccactat tcttgtttaa gagaataaag 76560 aaacctttgt tatatttagt atatttaaag agaaaatggc atgatttcct gatgttcaaa 76620 ataactaaaa aaactcaaat cctatcagac agtgtgtctt acaccagtat tggtaggaca 76680 acgctccgta acagaggtct ttatttacgt aagtctgaga tgctatagtt acacaaagtt 76740 aaacatattt tgttttgttt tgctttgttt tcctgcagaa gcaatcagaa ctcttatgaa 76800 aacttcaaag cttagaagaa agtataatat accaatttcc cacatataat ttcatcatat 76860 gttttccttc ttttatctct ggataataca tacttataac aaaaattgtt caattacata 76920 aatatgtatt taattttaaa ataaatataa atttaatttt aaaaaatata atctctatac 76980 gaatagcctc aaaatctaaa tggcaatttt tttctgattt attgatcttc aaattttata 77040 acatgaggtg cttttatatt aaaagtacat ggtaaattaa tcattaactc attgaagtga 77100 tataatgatt aatattcttg agataattca tatgattttt agttacattg ttatttttaa 77160 taatagttaa aaaaagaagg tatggatatc tgatttctag tccaattcgg gtactcttaa 77220 atacaattct taaaggaatt aaagtatatt cttcataaca aacttaaata catacttacc 77280 ttcacttttt tccaaatacg ttatactttt tttctcactt aactctcatt tgacattgtt 77340 tcctgttacc attattttcc ctttagtctg cttactgtca gtttctgtca aaaactgtgt 77400 ccctactctt aaaaagtgct gttctcaaaa ttatttggtc tactcccctg gttttccctg 77460 cccttcccca tctccttctc tctcctctcc cagtcaccct tccttttaca cactcttcta 77520 agtgatcttg ttaatactga aggtttcctt ttccttcatc acttatgaaa tacatatcca 77580 cagatcatgt cagtctgata gtctctaaac ttgcacttcc aaccacctat agactgcttc 77640 tcatgaaaga ccattgaatc tcaaactcaa tgatcaccag cccaactttg ttatcttgct 77700 tctaaactct attttctttc tccattcttc ccatacactg gaggcctgta ggatcccaag 77760 ccagaaactt gagaatcttt tctcatatcc agtccacttc aaagtcaatg ttgtatctta 77820 aatgtcaatt accatttctc cactctctgc tcctttcacc aaaatcagcc ttccttgcct 77880 tctagccaga cccttgcaag tacttcctgc ctaatctgac ctcatatata aagaattcta 77940 aatgtaaaat gaatcacttt actttccatt tgattggcat aaagttcaag gtctttcata 78000 atcttcatcc tatctttcta gccttgtctg ctaaatctcc acacacagca gttcgtcctg 78060 cagtagtgag cctcctctat gcacctgcct gttcttgtcc gtttgcctgt aaaacctttc 78120 cccatcatgg agatgctggc taggtctagt gtgttagcat ctatatcgta gtataccttc 78180 tctgcatagg ttaggtaccc ctcctgtcta atcccttaac atgctatgca tctacctatg 78240 attatgtcaa ttacttgctt cgtgacaacc attcaccttt tcttatacat ctttgtagcc 78300 tccacagaac ttgctgccct tggagacagg catgcatttg aatgtctttc tgtcttatat 78360 ttctagcagc aagcacagaa gctggtcctt gaaatgggct tgaggaatat ttcatagata 78420 aaagaatctt tgatttatct catggccttg ttttcagata gtattaggag aatttcatga 78480 ttcatgacta ttatgagtgg catttttatg agtaaccaaa atgtcttaga cttcatcacc 78540 ttcaaaggcg actggctttt gcattattgg ttgaccccag accactgcat tgtcccatga 78600 tgtcccatgg aggtgaaagg gtagaactta aggacttaaa aatagctgct agctagagat 78660 gccaatccag tgtataggcc caaagccctc catagaatca cgcctggggt gctcttcttc 78720 cttgtctctg atctaggggg agtattagca tgatgtattt aaggacgttt ctgcagtcag 78780 aatgctggaa ttctaattct actcctgata cgtcagctaa tgactttcac caagttactt 78840 aacctcctta tgcctcagtt ttattctcta taaattaagg ataataatag tatctactat 78900 atatggttga tgtaaagatt acaaggttta gtacttgtaa cgttgttaga gtaagggctg 78960 gaatatgatg agagctcaat aagttttagt tattatcttt ctttttattt ttttttaatc 79020 aacatagctt tctctaacag gactttcttc cagatctggg tagtatccag gacccagtta 79080 tttgggggct ctgagagaga ccataatctc ccccttatca catttaagtg aatttttcat 79140 tatgcaagag tgaccttttc aaaaactggc tgcctatggg actgtctaca tttttgtttg 79200 tttgtttgtt tgtttttgag acagaatgct gccgtgttgc ccaggctgga gtacagtgat 79260 gcaatctcgg ctaactgtaa cctccgcttc ccgggttcta aatgattctc ctgcatcagc 79320 cttcagagta gctgggatta caggcatgca ccaccacgcc cggataattt tgtattttcg 79380 gtagagacgg ggtttcacca tgttggccag gctggtctca aactcctgac ctcaggtgat 79440 ccactcacct cggcctccta aaatgctggg attacaggcg tgagccacga gtgcccagcc 79500 gggactgtct gcatttttca ggagatgtca atcccttccc tacaaagcta tgtggcattg 79560 ctctttgatt acaaaagaca gaaaatttgc tagtcctgta gacctacagt tcccaaaact 79620 gtgtttactt agggagacat aacaccattt gtggagcttt aacaacacag cccaaattgg 79680 gcttctactg ttctagcctt gttcattttt gcacacttat gtggacatga ggtgaatctc 79740 agcttctaac atctttcagc tgtcatctga actgaaaatc caacaatttt tgggcagaaa 79800 cacaaaaaaa acatatacat acatatacac acattacaag gaaaagcagt aattttcaga 79860 aagaaactac agtttaacct atatttaggt aaaaattatt tttttcttca aggtggaaat 79920 ctacagagaa aaatctccaa ccatagtaaa aacaagaatt tacatgatta tacattgcag 79980 tgttgcaaca ttgattccat ctttttcatt tcagaataga atctttgctg tccttatatt 80040 agttaaataa aaggatcttt aaatcattgg ctttcaaata ttcttgatga taatctaata 80100 taacacatag tgaataatac atacatatat attcaatata tttatgtata agtaacacga 80160 gtttcaccag acaatactga atataaagtg agtagatagt atactaataa tacagtttca 80220 tattttctat tttattcttc tctagttgac tatattttca aaaattaata tttgaattat 80280 taaattgatt ttaatactct gaatatatct tcagtttgta aaatgctgta tcaaaacaga 80340 gtttctcaaa cttagtagtt gataagaatt gatgaaatat cagacaaaac atactttgag 80400 gaaaaaatta ttactagaga taatggtcat tttataataa taaaagtgtc agtcatcaag 80460 acagaatgag tgtattcata tatacacata aaaacaatgc tccaaaatat atgaagtaaa 80520 actggtagaa ttgaagggtg aaatagataa tacaataaat aatagttgga gactgttata 80580 ccccacttac aataatagat agaacaacta agcagaagat caaaaaggaa agatctgaac 80640 agcactataa accaaactgg gcacaacaga caatctacaa cagacactct agacgtaata 80700 gcataataga acactctacc caacaacagc ataatacaca ttcttcttga aacatatggc 80760 attctacagt attgtggtta ggtcatgaaa caagtctcaa caaatttaaa acaattaaaa 80820 tcatgtagag tatattcttc taccccagtg gtagaagaat acttttaaat gacactaggg 80880 gcaaaaaaaa catcacacac agggaaatta gaacatactt tgagatgaat gaaaacgaaa 80940 cacagtatgc caaaacatat gagctaaaga agtgcttaga ggaaaattta tagctataaa 81000 cacctccatt aaaaaaaaag gaagagggcc gggcgcggct gcacgcctgt aatcccagca 81060 ctttgggagg ccaaggcggg cggatcacga ggtcaggaga tcgagaccat cccggctaaa 81120 aaacggtgaa accccgtctc tactaaaaat acaaaaaatt agccgggcgt aggtgcgggc 81180 gcctgtagtc ccagctactt gggaggctga ggcaggagaa tggcgtgaaa cccgggaggc 81240 ggagcttgca gtgagccgag atcccgccac tgcactccag cctgggcgac agcaaggacg 81300 tccgtctcaa aaaaaaaaaa aaaaaaaaaa ggaagatatc aaatcagtaa tcaaactttc 81360 caccttaagg gaaaaccaag ccaagaggta ggaaataata aagattagag cataaataaa 81420 tgaaatagaa aaaagaacaa taaacaaaat caacaaaacg caaaaatttg ttatttgaga 81480 ggatcaacaa aattaagaaa ccttaagtca aactaaccga aaaataaaaa taaaaataaa 81540 acacgctcat attactaaaa tcaggaatga aagtgaggct tttaccatag agaaattgaa 81600 aagtatctta gagggaataa catgaacaat tgtgtgtaca atttattgta tgctaatagg 81660 aaacctagac aaatggacaa gttcctagaa agatacaaac aattgaaatt gactcaagaa 81720 gaaacagaaa ccttaacaga cttatataac aagtaaagag attaaattcg tcatttaaaa 81780 cttttccaca aaataaagct aaggcccaaa tggcttcaat agtgaatttg gccgggtgct 81840 gtggttcacg cctgtaatcc cagcactttg ggaatccgag gcgggtggat cacctgaggt 81900 caggaatttg agaccagcct gaccaacatg gcgaaatccc atctctacta aaaatacaaa 81960 aattagctga caggtgcctg taatcccagc tacttgggac actgagacag gagaatggct 82020 tgatcccggg atgcagaagt tgcagtaagc aaagatcaca ccactgtact ccagcctggg 82080 tgacagttga gactacatca caaaaaaaaa aaaaaaagga aattttacta aatgctgcat 82140 gaaggtttta ataccagtca tttacaatgt cttccataga aatgaaagaa gaatgaattc 82200 ttcctagcta attctagagg ccagtattac ccaattagca aaatctgaca tagatgttac 82260 aagaaaagaa aactaaagat catatcccta ataaatatag aatcggactt tctcaacaaa 82320 ttactagcaa accagattta ggaacataaa aaaggattaa acaccatgac caagtgggat 82380 ttatcccatg gataaaagat tggtttatca cattaaatat catattaaaa cacatcaatg 82440 tatgtactat attaataaaa tatagtacaa acaccacatg accacatcag taagcacaga 82500 aatcacactt gacaaaatac aacatcctcc atgataaaaa cacttaagaa actagaaata 82560 ggaggaactc cctcaatctg ataaaagagt acctatgaaa aactcacacc aaacattatg 82620 tttaggagta aagactgaaa acgttcattt catctaagat caagaatgag acagggtatc 82680 tttcttgcca cttctattca gcattgtact ggaagttcta gccagagcaa ttagtcaaga 82740 aaaagaaaga aaattcatcc agattgaaag aaagaaacaa aaccatctcc atttgcagaa 82800 gacatgagcc tatatatgta aaaagtctaa gctgggtgca gtggtacact cctgtactcc 82860 tgtagtccca gttacctgga ggctagggta gaaggatcaa ttgagtccag ggatttgaga 82920 ctgcagtgaa ctatgatcat actactgcac ttcagcctgg gtgacagact gagaccctgt 82980 ctaaaaaaaa aaaaacccaa aaaacaaaaa aaaacaaaac aaaaaaaccc atatataccc 83040 acaaacagca caataaacaa gttcagcagt gtgttaggat ataagatcat aatacagaaa 83100 tccaaaagta tttctatata ttaacaatga aaaatgtaaa aagaaattaa aattataatt 83160 ccacatacaa taacattaaa aataacatac ccagaagtaa ctttaataaa aggagtaaaa 83220 tatctttcat attgaaaact ataaaacgtt gaaagaaatt aaagaagact acgtaagtgg 83280 aaaggcattt tacagatttg aaaagtaaat attgttaaat ggaaatgctc cttaaattga 83340 tctacagatt caacacaatt cttatcacag tggaattttt aaattgacag gctattcctc 83400 aaatacatat ggaaatgtaa aggattcaga atagcctaaa caatcttgaa aaaaaattgg 83460 aggactcaca attcccaatt tccaatttac tataaagcta cagaagtcaa taccacagta 83520 ctagcataaa gatagacata tagaccaatg agatagaatt gagagtctaa gaaataaacc 83580 caaacatctg tagccaactg attttttaca agcatgtcaa aataattcaa tagggaaaga 83640 atactctttt caacaaagga tctgagacaa atgaatatca acatacaaaa gaatgatttg 83700 aaactgtctc accctaaaca caaaaactct aaatgaatca aagatctatg tgtttgaaag 83760 acctatgtct aagagtgaaa actataaaac ttttacaaga tatagatgta agtatttatg 83820 tccttggatt aggcaatagt ttcttagata tgatatgaca ctctaaagca caaacaacca 83880 acaaaaaata aattggactt cataacaatt aaaaagtttt gtatatctaa ggacactatc 83940 aaagagaaaa gacaacctac acaatgagag aaaacacttg caaactatct ggcaagagac 84000 ttttatcttg aatatataaa gaacatttat aatgcaacaa taaaaagaca aatgattcag 84060 ttttaaagta ggcaaaagat ttaatagata gttctccaaa ggagatatac aaatggccaa 84120 taagcacatg aaaagatgct gaacatcatt agtaatcaga aaaatgcaaa taaaaatcac 84180 aataagatac aacttcatac ccactaagat gactaaaata aaaacagaca ataacaagta 84240 ttggtggagg atgtggagaa agtagaactc tcatatttgc aagtggacat gaaattgtaa 84300 agccactttg gaaaacagtt tggcagttaa taatggagtt actaaatatt tcagctaatt 84360 tcactcatag ctagagaact gaaaacatgt ccacactaaa acttgtacat ggaggatcac 84420 agcagtgtta tttataatag cccagagtga aagcaaccta aatgtccatt gactgattaa 84480 acaataccta aaatgtgata tatccacaca atagaatact actcagccat aaaatggaat 84540 taagtactta tatgtgctac aacatggatg aaccttgaaa acatgccaag tgtaaaaaaa 84600 aaaacagaca taaaggccta ttgtatgttt tcatttacat gaaaagtgta gattaggcaa 84660 atccacagat agtagtggtt ttcagggact gtggggaaga ggagatggaa attgctgcta 84720 atgggtatgg gtgttctttc tggtatgatg aaaattctgg gtttaggtag cagtgatggt 84780 tgcacaactt tgagaatata cttaaaacca ctacattgta cattttaaaa aaggatcaat 84840 gaaataaaat gttttgttaa tctcaagttt tgccatagag atcctgttgc aatagattgg 84900 aatgaggctc agaatctgga attttactaa gaactccaga ttatcttgaa ggacttggta 84960 tattgagcca caatttaaga aacaatatgt tgaggtgatt tttttctcta aatttaaaca 85020 tctgcctttg aaaatctgaa aaatctagtt ccatttttaa aaattgcctt catgtcttgt 85080 cactaaggct tcagatttta cagttcaagt cttagctggt attccctgct cataaaaagt 85140 tgtttttatt taatttaaac taaaatagat ccacagttgg acccctatat ttgtgaattc 85200 ttcatccatg gattcaaaaa agtgtggatt aaaaatattt taaaagcaca attaaaaatg 85260 acaataaaaa ttatacaata aaaataacac aaaaacaatt tatattagca tttacattgt 85320 gttagctatt gtaagtaatc tagacatcat ttaaagtata tgggaggctg tgagtaggtt 85380 acatgtaaat actacaccat tttatataag ggacttaagc atttgtaggt tttggtattt 85440 gagggagtcc tggaaccaat cctttatgaa tatcaaggga cgactatact gaaatcttaa 85500 cataaaatat cttgacttac ataacttatt ttgttttcaa ccacaggaca ttattcctta 85560 aattctctct taaaggagaa aaacctttct ttatctgagc ctggccttcc tgacagttca 85620 gacaacatca cttgtgggct gcttgtggct ctactactca caggatttca gttagagcta 85680 caagacctta gcaataagtt agggtctgtt gcatatttct gggtagacaa ccaagaccca 85740 gttatttata aattttaatt aattaatctt aaaaacttgg aaagtgaaac aaaaataaat 85800 tagtaatgat caaagttatt caaaaaattc ctggtaacca gacctagata gatatgcagt 85860 aatggcattc tcatacttat tgttggcaat tctttgactt taaaaaaaca tagtgaaatg 85920 caaagttacc actgcttatc ttaagagacc ttgataaaaa aattcctaaa gtcaaacatt 85980 agctgttgtg tgcttattca tttttatgag tactcttttt aaaaaatatt ttatttccat 86040 aggattttgg ggaacaggtg gtatttggtt atatgagtaa gttctttagt ggtgatattt 86100 tgtgagattc tagtgcaccc accacccaag cagtatacac tgaacccaat ttgtagcctt 86160 ttatccctca cccccttccc atcattaccc ctgagccccc aaagtccatt ccattgtatc 86220 atttctatgc ctttgcatcc tcatagctta gctcccactt acgtgtgaga acatacaata 86280 tttggttttc cattcctgaa ttactttcct tagaataata gtctccaatc gcatccaggt 86340 tgctgtgaat gccattaatt cattcctttt tatggctgag tagtattcca tcatatatat 86400 atgtaatccc acatttttct ttatccactc gtagattgat gggcatttgg gctagttccg 86460 tattatagca gtgaattcgc tgctataaac atgcatatgc aagtatcttt ttttgacttc 86520 ttttcccctg gataaatacc ccagtagtgg gattgctgga tcaaatggta gttctacttt 86580 tagttcttta aggaatctcc acactgtttt ccatagtggc tatactagtt tacattccca 86640 ccagcagtgt agaagtgttc cctgttctcc gtacatgtca acatctgtta ttttttgagt 86700 ttttgattat ggccattctt gcaggaataa ggggttatta cattgtggtt ttgatttaca 86760 tttccctgat cattagtgat gctgagtatt ttttcataca attgttggcc atttgtgtat 86820 cttcttttga gaattgtcta ttcatgtcct tatcccactt tttgatggga ttgtttgtat 86880 tttcttgcta atttgtttga gttcgttaca gattctggat attagtcctt tgtcagatgt 86940 atagattgtg tttgggttgt ctgtttactc tgctgactgt tgtttttgct gtgcaaaagc 87000 tctttagttt aattaagtcc cacctactta tcattgcttt tgttgcattt gcttttgggt 87060 ttttggtcat gaagtctttg cctaagccaa tatctagaag ggtttttctg atattatctt 87120 ctagaatttt tatagtttca ggtcttagat ttaagtgctt gatccatctt gcgttgattt 87180 ttatataagg tgagagatga gcatccagtt tcattctcat acatgtggct agccaattat 87240 cccagtacca tttgttgaat agggtgtcct ttccccactt tgtgttttgt ttgctttgtc 87300 aaagatcagt tggctgtatt tgggtttatt tttgggttcc ctattctgtt ccattggtct 87360 atgtgcctat ttttatacca gtaccatctt gttttggtga ctatgtcctt atagtatcat 87420 ttgaaatcaa gtaatgtgat gcctccagat ttgttctttt cacttactta gttttgcttt 87480 ggctatgcag gctctttttt ggttgcatat gaattttagg attgtttttt ctagttctgt 87540 gaagaacggt gatagtattt tgatgggaat tgcattgaat atgtagactg tgctcttaaa 87600 gcatgataaa atcttgtatc catttaagga aatctaggtt ccttgatgga cttataatga 87660 caaagataat tcatcagatc tctgattgaa ggtggaatgg ggagaaatga tagagggata 87720 agtgctgtgg gctgaatgtt tatatccctc ccaaattcac atattgaagt cccatttccc 87780 aatgtgatgt tacttggaag tggggccttt cagagaaaat taaatcaaaa gagtggagcc 87840 ctcatgatgg cactcatacc ctataagagg agacatgaga gggattctgt ctttctgtct 87900 ctctctctcc cccttcactc tgtgagcata tagcaagaag gtgaacatct gcaaaccagg 87960 aaaggctctc accaggtttg accatgctaa catttatctt tgaacttccc agcctccaga 88020 actataagaa agaaatgctt gttgtttaag ccactcagtt tgtgcttatt ttgttatagc 88080 agcataacta ctaagaaaat aactttaaga aattgaatct aaaagaggtc aggattgggg 88140 accagtctga gaactcgatg atgaagatat gtacaagcga ttgggtcaag gcaacctaaa 88200 atattcatta aaagcactcc tttgaaatga agtagacatt atttatgtaa ccacaaacaa 88260 taacaataga cataataaca aaaatttgca ggagtaatta tatgttagta attatacgtt 88320 agtaattaat acgttagtaa ttaatcccac tacaacctca ttaggtaagt ttattatctc 88380 caaggaggaa cctaatttat taagaagcta acatgtttct tctaatgttt caaaacttat 88440 ttttgtacca ttgaaatggg aataattatc ttataagctt taagaggatt aaatgaatta 88500 atatgtaaat aagtctccct aatacatcgt tgggtcatat gcaaccatga tctgcataaa 88560 gtgtgaatca aaaatggaac aagttgttat atttaagtgg atgtcgtgtg atctatttca 88620 tcgcatgtaa aaagttatgc taactttagt gttaataata tataacactt tgatttcttt 88680 tgaacacagg accccctgga acagctgtcc ctccacctac tggctaccca ggaggcttgc 88740 ctatgggata ctacagtcca cagcaaccca gtaccttccc tttgtaccag ccagttggtg 88800 gtatccatcc tgtccggtat cagcctggca aatatcctat gccaaatcag tctgttccaa 88860 taacatggat gccagggcca actcctatgg caaactgccc tcctggtctg gaatacttag 88920 ttcaggtact ccatgaaaat acaaattatt ttcttatgaa atgtgaccat agggatccaa 88980 caaagagaga aaaaaagcag accagagtga ataaaggaga tgggtcagtg atgacagatg 89040 ccatttgtga aactataaga acagtgatac cagtttcaga aatatgaagg ggaaacagca 89100 agtacaagga tgtttatagt gggatgagta tgtttttcat aaggatttat gttgaacttc 89160 aaggcattca agatgttttc ttgaaagaat tgtacaaatg gaaatagaaa aactatcata 89220 gaggatagtt gtgttatttg cttagaagta aacagttaac atcaaaaaaa gcacaaaaga 89280 gaacaaaaca caatacagtg ggtaaattac tgagtgcctt agcccattgc tttttaccac 89340 cacccatcat tttcattagc tactcttgtc acccccaaaa acaaacaata taaataaaaa 89400 taatggaccc tacaaagaat attgcttcag gccaagttcc agagaccccc ttcatacaac 89460 acaataactc cctaattaac atctatgtag atattctgct gccaccagga catgcagatc 89520 aaaaactggg gtaatatggg aagtttgtgc acaaatagtt ttgtttaaaa acccatgtct 89580 gaaactaaaa aacctgctta atgaaaataa gataaagctg gcagagtaga cgccttttat 89640 ttgtggcgtt gattcctgcg gtttcagtta ccaatggtca accaggttcc aaaaatatta 89700 aatggaaaat tctagaaata aaccattcat aaattttaaa tttattctga gtagcatgat 89760 gaaatcttgc acagtcctgc tgtgttctgc ctggcacata tatcattcct ttgtccagtg 89820 tatccacgct gtagatgtta tccatagtat acagacccag agtcacatct tggttatcag 89880 attgacttac agtatcacag tgcttgcatt gaagtaactt attttactta attatgtctc 89940 caaagcacaa gagtagtaat gctgggaatt tggatatgtc aaggaaagac caaagagagg 90000 ccataaggtc ttcctttcca tgtaaaggtg aaggtttttt acttaataat aaaaaaattc 90060 ctatgctaag gttactaaga tctatagtaa aattaatatg tccatgaaat tgtaaagaag 90120 aaaagaaaaa tttgtgcata gtatatacag gatttggtac aatctgtggt ttcaggtatc 90180 cactgagggc ttggaaagta tcccctgagg ataagaggga gactacttta ttggagattc 90240 catagaacct tctgaatctt ttttgttgtt gtttatagaa aaaggaagtg ctgaaataca 90300 ttataaagaa gaaacttccc aatttaatac ttacctcccc aggtcaacag ccaagtattt 90360 cctcgagttc tgtcatttct cttttcaatt ctgtatattg acagggaccc tgataatctt 90420 gtgtgctgaa aactatttgt ataatattat aacattggtg tatagaagtc aatacagttg 90480 gatcaggaaa atttggattt tacaaaagcc aaaatttatc ctaaattatt atttggacaa 90540 aattttgaca aaatgcaaaa ctcattcagg tgaagtgcta gagtaaacat ctacattatt 90600 tcagaagata ataaaatgtt tgtagcttat caagtttaga aagtctcatt tctatacttg 90660 gtgataaata cagaagttgt tcttgggaat ctaacatctt ctacagtcaa ttctcttttc 90720 aaattgtata gctttgttta tttaaatatt aaaaacttgt ttcttaattt cttttatgat 90780 tctgacagag gttaatttaa cgtattttat gagttttccc ttttaggaat atttagagtt 90840 aaagaaataa gtgaaaaaat aaacaaaaca caggtttgga cccaggcaaa cctggttttt 90900 taattctgtc ctactctcta gtaactcaaa aactttgata aaatttctaa cctcttgctg 90960 cttgaatttt atcatctata aaatagtatt atcaatacct accttaccag attgttagga 91020 gaatttttaa tgagataagg gtcacaatgt gcctaatatt tttgacataa agggccgtcc 91080 caatggatga aagctatgtg gctgttatta gcttaaatac cttcttatgt gtgaatgcaa 91140 gacatagagc caatcttttt cctctatcta ccctagtctt tttgagatct cacatgaaga 91200 ttacatgaat ctttatcaag gttcccaaga atcctaaaac atccaaatta gcacgattat 91260 attattttca gagtcttggc tttaccagtg actttaccaa tttgtcaaag aactacccct 91320 taacagacac atattattga gttccaggaa gggacacaat aatattgaaa ttaggccagt 91380 taataatcct gtgatggcct ctgagtgttc aagtgaaaga aacaattgca catctctcac 91440 tgtaaataag aaagctggaa atgatttagc ttaatgagga aggcatgttg aaagttgaga 91500 taggccaaaa gctagtcttc tagcaccagt tagccaagct gtgaatgcaa aggaaaagtt 91560 cttgaaggaa attgaaagtg atattactcc aatgaacata tgaatggtga aaagtaacag 91620 agcctaattg ctgatatgga gaaagtttta gtggtctaga aagaagatca aaccagtcac 91680 aacatttcct taagccaaag cataattcag agcaaagccc tatctctcct aaattctatg 91740 taggctgaga aaggtgagga agctacagaa aaaaaaagtt tgaagctggc agaggttggc 91800 tcacaaggct taagggggga aaaaaggcac ttttgtaaca tagaagtgca aggtgaagca 91860 gcaagtcctg atgtagaagc tgcagtaagt ttttcagaag atcctaacta taacaagatc 91920 attgatgaag gtgactctgc taaacaacag attttgaata tagatgcaac agccttctgt 91980 tggaagaaga tgccttctag gactttcata gctaaaaagt agaagtcaac gcctgacgtg 92040 aaaacttcaa aggacagact gacttccctg ttagggtctc ttgcaaaaca ttactactca 92100 ctgacaacac atctggtcac ccaagagctc tgatggagac gtataaggag attaatgttg 92160 ttttaatgcc tgctaacaca acatccattc tgcagcccat gggtcaaagt ataatttcaa 92220 tttacaagtc ttattgttaa aaaatgaatt tcgttaggct atagttgcca tagatggtgt 92280 catttctcag acagatctgg gcaaaataaa ttgaaaacca tgatgaaaac gattcaccat 92340 tcgtagatgc caataaggac attcatgatt cactgggaag aggtcaaaat atcagcatta 92400 acaggtgttt gggagaagct gattgccact tttatgatga ttttgaaggg ttcaagattt 92460 cagtggagga agtaatttca gatatgatgg aaacagcaag agaactagaa tttgaagtgg 92520 aactgcagat gtgactgaat tactgtaact catgatacaa ctttaacaga tgagcacttg 92580 cttcttatgt ataagcaaag aaagtgcttc cttgagatga aatttactcc tggtgagaat 92640 tctgtgaaca ttgttgaaat gacaaaggtt ttagaatact acacaaatat aattgataaa 92700 gcagtggcag tttttaggtg gattgactcc aattttgaag gaagttctac tgtggtaaag 92760 tactaaaaag aacatcatgt gctacaagga aatctttcat gcagagaaga gtcagtcaat 92820 tgatatggca aacttcatta tcttttgtta agaaattgct gccgccaacc tgggcttcag 92880 caatcaccac cctgaccatt tagcaatcat taacatagag acaagaccct ctaccagcaa 92940 gaggattgtg actagctgaa gtctcagatg attgttagca gtttttagca ataaagtttt 93000 ttaaaattaa gatatatact tcttttagat taatactctt acacacactg tagactacat 93060 tatagtgtaa acataatttt agattcaata agaaaataaa acattcatgt cactcacttt 93120 cttacaataa ttgctttatt gccttggtct ggaaccaaac ttgtagtatc ttcagagtat 93180 gcctgtagtt tatattttta cttttcactt ctagatttta ataccctact tttctaaaat 93240 ggactataaa ccattttagt agtcactttt ggtattttat gaggcatatt tatgtctcct 93300 tatgtcattg tgtttttatg taagaaaaag gttttaatta agcatagatt gtgccctttg 93360 taccctcctg taattaatca caccataaaa cattcgtgtt taggtacatt attttaattt 93420 catgtattac tgcattcata tattcttcat taattaatgt acttaaccaa tgtttggtga 93480 aatatggcac ttcaggcagt gttctgggct cagggattag gaatggtcta atggtctaaa 93540 tgatgtaaaa ttatacaaat ataatcagtg tgtcctcaag aaggtttctt ttcttctgct 93600 agaatgttct cacatgtaac agataatgtg cccatcaaac tgctcatctt tagaatgatt 93660 cctaagatag aaatttctct aatggtatat acccagccgt ccttttcatg ggttgccatc 93720 taacaatgtt tcctttctct tcccctaatc ctgttcacat gcttcctagt gtaatagacc 93780 cttcccttat taaagtgtgc acttggggaa gaccctggcc tttgtagatc aagtgaatgc 93840 aagtcagttt ataaacctct gctggaggta cctgtaaaat aatataaaat ggggacactc 93900 catgtgaggt tcaccctggc ttgtttgttc tccttaagcc actgagagac ttcccttttc 93960 tatggctggt ccgtgttaat cgttctgaac ttaactaaac aactacaggc tatggatgac 94020 atgtagagag accagtgagt agggacttat ctaggaacaa tctataagca cagcttcttc 94080 tgatgtgatt actacagcaa gtagatgttt tgtttttctg atatagcaga caactttttt 94140 aaagtggtac tgaaagaaag tgtttttcta atatggacaa ctctgctaat atccatccga 94200 tcagatgcag ataagctaat ttcagttggt aaaatttttt tgattctatt gactttcaaa 94260 aatatatttt ggtatcaatt gatgcatttt aatatctatt tcatcagttt attttacagt 94320 cggtatttta gttctgttat ttctgtcttc tgattgcttt gttttatccc aacagttgga 94380 caacatacat gttcttcagc attttgagcc tctggaaagt atgtataatt tttgtagtgc 94440 tcagcagtat tttaatcaga tggaaatttg cattatccaa tatctagttc cttctttata 94500 ttgatcatgt tttagtggct caaagaaaaa aaaactgctc tattacccta tcttcaagaa 94560 agtaataaag tgaattattt tgtataattt tatccttcta tacatcatat aatcataagc 94620 tcttagattt gaaaagggct tacattttat ctggtcaata gccctacact ttacccattg 94680 ttcctactcc acatttacct ttcaaagatg agtaaaaaaa ggagccaaga gactaaatga 94740 gttagccagg gacaccacag tcagctaatc acctccagat caggaaatag catttaaacc 94800 acagtcagct aatcagtggc agagctggaa atagaatcca aatctgccaa atcgtagtgc 94860 agtgccctcg ctttggaagt aagaagaaaa gatctcagtc aaaatgatgc ctgttctcag 94920 ttcatcctac aagagtactg accctcacta aaccagctgt gcacattcat ttgccaccac 94980 atagggcctt tgacttttct tggtttgttc tcttgtttgt aattagtaat gaccctactc 95040 ctccaagcat gtttcgtgaa ctgattaatt aatggtcaaa tgtataattt ttttaaatgg 95100 ttttataatt aaagttttct gaattcagat actccaggaa ttgaaacaaa agggttgttt 95160 caatcttttc ttttatgtaa aattttttta atgtttacac tgaacttctt aaaagaaatg 95220 ttttaaattt tcacaattgc ttaaatactt ttagataata tgatttttgg ggtactctaa 95280 tcaattctac atatttcacc tgaaacttta aaaaagctat gttgctttaa gcccttaaga 95340 aatactaaac aaggactttc tgaggcccat tttaaatgtt tctaatatag acttactcat 95400 tttatttttt agtgatgaca tgttttgaaa ctaataatag atatgatatt aaaaacaact 95460 cagaccagat ggtttacatt gtaaccgaag acacagatga ctttaccagg aatgcctatc 95520 ggacactaag gcccttcgtc ctccgggtca ctgattgtat gggccgagaa atcatgacaa 95580 tgcagagacc cttcagatgc acctgctgtt gcttctgttg cccctctgcc agacaagagg 95640 tcagagaatg gaagtctgat ccacagcttg cttctgatct aactcttcat ggcatagtgt 95700 gctccttcca ctacataggg aggatattcc ctggccctgc cagccagaat ggaagaagat 95760 agtggggagg gaggaaccaa attgtctcgc ctaaggaaaa tcatagagga ttttttcttt 95820 ttggttacta ctttttagtg cttaaataag tgggtcaagc acaattgaca tatgtgtagt 95880 caataattat gattccatca gttgcatcta cttaattaga aatttaccta ccacatttat 95940 ctaaatgtac gtacctatca ctagataaag caatgctaaa gataaacata tgcttttaga 96000 attggaaggg acttaaatat gtttagagta cccatcacaa cgcatacctt gccacagata 96060 aagagtggct caaaattact aaatggctga ggtgttacat ttggctaagg acagggctgg 96120 aactagaata cagatgtgct gagttacagt gtggttactc attatcttgc atttctaagc 96180 aagttatttt ctgtagggaa aagagaagcg gttttggaga gaaaccaaac agagtctgaa 96240 ttctagatat gtcacctact taaatctgta aaatttaatt aacctgtttg agccttagtg 96300 ttcttataca taaactgggt agtataatac atcataggat tactgaaata cttaaatgat 96360 ctgttaaata acatccttta ctaaatatta attttttaca accgtctcca ggccttattt 96420 acctgtaaaa tggaaatatt aatagtacct atcggatagg atgatcattt tagggattaa 96480 gtcaattctt ctgcacagtt cctagcaaat agtatagtac tcaatgaata ttttctcttt 96540 tcagaaatct tactcctttg ttattattgt ctttgtgata acagccttat atgtgaagtg 96600 aatacctatt atccttgatc cttttggata tagtaggcat ttatcttcat atttatgagt 96660 tagatttttt tttaatcaaa gcctatagat acagccttct gaaattatag gaagccagaa 96720 taaaggaaag caaatcaaaa ttacagctgg gcaggatggt ttacacctgt aattccaaca 96780 ctttgagagg ctgaggtggg aggatcactt gaggccagga gtttgagatc agcctgggca 96840 acatggtaaa accccatctc tacaaaaata aaaaataaaa aaattagcca ggcctggtga 96900 tgtgtgtctg tggtcccagc tacttgggtg actaaggtag gaggatcact tgagcccagg 96960 atatcgaggc tgcagtgacc tgtgattaca ccacttcact ccagcctggg tgacagagaa 97020 agacccttac tcctaaaaaa aattacaagc ctagtccaat ttatgacact tttgtctcat 97080 aactttactc taggtttttc ttcagatttc tccagtttta cttgtattaa tttgtgtgtg 97140 tgtgtataca tttagtttgt gcagttttat catttgtgta gattcctgtt tccatcagca 97200 caatacaaat cccaaacagt tccatcatca ccaaagtcct cttttattac catatccaca 97260 ttcctccctc ctctttgtcc ctagcccttc agaaccacta atctgttctc tatgtttata 97320 atcttgtcat ttcgagagtg ttattttagc agaatcatat agtatgtaac ttttcaggat 97380 tggtcttttt catccacagt aattaactgg agattcgtac aagctgttac cactagttca 97440 ttccctttta tggctgagta gtataccatg gtatgaattt ttaaggaatt tatttttgta 97500 catttttatt tttatctcat aggtttaaac ttatatgaga gctctatgat actctcaaat 97560 ttatatattt gtatataggt gtgaatttat acatatgaac aataatacct taatttaata 97620 atttatgaag ctgtgcagtc ctgttccatg tcctgggtaa tcctttcccc aaattcttat 97680 gaaagtacat gtaacaccag agaaatagtc aataaaattt tcactttggg cttttaccaa 97740 ataatttaat ctttatgact cattattatt aaacaggaag atcttaatta ttcacaaaat 97800 aatattgttg aagataaata gctaaaaaca gggtagtgga caatatttta aaacttttaa 97860 aaaatggctt tataaaccca tgtacacatt ttgttgtttt cacaatatat aattttcaaa 97920 atgcctcttt tttgttttct gttataattt tcatgtctga gatttgattt tacccaattt 97980 caaatctaaa aagtcagctt aactgtttaa tagactgagt cagaagaaat gagactccta 98040 ggaaggagac agaggaccgt tttacagcac agcaagcagc ataagtgtgt aggttcccct 98100 catctccaag ttctgaggtt gacttggaga agcccattgc ttcctcattg taagcctttt 98160 attttttact tatcctgaga aaattgttct ttctgatgga gaagcagtgt agtgtagtat 98220 caacagtaag ccttgaaacc aagccaactt atctctgtgc cacttcctag ttccatgttt 98280 tagaaagtgt ttaacacttg caagcctcag tttcctcatc tgtaaaatgg agattaaaat 98340 acttatattt ttcagagtta taaatatcag ctgtttatgc agcttgccaa cactgaactt 98400 ggacaactgg ccattatgta acaagcccta attaagcctg ctgtctatcc cagaggcaaa 98460 catgacctca tccgttaaag cttttcactg aaatccaacc tgaagaatgg cctgggtgag 98520 atggaaggct gtcactccca acaataattt ccctagtctt tgaatgagtg aggacacatc 98580 tagattgtgt atgtgcgtat gtgtaagtgt atgtgtatgc atgtagcatc ctaacttctg 98640 tcactgtttt gtttgcagct ggaggtgcag tgtcctcctg gtgtcaccat tggctttgtt 98700 gcggaacatt ggaacctgtg cagggcggtg tacagcatcc aaaatgagaa gaaagaaaat 98760 gtgatgagag ttcgtgggcc atgctcaacc tatggctgtg gttcagattc tgtttttgag 98820 gtgaaactat gtaaaaatag tgtttctgat atttttccta ctcatattaa cagaccatgg 98880 aaagatctgg ttgtagacat ttttttttaa tgtgaatgaa taacatagtg ttaggaaaga 98940 gttaattaac cagttgacat caaaagattt taaagttatt gtgagtagat tgaggttttc 99000 caaaatgaaa gcttttttta tgacttcagt acttgataaa aataaaaaga aatcatttaa 99060 tacattaaat attctgagag taaatagctt gacctaattc atctattcta ttgttggcta 99120 tatgtaatta accatttttt tccctagatt tctaggctgg gaatataggc tctaagtaat 99180 gcaagtgccc aacatgtcac agaacatacc aagtactcct taggctgtgg aaatacttat 99240 ttgcaggata caagtctgtc agcatcctca agaaatcgga taacactaac aatatggata 99300 gaacttatag tagtctgtac atttttgtcc aataaaaaga aaaattattt tgttttgcct 99360 ttatctcact ggctacaaaa tgctggttca ttaccctacg agtctgacac aggaaattcc 99420 tagaaatatt tcctaggctt cttaaagaat attttttgaa tgccttgcaa ttaggcaaga 99480 ttcatcatct tcaaaactgc ttgctcatat gtttcctatg atactcaaga aactttcctt 99540 agttcttatt ttctattact gtatcgttaa gcattgctta tttattaaaa gagcaatgta 99600 gataagccag attgctaggg cagggtgtgt gtgatcattc ccattgccaa gtgacattag 99660 aagttagtat ttggatattt tccctgtgac aagtgccagg tttccccttt tagaaactga 99720 agctcgttgg tatctggccg tatattaaga agacaaggtg aatttcactc acaaaaactt 99780 aagtgatgtg aagtgaacag tacttgtttc ccggtttttg ctcataggtt tccctagttt 99840 ggaagtgact ctctcccaat tcccaccctt tactatgttg agaagaattt cataatcagt 99900 tcaaatcata cctcttctta aaaggtccct taataactca tttgaagatg aagaaagagc 99960 agcagtctga gacttttaag aataccctag ctcagttatt aaccagttgc aaggcagtta 100020 accctttttg gccattattt tctcatttca aattatataa ttacatagtc tttttctgca 100080 ttgtatttat gttatctgaa cataagcaga acattaaaac atgcttcaat gcgtttcaat 100140 catcataaag gcacattctt gtcattccag gtcaaatccc ttgatggcat atccaacatc 100200 ggcagtatta tccggaagtg gaatggtttg ttatcagcaa tggcagatgc tgaccatttt 100260 gacattcact tcccactaga cctggatgtg aagatgaaag ccatgatttt tggagcttgc 100320 ttcctcattg taagccttct atttttgagt tatcctgaga gagttgttct ttctgatgga 100380 gaagcagtat agtgtagtat aaagaataag ccttgaaacc aatccaactt atctctgtgc 100440 cacttactag ttacatggtt tagaaagtgt ttacacttga aagcctcagt ttcctcatct 100500 gtaaaatgga gattaaaata cttataattt tcagggttat gaatgttagc tatcatggta 100560 aaatgaccag gggagtactt agataacatt aggtatccat tgggtataat tatcatcatt 100620 gcatgttatt tgtcattgtc actacttaaa aatgcctagc ctatgatttc ttagtgaaat 100680 aactctaaag tggatgtccc attcctcctt cctttctgcc tgtcactgta ctctttgggg 100740 ttgtccaatc ctgagattat gaagtttttc ctctttttaa tgatgagatt cagttaattg 100800 gcacttcaaa tggaaaacta acagttccaa atttgtaact gctgctcttc acagtaggtg 100860 ctcttcataa atatttccct aaatttatgt attttaactg gaatggggga atcccctaat 100920 aaattacaaa ggataatacc gcatgcatta tacctaatta tctatatatc tacatataat 100980 tctttttcca atttcaggac ttcatgtatt ttgaaagatc tccaccacaa cgttcaagat 101040 agagagacac agcaagccat caactatggt taattttgaa aaatggaaaa gttggattgg 101100 gcttacagtc agcactcagt tatttgcaag tgtatttctt tgctttgtag agtattttta 101160 ttgggtgtta actttgacag ctgagagtgg gcttgcaaga acacaatcta aaagtgtgtt 101220 tcaattgagt atctctctag tagaatagga gttcatcctg aaaagctgtg actcattaac 101280 ccagtaaaca tatacaaagt aagcttaaaa cactataaac atgagataag ggaaaatgaa 101340 tccagagttc tcatattaat aggtagtgaa acaataaggc tttttagagc agactttgtt 101400 ggcataaaat aacctggctt ctatccctaa ccctttccta cctttcctct ccgtcaacat 101460 gtcctcatac tgaagacaaa cttgtttcaa tgatagtctt catttttaaa aacaaaaagg 101520 caggcagaca gaaataatga tgttttcttg cactaagaag gtactacttg tacacatata 101580 tcaaaacctc attctgcaaa gtttttgaag gtttcaatgg gaaatttgat tttattacaa 101640 aataaaacat tttttaatgt taaagtttat atattccatg cttgttttct cattcactgg 101700 catggatgat caggagctgc ctatatatga aggcagaatc agactatcag gaaaggagct 101760 ggccagggca cagccagtca agatctctga gcaacttaga gacattggtg tcattatatg 101820 aagcttgcat ttaatacatt tatacataat acatttgtac atttaattca taacgtctct 101880 tggtcacaga tgccttatat ataaaataag ttgccagatc tctaagattg cctagtacac 101940 ctttgtatct catttgatgt gatacccaga agagatcatt gttttttgtt tttgtttttg 102000 tttttttcaa gaagatcctt cgtgatcacc atgctgttct catggtaaga actggagtta 102060 tgtttttaaa tttggaaata tgacatttta tgtagcactt tataaaaagt gaaagcgaca 102120 aattccaccg ctgcttaata ctgctttgct tctttttatt gacatgatag ataaatatgt 102180 atctacacag agtaataata ataaaacaca gtaaacattc tatttctcta tggtctacag 102240 catgccagta aataatatgt aggaccaata ataaattatc aattacacat ttttgtgtta 102300 actaattaaa agcatagtgt ataagtgagt acactctaat taacttgctt ctgttgcact 102360 ttagttttct acctgcatat ggactgcatt tttttttttt aacacagtca gtatgtagaa 102420 tgggatgtat tcttctgctg ctgcttatta aataaagaaa gcctgagtgt tcttagatgg 102480 ggttattctg agatgagggt cttagcctac agttcttttt gaaatgaaag gtgctttgtt 102540 ttttaattat attcatcttt tcagggtaaa tttgtttttc tgagtttctc gtaatgctca 102600 tttttacatg ctgctactag cttttttttt taaaaaaagt aaaagttgct gctttctaaa 102660 atattaattg ccttatattt gaaagtgcca ttgcaatcgt aagtagacta tgtatttcct 102720 ataatgatgt ctgatattta aataggaaat cagacaaaca atattcagaa agtttaagca 102780 tataaacttt ttatttttaa cttgcctaaa tccctgtatt ccaaaacctg ctgcatcata 102840 ataaatatat ctatatatat ttagcataag acgtgatatt tttaatttct tttttaaaaa 102900 attatatttg tctcttagag ttaaaatttt ctttatataa tattgtcata tgtcatagtt 102960 ttaatacaat tcacatgatt tctatgtttc ttaatgatat tttgttgtgt aaaattgatc 103020 ggattgatta aaaaacaaat tctctggaat ttgtgcgttc atgctttttc gtattcttta 103080 tggcttttaa ataaatatac aatggttaat agtaaaacac tgttttattt tttgactttg 103140 aatcttcaaa tacttttttc acagggattt tgaagtaatt tttattgatt attaggttta 103200 ttcaaggccc ttgctttcta atataaattt taaattattt ttaatttata tatttaatat 103260 atatttaatt tatatatttt taattatata tatttatata taatatatat aatttatata 103320 tggggatcct ctaaaatttt tcctgctaga catgcaaact tgcactggcg ctgctgtttt 103380 aaagtnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 103440 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnatgtt aaacacacgg 103500 acgcctacgt gctacagctt tgctatgacc tgcacgagtc gactgctacg acggatcccc 103560 acaaaaaaaa aaaaaaaaaa atatatatat atatatcctc actctatata tatatataaa 103620 aagtcatttc tgtagtgttg cttagtggta actagctttc ttatatgacc aagttatttg 103680 taaatgctta tttctaatcc tcctaagata catttaaatt tcaagtataa tttcaatgtc 103740 agtatatcat gaaggaaaat tgctagaatt tgtaaccatc agtgaagaat gcattttaaa 103800 cattttttct aaatgaccat tttttccaga aattatacaa aaatcaggtt acaagactta 103860 ttttttctga ccaactagat attaaatcaa attcaggtat agaataatca gagtgattct 103920 agagtatggt atattgatcc tgttggagca gctggctgct tttcagtctt tttttccccc 103980 agtgttcaag gtcggattta 104000 15 20 DNA Artificial Sequence Antisense Oligonucleotide 15 aggatttttc aagttataaa 20 16 20 DNA Artificial Sequence Antisense Oligonucleotide 16 tctagttgta ctggcagagg 20 17 20 DNA Artificial Sequence Antisense Oligonucleotide 17 atccgcctgc cccgcagaat 20 18 20 DNA Artificial Sequence Antisense Oligonucleotide 18 acacctgaca ttttgaagaa 20 19 20 DNA Artificial Sequence Antisense Oligonucleotide 19 gttgctgtgg actgtagtat 20 20 20 DNA Artificial Sequence Antisense Oligonucleotide 20 actggctggt acaaagggaa 20 21 20 DNA Artificial Sequence Antisense Oligonucleotide 21 ctggcatcca tgttattgga 20 22 20 DNA Artificial Sequence Antisense Oligonucleotide 22 tgttgtccaa ctgaactaag 20 23 20 DNA Artificial Sequence Antisense Oligonucleotide 23 tttccagagg ctcaaaatgc 20 24 20 DNA Artificial Sequence Antisense Oligonucleotide 24 ccatctggtc tgagttgttt 20 25 20 DNA Artificial Sequence Antisense Oligonucleotide 25 tctgtgtctt cggttacaac 20 26 20 DNA Artificial Sequence Antisense Oligonucleotide 26 attcctggta aagtcatctg 20 27 20 DNA Artificial Sequence Antisense Oligonucleotide 27 taggcattcc tggtaaagtc 20 28 20 DNA Artificial Sequence Antisense Oligonucleotide 28 tccgataggc attcctggta 20 29 20 DNA Artificial Sequence Antisense Oligonucleotide 29 cggaggacga agggccttag 20 30 20 DNA Artificial Sequence Antisense Oligonucleotide 30 cagcaggtgc atctgaaggg 20 31 20 DNA Artificial Sequence Antisense Oligonucleotide 31 gaagcaacag caggtgcatc 20 32 20 DNA Artificial Sequence Antisense Oligonucleotide 32 gcacctccag ctcttgtctg 20 33 20 DNA Artificial Sequence Antisense Oligonucleotide 33 gcaacaaagc caatggtgac 20 34 20 DNA Artificial Sequence Antisense Oligonucleotide 34 ttccaatgtt ccgcaacaaa 20 35 20 DNA Artificial Sequence Antisense Oligonucleotide 35 ttttggatgc tgtacaccgc 20 36 20 DNA Artificial Sequence Antisense Oligonucleotide 36 gggatttgac ctcaaaaaca 20 37 20 DNA Artificial Sequence Antisense Oligonucleotide 37 tccggataat actgccgatg 20 38 20 DNA Artificial Sequence Antisense Oligonucleotide 38 ctagtgggaa gtgaatgtca 20 39 20 DNA Artificial Sequence Antisense Oligonucleotide 39 acatccaggt ctagtgggaa 20 40 20 DNA Artificial Sequence Antisense Oligonucleotide 40 ctttcatctt cacatccagg 20 41 20 DNA Artificial Sequence Antisense Oligonucleotide 41 gaagtcaatg aggaagcaag 20 42 20 DNA Artificial Sequence Antisense Oligonucleotide 42 tacatgaagt caatgaggaa 20 43 20 DNA Artificial Sequence Antisense Oligonucleotide 43 gtgtctctct atcttgaacg 20 44 20 DNA Artificial Sequence Antisense Oligonucleotide 44 tgagtgctga ctgtaagccc 20 45 20 DNA Artificial Sequence Antisense Oligonucleotide 45 gcaagcccac tctcagctgt 20 46 20 DNA Artificial Sequence Antisense Oligonucleotide 46 cacactttta gattgtgttc 20 47 20 DNA Artificial Sequence Antisense Oligonucleotide 47 atgagtcaca gcttttcagg 20 48 20 DNA Artificial Sequence Antisense Oligonucleotide 48 ttactgggtt aatgagtcac 20 49 20 DNA Artificial Sequence Antisense Oligonucleotide 49 ccaacaaagt ctgctctaaa 20 50 20 DNA Artificial Sequence Antisense Oligonucleotide 50 gggatagaag ccaggttatt 20 51 20 DNA Artificial Sequence Antisense Oligonucleotide 51 ttcttagtgc aagaaaacat 20 52 20 DNA Artificial Sequence Antisense Oligonucleotide 52 tagtaccttc ttagtgcaag 20 53 20 DNA Artificial Sequence Antisense Oligonucleotide 53 gatcatccat gccagtgaat 20 54 20 DNA Artificial Sequence Antisense Oligonucleotide 54 ctcctgatca tccatgccag 20 55 20 DNA Artificial Sequence Antisense Oligonucleotide 55 tgtctctaag ttgctcagag 20 56 20 DNA Artificial Sequence Antisense Oligonucleotide 56 tgtacaaatg tattatgtat 20 57 20 DNA Artificial Sequence Antisense Oligonucleotide 57 gttatgaatt aaatgtacaa 20 58 20 DNA Artificial Sequence Antisense Oligonucleotide 58 catctgtgac caagagacgt 20 59 20 DNA Artificial Sequence Antisense Oligonucleotide 59 cttattttat atataaggca 20 60 20 DNA Artificial Sequence Antisense Oligonucleotide 60 ttcttaccat gagaacagca 20 61 20 DNA Artificial Sequence Antisense Oligonucleotide 61 atagtgctac ataaaatgtc 20 62 20 DNA Artificial Sequence Antisense Oligonucleotide 62 ggaatttgtc gctttcactt 20 63 20 DNA Artificial Sequence Antisense Oligonucleotide 63 gcaaagcagt attaagcagc 20 64 20 DNA Artificial Sequence Antisense Oligonucleotide 64 gtatctatca tgtcaataaa 20 65 20 DNA Artificial Sequence Antisense Oligonucleotide 65 atttactggc atgctgtaga 20 66 20 DNA Artificial Sequence Antisense Oligonucleotide 66 atgcagtcca tatgcaggta 20 67 20 DNA Artificial Sequence Antisense Oligonucleotide 67 tattttagaa agcagcaact 20 68 20 DNA Artificial Sequence Antisense Oligonucleotide 68 ctttcaaata taaggcaatt 20 69 20 DNA Artificial Sequence Antisense Oligonucleotide 69 cgattgcaat ggcactttca 20 70 20 DNA Artificial Sequence Antisense Oligonucleotide 70 atcagacatc attataggaa 20 71 20 DNA Artificial Sequence Antisense Oligonucleotide 71 atgatgcagc aggttttgga 20 72 20 DNA Artificial Sequence Antisense Oligonucleotide 72 aaatatcacg tcttatgcta 20 73 20 DNA Artificial Sequence Antisense Oligonucleotide 73 aattaaaaat atcacgtctt 20 74 20 DNA Artificial Sequence Antisense Oligonucleotide 74 tagaaatcat gtgaattgta 20 75 20 DNA Artificial Sequence Antisense Oligonucleotide 75 cgatcaattt tacacaacaa 20 76 20 DNA Artificial Sequence Antisense Oligonucleotide 76 acaaattcca gagaatttgt 20 77 20 DNA Artificial Sequence Antisense Oligonucleotide 77 tttcaagtta taaacaaagt 20 78 20 DNA Artificial Sequence Antisense Oligonucleotide 78 tccaattaat ccgcctgccc 20 79 20 DNA Artificial Sequence Antisense Oligonucleotide 79 gcacctccag tttccagagg 20 80 20 DNA Artificial Sequence Antisense Oligonucleotide 80 catggttggt taatatgagt 20 81 20 DNA Artificial Sequence Antisense Oligonucleotide 81 ccagatcttt ccatggttgg 20 82 20 DNA Artificial Sequence Antisense Oligonucleotide 82 ccaattaatc ctgcgagtgg 20 83 20 DNA Artificial Sequence Antisense Oligonucleotide 83 ccctgggcag gaaactgctc 20 84 20 DNA Artificial Sequence Antisense Oligonucleotide 84 gaaacccaat caagcgagac 20 85 20 DNA Artificial Sequence Antisense Oligonucleotide 85 caagcgagac ctgtcacgca 20 86 20 DNA Artificial Sequence Antisense Oligonucleotide 86 gcgtttttac ctgcgagtgg 20 87 20 DNA Artificial Sequence Antisense Oligonucleotide 87 aatatcaggt gtctcctttt 20 88 20 DNA Artificial Sequence Antisense Oligonucleotide 88 ttaaattgct gatggctggg 20 89 20 DNA Artificial Sequence Antisense Oligonucleotide 89 tggtaagttc taggagagtc 20 90 20 DNA Artificial Sequence Antisense Oligonucleotide 90 tactcttgtg ctttggagac 20 91 20 DNA Artificial Sequence Antisense Oligonucleotide 91 ttatacatac tttccagagg 20 92 20 DNA Artificial Sequence Antisense Oligonucleotide 92 gaaggcttac aatgaggaag 20 

What is claimed is:
 1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding phospholipid scramblase 4, wherein said compound specifically hybridizes with said nucleic acid molecule encoding phospholipid scramblase 4 and inhibits the expression of phospholipid scramblase
 4. 2. The compound of claim 1 which is an antisense oligonucleotide.
 3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 16, 19, 21, 24, 25, 26, 27, 28, 29, 33, 35, 37, 38, 39, 43, 44, 45, 46, 47, 48, 51, 52, 55, 58, 62, 63, 65, 66, 69, 71, 72, 75, 81, 83, 86, 87, 90, 91 or
 92. 4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
 5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
 6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
 7. The compound of claim 6 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
 8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
 9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
 10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
 11. A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding phospholipid scramblase
 4. 12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
 13. The composition of claim 12 further comprising a colloidal dispersion system.
 14. The composition of claim 12 wherein the compound is an antisense oligonucleotide.
 15. A method of inhibiting the expression of phospholipid scramblase 4 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of phospholipid scramblase 4 is inhibited.
 16. A method of treating an animal having a disease or condition associated with phospholipid scramblase 4 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of phospholipid scramblase 4 is inhibited.
 17. The method of claim 16 wherein the disease or condition is a hyperproliferative disorder.
 18. The method of claim 16 wherein the disease or condition is an autoimmune disorder.
 19. The compound of claim 1 targeted to a nucleic acid molecule encoding phospholipid scramblase 4, wherein said compound specifically hybridizes with and differentially inhibits the expression of one of the variants of phospholipid scramblase 4 relative to the remaining variants of phospholipid scramblase
 4. 20. The compound of claim 19 targeted to a nucleic acid molecule encoding phospholipid scramblase 4, wherein said compound hybridizes with and specifically inhibits the expression of a variant of phospholipid scramblase 4, wherein said variant is selected from the group consisting of PLSCR4 and PLSCR4B. 